Alpha-D-galactopyranoside derivatives

Abstract

The present invention is 1 , A, R 1 and R 2 The present invention relates to compounds of formula (I), as described herein, their preparation, pharmaceutically acceptable salts thereof, and their use as medicaments, pharmaceutical compositions comprising one or more compounds of formula (I), and their use, in particular as galectin-3 inhibitors. [Formula 1] TIFF2022546029000116.tif52168

Description

[Technical field]

[0001] The present invention relates to compounds of formula (I) that are galectin-3 inhibitors and their use in the prevention or treatment of diseases and disorders involving the binding of galectin-3 to its natural ligands. The invention also relates to related aspects including processes for the preparation of said compounds, pharmaceutical compositions comprising one or more compounds of formula (I) and their medical use as galectin-3 inhibitors. The compounds of formula (I) may inter alia be used as single agents or in combination with one or more therapeutic agents. [Background technology]

[0002] Galectins are a family of proteins defined based on a conserved β-galactoside-binding site found within their characteristic ∼130 amino acid (aa) carbohydrate recognition domain (CRD) (Barondes SH et al., Cell 1994;76,597-598). Genome sequences of human, mouse and rat have revealed the presence of at least 16 conserved galectins and galectin-like proteins in a mammalian genome (Leffler H. et al., Glycoconj. J. 2002,19,433-440). Three galectin subclasses have been identified so far: prototypical galectins, which contain a single carbohydrate recognition domain (CRD); tandem repeats of proline- and glycine-rich short stretches fused to the CRD; and tandem-repeat-type galectins, which have two distinct CRDs linked in tandem by a linker (Zhong X., Clin Exp Pharmacol Physiol. 2019;46:197-203). Galectins can bind bivalently or multivalently, e.g., crosslinking glycoconjugates on the cell surface to trigger cell signaling events. By this mechanism, galectins regulate a wide range of biological processes (Sundblad V. et al., Histol Histopathol 2011;26:247-265).

[0003] Galectin-3 (Gal-3), the only chimeric form of the galectin family, has a molecular mass of 32-35 kDa and consists of 250 amino acid residues in humans, a highly conserved CRD and an atypical N-terminal domain (ND). Galectin-3 is monomeric up to high concentrations (100 μM) but can aggregate with ligands at much lower concentrations, which is promoted by its N-terminal non-CRD region through an oligomerization mechanism that is not fully understood (Johannes, L. et al., Journal of Cell Science 2018;131, jcs208884).

[0004] Gal-3 is widely distributed in the body, but its expression level varies among different organs. Depending on its extracellular or intracellular localization, it can exhibit a wide range of biological functions, including immune regulation, host-pathogen interactions, angiogenesis, cell migration, wound healing, and apoptosis (Sundblad V. et al., Histol Histopathol 2011;26:247-265). Gal-3 is highly expressed in many human tumors and cell types such as myeloid cells, inflammatory cells (macrophages, mast cells, neutrophils, T cells, eosinophils, etc.), fibroblasts, and cardiomyocytes (Zhong X. et al., Clin Exp Pharmacol Physiol. 2019;46:197-203), indicating that Gal-3 is involved in the control of inflammatory and fibrotic processes (Henderson NC. et al., Immunological Reviews 2009;230:160-171; Sano H. et al., J Immunol. 2000;165(4):2156-64). Furthermore, the expression level of Gal-3 protein is upregulated in certain pathological conditions such as neoplasia and inflammation (Chiariotti L. et al., Glycoconjugate Journal 2004 19, 441-449; Farhad M. et al., OncoImmunology 2018, 7:6, e1434467).

[0005] asthma (Gao P. et al., Respir Res. 2013, 14:136; Rao SP et al., Front Med (Lausanne) 2017;4:68), rheumatoid arthritis, multiple sclerosis, diabetes, plaque psoriasis (Lacina L. et al., Folia Biol (Prague) 2006;52(1-2):10-5), atopic dermatitis (Saegusa J. et al., Am J Pathol. 2009, 174(3):922-31), endometriosis (Noel JC et al., Appl Immunohistochem Mol Morphol. 2011 19(3):253-7) or viral encephalitis (Liu FT et al., Ann N There is a large body of evidence supporting the functional involvement of Gal-3 in the progression of inflammatory / autoimmune diseases such as inflammatory bowel disease (Y Acad Sci. 2012;1253:80-91; Henderson NC et al., Immunol Rev. 2009;230(1):160-71; Li P et al., Cell 2016;167:973-984). Recently, Gal-3 has been implicated in the progression of chronic inflammation and fibrosis in organs, e.g., the liver (Henderson NC et al., PNAS 2006;103:5060-5065; Hsu DK et al., Int J Cancer. 1999;81(4):519-26), kidney (Henderson NC et al., Am. J. Pathol. 2008;172:288-298; Dang Z. et al., Transplantation. 2012;93(5):477-84), lung (Mackinnon AC et al., Am. J. Respir. Crit. Care Med 2012;185:537-546; Nishi Y. et al., Allergol Int. 2007;56(1):57-65), heart, (Thandavarayan RA et al., Biochem Pharmacol.2008, 75(9):1797-806;Sharma Gal-3 has been noted to play an important role in the nervous system (Burguillos MA et al., Cell Rep. 2015, 10(9):1626-1638) and corneal neovascularization (Chen WS. et al., Investigative Ophthalmology & Visual Science 2017, Vol. 58, 9-20). Furthermore, Gal-3 has been found to be involved in dermal thickening of keloid tissue (Arciniegas E. et al., The American Journal of dermatopathology 2019; 41(3):193-204) and systemic sclerosis (SSc), particularly in the dermal fibrosis and proliferative vasculopathy observed in such pathologies (Taniguchi T. et al., J Rheumatol. 2012, 39(3):539-44). Gal-3 was found to be upregulated in patients with chronic kidney disease (CKD)-related renal failure, especially in those with diabetes. Interestingly, data from this patient population showed a correlation between Gal-3 upregulation in the glomeruli and the observed urinary protein excretion (Kikuchi Y. et al., Nephrol Dial Transplant. 2004, 19(3):602-7). In addition, a recent prospective study in 2018 showed that high plasma levels of Gal-3 increase the risk of developing CKD, especially in hypertensive populations (Rebholz CM. et al., Kidney Int. 2018 Jan;93(1):252-259). Gal-3 has been shown to play a key role in atherosclerosis (Nachtigal M. et al., Am J Pathol. 1998;152(5):1199-208), coronary artery disease (Falcone C. et al., Int J Immunopathol Pharmacol 2011,24(4):905-13), heart failure and thrombosis (Nachtigal M. et al., Am J Pathol. 1998;152(5):1199-208; Gehlken C. et al., Heart Fail Clin. 2018,14(1):75-92; DeRoo EP. et al., Blood. 201 5, 125(11):1813-21) and cardiovascular diseases (Zhong X. et al. Clin Exp Pharmacol Physiol. 2019, 46(3):197-203). Circulating levels of Gal-3 are elevated in obese and diabetic patients and are associated with increased risk for micro- and macrovascular complications (such as heart failure, nephropathy / retinopathy, peripheral arterial disease, cerebrovascular events or myocardial infarction) (Qi-hui-Jin et al., Chin Med J(Engl). 2013, 126(11):2109-15). Gal-3 promotes carcinogenesis, cancer progression and metastasis (Vuong L. et al., Cancer Res. 2019(79)(7)1480-1492), and by acting within the microtumor environment, it has been shown to function as a pro-tumor factor and suppress immune surveillance (Ruvolo PP. et al., Biochim Biophys Acta. 2016 Mar, 1863(3):427-437; Farhad M. et al., Oncoimmunology 2018 Feb 20;7(6):e1434467). Among the cancers expressing high levels of Gal-3, lymphomas, carcinomas, non-small cell lung cancers, melanomas and neuroblastomas have been found, in addition to those involving the thyroid, central nervous system, tongue, breast, gastric cancer, head and neck squamous cells, pancreas, bladder, kidney, liver, parathyroid and salivary glands (Sciacchitano S. et al., Int J Mol Sci 2018 Jan 26, 19(2):379).

[0006] In addition, inhibition of Gal-3 has been shown to be effective in preventing COVID-19 (Caniglia JL et al., Peer J 2020, 8:e9392) and influenza H5N1 (Chen YJ et al., Am. J. Pathol. 2018, 188(4), 1031-1042), possibly due to its anti-inflammatory effects.

[0007] Recently, Gal-3 inhibitors have been shown to have positive effects when used in combination immunotherapy (Galectin Therapeutics. Press release, February 7, 2017) and in idiopathic pulmonary fibrosis (Galecto Biotech. Press release, March 10, 2017) and NASH cirrhosis (December 5, 2017). W020180209276, W02018209255 and W020190890080 disclose compounds having binding affinity to galectin proteins for the treatment of systemic insulin resistance disorders. Thus, Gal-3 inhibitors, alone or in combination with other therapies, would be useful in the prevention or treatment of diseases or disorders such as organ fibrosis, cardiovascular diseases and disorders, acute and chronic kidney injury, liver diseases and disorders, interstitial lung diseases and disorders, eye diseases and disorders, cell proliferative disorders and cancer, inflammatory and autoimmune diseases and disorders, gastrointestinal diseases and disorders, pancreatic diseases and disorders, abnormal angiogenesis-related diseases and disorders, brain-related diseases and disorders, neuropathic pain and peripheral neuropathies, and / or transplant rejection.

[0008] Synthetic inhibitors of Gal-3 that have been explored as antifibrotic agents have been described in various publications and patent applications (see, for example, WO2005113568, WO2005113569, WO2014067986, WO2016120403, US20140099319, W02019067702, W02019075045, W02014078655, W02020078807 and W02020078808). WO2002057284, WO2005113569 and WO2014078655 disclose broad-spectrum beta-configured galectin inhibitors. WO2016120403 and WO2020104335 disclose broad spectrum alpha-D-galactoside inhibitors of galectins. Summary of the Invention

[0009] The present invention provides novel compounds of formula (I) that are alpha-configured galectin-3 inhibitors. The compounds of the present invention may therefore be useful in the prevention or treatment of diseases and disorders in which modulation of Gal-3 binding to natural carbohydrate ligands is required.

[0010] 1) In a first aspect, the present invention relates to a compound of formula (I):

[0011] [ka] (In the formula, Ar 1 teeth, - aryl (especially phenyl), which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents (especially substituted by 1, 2 or 3 substituents), said substituents being independently selected from halogen, methyl, cyano, methoxy, trifluoromethyl, trifluoromethoxy and ethynyl; [the aryl is phenyl, substituted with one, two or three substituents, at least one of which is attached at the meta or para position of the phenyl; in particular, if a para substituent is present, said para substituent is selected from halogen, methyl, cyano, methoxy, trifluoromethyl, trifluoromethoxy and ethynyl (in particular, selected from halogen, methyl, cyano and methoxy); and if a meta substituent is present, said meta substituent is halogen.]; - 5- or 6-membered heteroaryl (particularly thiazolyl, pyridinyl), which is independently unsubstituted or substituted by 1 or 2 substituents, said substituents being independently selected from halogen, methyl, cyano and methoxy; or - 9- or 10-membered heteroaryl (especially benzothiazolyl), which 9- or 10-membered heteroaryl is independently unsubstituted or substituted by one methyl; represents; R 1 teeth, - Hydroxy; - C 1-4 - alkoxy (especially methoxy); - -O-CO-C 1-3 -alkyl; - O-CO-NH-R N11 (R N11 is hydrogen or C 1-3 -Alkyl; -O-CH 2 -C 1 -fluoroalkyl; - -O-CH 2 -HET 1 (H.E.T. 1 represents a 5-membered heteroaryl (particularly oxazolyl, thiazolyl or imidazolyl), which 5-membered heteroaryl is independently unsubstituted or substituted by one methyl; or - -O-CH 2 -CO-R 1X (R 1X teeth, -- -hydroxy; -- C 1-3 - alkoxy (especially methoxy); --morpholin-4-yl; or -- -NR N21 R N22 (R N21 and R N22 each independently represents hydrogen or methyl; or R N21 and R N22 together with the nitrogen atom to which they are attached, form azelates. forming a 4-6 membered heterocycloalkyl selected from pyridin-1-yl, pyrrolidin-1-yl and piperidin-1-yl, said 4-6 membered heterocycloalkyl being substituted by one hydroxyl; represents ); represents; A represents a 5-membered heterocycloalkylene or a 5-membered heteroarylene; the 5-membered heterocycloalkylene is selected from 4,5-dihydroisoxazole-3,5-diyl, imidazolidin-4-one-1,3-diyl, oxazol-2-one-3,5-diyl, and oxazolidine-2-one-3,5-diyl; the 5-membered heteroarylene is selected from 1,2,3-triazole-1,4-diyl, isoxazole-3,5-diyl, imidazol-1,4-diyl, and isothiazole-3,5-diyl; R 2 teeth, - C 1-6 - alkyl (especially tert-butyl); - C 1-6 -Alkyl(C 1-6 -Alkyl has one C 1-3 -Alkoxy (especially methoxy, ethoxy), -CO-C 1-4 -Alkoxy, -NH 2 or -NH-CO-C 1-4 - substituted by alkoxy; - C 1-4 -fluoroalkyl; - C 3-6 -Cycloalkyl(C 3-6 -cycloalkyl is independently unsubstituted or substituted with 1 or 2 substituents, the substituents being oxo, fluoro, -NH-CO-C 1-4 -Alkoxy, C 1-3 -Alkyl (especially methyl), C 1-3 -Alkoxy (especially methoxy), C 1 -Fluoroalkyl, cyano, -CH 2 -CN and -NH-CO-C 1-4 -Alkyl(C 1-4 -Alkyl is one -NH 2 or -NH-CO-C 1-4 -alkoxy; or 3-6 -Cycloalkyl together with 1,3-dioxolane-2,2-diyl forms a spiro-bicyclic group; - 4-6 membered heterocycloalkyl, wherein the heterocycloalkyl has one ring oxygen atom and the 4-6 membered heterocycloalkyl is independently unsubstituted or has one C 1-4 - substituted by alkyl (especially methyl or ethyl); - 4-6 membered heterocycloalkyl, which has one ring sulfur atom (especially tetrahydro-2H-thiopyranyl) and the sulfur atom is unsubstituted or substituted by one oxo (=O); or the sulfur atom is substituted by two substituents, one of which is oxo (=O) and the other of which is oxo (=O), imido (=NH), C 1-3 -Alkyl imide (=NC 1-3 -alkyl), 4,4-difluorocyclohexylimide and benzylimide (=N-benzyl) (thus forming sulfinyl, sulfonyl, sulfonimidoyl, N-alkylsulfonimidoyl N-(4,4-difluorocyclohexyl)-sulfonimidoyl or N-benzylsulfonimidoyl groups); - 4-7 membered heterocycloalkyl having one ring nitrogen atom which is unsubstituted or has one -- C 1-6 -alkyl; -- -CO-C 1-6 -Alkyl; -CO-C 4-6 -Cycloalkyl; -CO-C 1-3 -Fluoroalkyl; -CO-C 1-4 -Alkoxy; -CO-NH-C 1-4 -alkyl; --SO 2 -C 1-4 -Alkyl; -SO 2 -NH-C 1-4 -alkyl; -- -CH 2 -C 3-6 -cycloalkyl; -- -CO-C 1-6 -Alkyl(C 1-6 - alkyl is substituted with one amino; -- -CH2 -Oxetanyl; -- Thiazol-2-yl; oxazol-2-yl; benzo[d]thiazol-2-yl; ---CO-benzyloxy; -- -CO-NH 2 ;-CO-NH-C 3-6 -cycloalkyl; -- -CO-NR N31 R N32 (R N31 and R N32 are each independently 1-3 - alkyl (in particular methyl or ethyl); -- -CO-NR N41 R N42 (R N41 and R N42 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl (particularly a pyrrolidinyl, piperidinyl or piperazinyl ring), which 5- or 6-membered heterocycloalkyl is independently unsubstituted or 1-3 - substituted by alkyl (especially methyl); -- -SO-C 1-6 -alkyl; --SO 2 -C 1-3 -Fluoroalkyl; -SO 2 -NH 2 ; --SO 2 -NR N51 R N52 (R N51 and R N52 are each independently 1-3 - alkyl (especially methyl); --SO 2 -NR N61 R N62 (R N61 and R N62 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl (particularly a pyrrolidinyl or piperidinyl or morpholinyl ring), which 5- or 6-membered heterocycloalkyl is independently unsubstituted or substituted by 2 fluoro; --SO 2 -phenyl, which is unsubstituted or substituted by one methyl; -- -SO(NH)-C 1-6 -Alkyl; or -SO(NC 1-3 -alkyl)-C 1-6 -alkyl; Replaced by; The 4- to 7-membered heterocycloalkyl may bear no further substituents in addition to the substituents on the ring nitrogen atoms, or may be C 1-4 - carrying one further substituent which is alkyl (especially methyl) (this C 1-4 -Alkyl is intended to be attached to a ring carbon atom.

[0012] [ka] (R N71 is hydrogen or -CO-C 1-4 -alkoxy (especially -CO-tert-butoxy); - cyclopentenyl; - L-OH (L is -- C 1-6 -alkylene; -- Chloro-C 2-6 -alkylene; 1-phenyl-ethane-1,1-diyl or 1-(2-fluorophenyl)-ethane-1,1-diyl; -- (cyclopropyl)-(pyridin-2-yl)-methylene; -- C 4-6 -Cycloalkylene (the C 4-6 -cycloalkylene is independently unsubstituted or substituted with 1 or 2 substituents, the substituents being independently methyl, fluoro or -CO-R O2 (R O2 is hydroxy or C 1-4 -alkoxy.) ); -- Cyclopropylene-(CH 2 ) n - *(n represents an integer of 0 or 1, and the asterisk represents a bond bonded to the -OH group); -- 4- to 7-membered heterocycloalkylene, the heterocycloalkylene having one ring oxygen atom; or -- 4- to 7-membered heterocycloalkylene, the heterocycloalkylene having one ring nitrogen atom, the nitrogen atom being unsubstituted or having one --CO-C 1-4 -Alkyl or -CO-C 1-4 - substituted by alkoxy; represents ); - 5- or 6-membered heteroaryl (especially pyrazolyl, thiazolyl, pyridinyl, pyrimidinyl), which 5- or 6-membered heteroaryl are independently unsubstituted or substituted by one substituent, which substituents are independently selected from the group consisting of C 1-4 -Alkyl (especially methyl), C 1-3 -Fluoroalkyl, halogen (especially bromo), C 1-4 -alkoxy (especially methoxy) or C 1-4 -fluoroalkoxy; - 2-oxo-1,2-dihydropyridin-4-yl, 6-oxo-1,6-dihydropyridin-3-yl or 1-methyl-2-oxo-1,2-dihydropyridin-4-yl;

[0013] [ka] (m and p each independently represent an integer of 1 or 2; R N81 is hydrogen or C 1-4 - alkyl (especially methyl); - C 0-3 -Alkylene-phenyl (especially phenyl, -CH 2 -phenyl or -CH(CH 3 )-phenyl; wherein the phenyl is independently unsubstituted or substituted with 1, 2 or 3 substituents, the substituents being independently selected from the group consisting of: 1-4 -Alkyl, C 1-3 -fluoroalkyl, halogen (especially fluoro or chloro), hydroxy, C 1-4-alkoxy (especially methoxy) or C 1-4 -fluoroalkoxy (especially difluoromethoxy); - 9-membered heteroaryl (especially indazolyl and 1H-benzo[d]imidazolyl);

[0014] [ka] (R N91 is hydrogen or -CO-C 1-4 -alkoxy (especially -CO-tert-butoxy); represents; - or R 2 is the structure (R 2-B ) group:

[0015] [ka] (Ring (B) represents a non-aromatic 5-membered ring fused to the phenyl group, Ring (B) has two heteroatoms independently selected from nitrogen and oxygen; Ring (B) is independently substituted with 1 or 2 substituents, one of which is oxo, and the other substituent, if present, is C 1-3 - alkyl (especially methyl); [In particular, the above groups, (R 2-B ) is 1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl or 2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl. ]. ).

[0016] The compound of formula (I) has five chiral or asymmetric centers located in the tetrahydropyran moiety and in the absolute configuration described in formula (I). In addition, the compound of formula (I) may contain one, and possibly more, additional chiral or asymmetric centers, such as one or more additional asymmetric carbon atoms. Thus, the compound of formula (I) may exist as a mixture of stereoisomers or, preferably, as a pure stereoisomer. The mixture of stereoisomers may be separated by methods known to those skilled in the art.

[0017] When the linker A represents 4,5-dihydroisoxazole-3,5-diyl, the carbon atom at position 5 of the ring is preferably in the absolute (S)-configuration:

[0018] [ka] When the linker A represents oxazolidin-2-one-3,5-diyl, the carbon atom at position 5 of the ring is preferably in the absolute (R)-configuration:

[0019] [ka] When a particular compound (or generic structure) is described as being in a particular absolute configuration, e.g., as the (R)- or (S)-enantiomer, such description is understood to mean the respective compound (or generic structure) in enriched, especially essentially pure, enantiomeric form. Similarly, when a particular asymmetric center of a compound is described as being in the (R)- or (S)-configuration, or in a particular relative configuration, such description is understood to mean said compound in enriched, especially essentially pure form, with respect to each configuration of said asymmetric center. When a compound is described in its chemical name as having any chiral or asymmetric center in the (RS)-configuration, such description is understood to mean the respective compound in enriched, especially essentially pure form, with respect to each configuration of said asymmetric center. When listed, this means that the chiral or asymmetric center in the compound may be present in the (R)-configuration, the (S)-configuration, or any mixture of epimers about said center. When two such chiral or asymmetric centers of the (RS)-configuration are present in one molecule, the order of absolute configuration is not intended to imply any definitive relative configuration for said two centers.For example, the compound (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-((5-((1RS,2RS)-2-hydroxycyclopentyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate is enantiomerically enriched (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-((5-((1R,2R)-2-hydroxycyclopentyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl Acetate, (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-((5-((1R,2S)-2-hydroxycyclopentyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl Acetate, (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-((5-((1S,2R)-2-hydroxycyclopentyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate and (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-((5-((1S,2S)-2-hydroxycyclopentyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate, or any mixture of epimers for the ((1RS,2RS)-2-hydroxycyclopentyl)isoxazol-3-yl) portion of the compound.

[0020] In this patent application, bonds drawn as dotted lines or interrupted by wavy lines indicate the attachment points of the depicted groups.

[0021] [ka] describes the 3,4,5-trifluorophenyl group.

[0022] The term "enriched", when used in connection with stereoisomers, is understood in the context of the present invention to mean that the respective stereoisomer is present in a ratio of at least 70:30, in particular at least 90:10, with respect to the total of each other stereoisomer / each other stereoisomer (i.e. with a purity of at least 70% by weight, in particular at least 90% by weight).

[0023] The term "essentially pure", when used in relation to stereoisomers, is understood in the context of the present invention to mean that each stereoisomer is present in a purity of at least 95 percent by weight, in particular at least 99 percent by weight, with respect to each other stereoisomer / total of each other stereoisomer.

[0024] The present invention also relates to isotopically labeled, especially 2 H (deuterium)-labeled compounds of formula (I) according to embodiments 1) to 23), which are identical to compounds of formula (I) except that one or more atoms are respectively replaced by atoms having the same atomic number but an atomic mass different from that normally found in nature. Isotopically labeled, especially 2 H (deuterium) labeled compounds of formula (I), (II) and (III) and salts thereof are within the scope of the present invention. 2Substitution with H (deuterium) can increase metabolic stability, e.g., increase in-vivo half-life, or reduce the required dose, or reduce inhibition of cytochrome P450 enzymes, e.g., improve safety profile. In one embodiment of the present invention, the compounds of formula (I) are not isotopically labeled, or they are labeled only with one or more deuterium atoms. In a subembodiment, the compounds of formula (I) are not isotopically labeled at all. Isotopically labeled compounds of formula (I) may be prepared similarly to the methods described below, except that appropriate isotopic species of suitable reagents or starting materials are used.

[0025] When the plural forms are used with respect to compounds, salts, pharmaceutical compositions, diseases, and the like, these are intended to refer to a singular compound, salt, or the like.

[0026] Any reference to compounds of formula (I) according to embodiments 1) to 23) will, where appropriate, be understood to also refer to the salts (especially the pharma- ceutically acceptable salts) of such compounds.

[0027] The term "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the subject compound and exhibits minimal undesired toxicological effects. Such salts include inorganic or organic acid and / or base addition salts, depending on the presence of basic and / or acidic groups in the subject compound. For reference, see, for example, "Handbook of Pharmaceutical Salts. Properties, Selection and Use.", P. Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008; and "Pharmaceutical Salts and Co-crystals", Johan Wouters and Luc See Quere (Eds.), RSC Publishing, 2012.

[0028] The definitions set forth herein are uniformly applied to the compounds of formula (I) defined in any one of embodiments 1) to 21) and apply mutatis mutandis throughout the specification and claims unless a broader or narrower definition is given by a specific definition. It is understood that a definition or preferred definition of a term may independently (and together) define and replace the respective term in any or all other terms or preferred definitions defined herein.

[0029] In this patent application, compounds are named using the IUPAC nomenclature system, but may also be named using the carbohydrate nomenclature system. Thus, the group:

[0030] [ka] can be named (2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl, or alternatively 1,3-di-deoxy-3-[4-phenyl-1H-1,2,3-triazol-1-yl]-α-D-galactopyranosid-1-yl, where the absolute configuration of the carbon atom carrying the point of attachment to the remainder of the molecule is (2R)-, or alpha. For example, the compound 4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-N-ethylpiperidine-1-carboxamide is also understood to be: 1-(1,3-di-deoxy-3-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-α-D-galacto-pyranose)-1-(5-((1-ethylamino-carbonyl)piperidin-4-yl)-1H-isoxazol-3-yl)-methane.

[0031] Whenever a substituent is described as optional, it is understood that such a substituent may be absent (i.e., each residue is unsubstituted with respect to such optional substituent), in which case all sites having a free valence (e.g., in an aromatic ring, a ring carbon atom and / or a ring nitrogen atom having a free valence to which such optional substituent may be attached) are replaced with hydrogen, as the case may be. Similarly, when the term "optionally" is used in reference to (ring) heteroatoms, this term means that each optional heteroatom, etc. is absent (i.e., a group has no heteroatoms / is a carbocyclic ring / etc.) or that each optional heteroatom, etc. is present as expressly defined. Unless expressly defined otherwise in each embodiment or claim, the groups defined herein are unsubstituted.

[0032] In some cases, compounds of formula (I) may include tautomers. Such tautomers are included within the scope of the present invention. Where tautomers exist for a particular residue and only one form of such residue is disclosed or defined, it is understood that the other tautomers are encompassed by such disclosed residue. For example, the group 2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl is understood to also encompass its tautomer, 2-hydroxy-1H-benzo[d]imidazol-5-yl. Similarly, the group 2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl is understood to also include its tautomer, 2-hydroxybenzo[d]oxazol-6-yl; the group 2-oxo-1,2-dihydropyridin-4-yl (alternatively named pyridin-2(1H)-one-4-yl) is understood to also include its tautomer, 2-hydroxypyridin-4-yl.

[0033] The term "halogen" means fluorine, chlorine or bromine, preferably fluorine.

[0034] The term "alkyl", used alone or in combination, means a straight or branched chain saturated hydrocarbon group having 1 to 6 carbon atoms. x-y The term "-alkyl" (x and y are each integers) refers to an alkyl group as defined above having x to y carbon atoms. For example, C 1-6 -Alkyl groups have 1 to 6 carbon atoms. Representative examples of alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, pentyl, 3-methyl-butyl, 2,2-dimethyl-propyl and 3,3-dimethyl-butyl. For the avoidance of any doubt, when a group is described as, for example, propyl or butyl, it is meant to be n-propyl or n-butyl, respectively. R 2 "C 1-6 When referring to "C-alkyl", this term means in particular methyl, ethyl, isopropyl or tert-butyl; especially tert-butyl. 1-6 -alkyl" 2 In a subembodiment of this term, 1-3 -alkyl. 1-6 -alkyl" 2 In another subembodiment of the term, 4-6 -alkyl, in particular tert-butyl.

[0035] "-C x-y The term "-alkylene-", used alone or in combination, refers to a bivalently bound alkyl group, as defined above, having x to y carbon atoms. 0-y The term "-alkylene-" refers to a direct bond or to the above-defined -(C 1-y ) alkylene-. Preferably, -C 1-y The attachment points of the alkylene groups are in the 1,1-diyl or 1,2-diyl or 1,3-diyl configuration. 0-y When the -alkylene group is used in combination with another substituent, the term also applies when that substituent is C 1-y- is attached to the remainder of the molecule via an alkylene group or it is attached directly to the remainder of the molecule (i.e., C 0 An alkylene group represents a direct bond connecting the substituent to the remainder of the molecule. Unless expressly stated otherwise, an alkylene group -C 2 H 4 -HA-CH 2 -CH 2 - means "C 1-6 Examples of L representing "-alkylene" are methylene, ethylene, propane-2,2-diyl and 2-methyl-propane-1,2-diyl; in addition, 2-methyl-propane-2,3-diyl and pentane-3,3-diyl.

[0036] "Chloro-C 2-6 The term "-alkylene" refers to a C-alkylene as defined above, in which one hydrogen atom is replaced by chloro. 2-6 R means an -alkylene group. 2 L-OH (L stands for "chloro-C 2-6 -alkylene". When referring to 1-chloro-3-hydroxy-2-methyl-propan-2-yl, the term in particular denotes 1-chloro-3-hydroxy-2-methyl-propan-2-yl.

[0037] The term "alkenyl", used alone or in combination, means a straight or branched hydrocarbon chain having from 2 to 5 carbon atoms and one carbon-carbon double bond. x-y The term "-alkenyl" (x and y are each integers) refers to an alkenyl group as defined above having x to y carbon atoms. For example, C 2-5 -Alkenyl groups have 2 to 5 carbon atoms. Examples of alkenyl groups are especially prop-1-en-2-yl.

[0038] The term "fluoroalkyl", used alone or in combination, means an alkyl group as defined above having one to four carbon atoms in which one or more, and in some cases all, hydrogen atoms have been replaced by fluorine. x-yThe term "fluoroalkyl" (x and y are each integers) refers to a fluoroalkyl group as defined above having x to y carbon atoms. For example, C 1-3 A -fluoroalkyl group has 1 to 3 carbon atoms and 1 to 7 hydrogen atoms are replaced by fluorine. Representative examples of fluoroalkyl groups include trifluoromethyl, 2-fluoromethyl, 2-fluoroethyl ... R is 1,1-difluoro-2-methyl-propan-2-yl, especially trifluoromethyl. 2 "C 1-4 When referring to "C-fluoroalkyl", the term specifically refers to 1,1-difluoro-2-methyl-propan-2-yl. 1 The term "-fluoroalkyl" specifically refers to difluoromethyl.

[0039] The term "fluoroalkoxy", used alone or in combination, means an alkoxy group as defined above having 1 to 3 carbon atoms in which one or more (and in some cases all) hydrogen atoms have been replaced by fluorine. x-y The term "fluoroalkoxy" (x and y are each integers) refers to a fluoroalkoxy group as defined above having x to y carbon atoms. For example, C 1-3 -Fluoroalkoxy groups have 1 to 3 carbon atoms, and 1 to 7 hydrogen atoms are replaced by fluorine. Representative examples of fluoroalkoxy groups include trifluoromethoxy, difluoromethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, and 2,2,2-trifluoroethoxy. C-fluoroalkoxy groups such as trifluoromethoxy and difluoromethoxy are preferred. 1 -fluoroalkoxy groups as well as 2,2,2-trifluoroethoxy.

[0040] The term "cycloalkyl", whether used alone or in combination, specifically refers to a saturated monocyclic hydrocarbon ring having from 3 to 7 carbon atoms.x-y The term "cycloalkyl" (x and y are each integers) refers to a cycloalkyl group as defined above having x to y carbon atoms. For example, C 3-6 -Cycloalkyl groups have 3 to 6 carbon atoms. Representative examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Preferred are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Said cycloalkyl groups are unsubstituted or substituted as expressly defined. R 2 "Together with 1,3-dioxolane-2,2-diyl, forms a spiro-bicyclic group, C 3-6 When referring to "-cycloalkyl", this term specifically refers to 1,4-dioxaspiro[4.5]decan-8-yl.

[0041] "-C x-y The term "-cycloalkylene-", whether used alone or in combination, refers to a two-linked cycloalkyl group as defined above having x to y carbon atoms. Preferably, the attachment points of the two-linked cycloalkyl group are in a 1,1-diyl configuration, or a 1,4-diyl configuration; or, in addition, in a 1,2-diyl configuration. 4-6 Examples of -cycloalkylene groups are cyclopentane-1,1-diyl, cyclohexane-1,1-diyl and cyclohexane-1,4-diyl; and, in addition, cyclopropane-1,1-diyl, cyclopropane-1,2-diyl, cyclobutane-1,1-diyl, cyclobutane-1,2-diyl and cyclopentane-1,2-diyl.

[0042] R 2 represents L-OH, and L is "cyclopropylene-(CH 2 ) n - * ", this term in particular means 2-hydroxy-cyclopropan-1-yl, 1-hydroxy-cyclopropan-1-yl or 1-hydroxymethyl-cyclopropan-1-yl.

[0043] The term "alkoxy", used alone or in combination, means an alkyl-O- group, wherein the alkyl group is as previously defined. x-y The term "alkoxy" (x and y are each integers) means an alkoxy group as defined above having x to y carbon atoms. Preferred are ethoxy and especially methoxy. 1-4 -alkoxy" stands for R 1 Examples of methoxy, ethoxy, n-propionyl oxy and n-butoxy (especially methoxy); and, in addition, isopropoxy; most preferably methoxy.

[0044] The term "heterocycloalkyl", whether used alone or in combination, unless a broader or narrower definition is expressly indicated, refers to a saturated or unsaturated non-aromatic monocyclic hydrocarbon ring having one or two ring heteroatoms independently selected from nitrogen, sulfur and oxygen (particularly one oxygen atom, one sulfur atom, one nitrogen atom, two nitrogen atoms, two oxygen atoms, or one nitrogen atom and one oxygen atom). The term "x-y membered heterocycloalkyl" refers to such a heterocycle having a total of x-y ring atoms. For the avoidance of doubt, when a 4-7 or 4-6 membered heterocycloalkyl is defined as having one ring heteroatom (such as one ring sulfur atom, one ring oxygen atom or one ring nitrogen atom), said 4-7 membered heterocycloalkyl shall have exactly that one ring heteroatom and no further ring heteroatoms. Heterocycloalkyl groups are unsubstituted or substituted as expressly defined. Examples of 4-6 membered heterocycloalkyl groups in which the heterocycloalkyl has one ring oxygen atom are oxetan-3-yl and tetrahydro-2H-pyran-4-yl. Examples of 4-7 membered heterocycloalkyl groups in which the heterocycloalkyl has one ring nitrogen atom are azetidin-3-yl, pyrrolidin-3-yl and piperidin-4-yl. Examples of 4-7 membered heterocycloalkyl groups in which the heterocycloalkyl has two nitrogen atoms are piperazin-1-yl, and preferably, all of the substituents of such piperazin-1-yl are bonded to the nitrogen atom of the piperazin-1-yl. Examples of 4-7 membered heterocycloalkyl groups in which the heterocycloalkyl has two oxygen atoms are 1,3-dioxolyl or 1,4-dioxinyl. An example of a 4-7 membered heterocycloalkyl group, where the heterocycloalkyl has one nitrogen atom and one oxygen atom, is morpholin-4-yl, preferably such a morpholin-4-yl group is unsubstituted.

[0045] R 2"A 4- to 6-membered heterocycloalkyl having one ring oxygen atom, wherein the 4- to 6-membered heterocycloalkyl is independently one C 1-4 When referring to "4- to 6-membered heterocycloalkyl substituted by -alkyl", this term especially means 3-methyloxetan-3-yl, 3-ethyloxetan-3-yl or 4-methyltetrahydro-2H-pyran-4-yl; especially 3-methyloxetan-3-yl.

[0046] R 2 is "a 4- to 6-membered heterocycloalkyl (wherein the heterocycloalkyl has one ring sulfur atom, the sulfur atom is unsubstituted or substituted with one oxo; or the sulfur atom is substituted with two substituents, one of which is oxo (=O) and the other of which is oxo, imido, C 1-3 -alkylimide, 4,4-difluorocyclohexylimide and benzylimide), this term especially denotes the following radicals:

[0047] [ka] R 2 "4-7 membered heterocycloalkyl (the heterocycloalkyl has one ring nitrogen atom, and the nitrogen atom is one -SO(NH)-C 1-6 -Alkyl or -SO(NC 1-3 -alkyl)-C 1-6 -alkyl)” this term especially refers to the following group:

[0048] [ka] The term "heterocycloalkylene", whether used alone or in combination, refers to a heterocycloalkyl group as defined above, attached at two positions. Preferably, the attachment point of the linker A representing a 5-membered heterocycloalkylene is in the 1,3-diyl configuration (which 1,3-diyl configuration is intended to mean the "meta" configuration, including the respective 1,4- or 3,5-diyl configurations, when the numbering is adapted to the nomenclature of the particular heterocycloalkylene ring). Examples of A representing a "5-membered heterocycloalkylene" are 4,5-dihydroisoxazole-3,5-diyl; and, in addition, imidazolidin-4-one-1,3-diyl, oxazol-2-one-3,5-diyl and oxazolidin-2-one-3,5-diyl; in particular 4,5-dihydroisoxazole-3,5-diyl. The term "x-y membered heterocycloalkylene", whether used alone or in combination, refers to a heterocycloalkyl group as defined above, bonded at two positions, having a total of x to y ring atoms. Examples of 4-7 membered heterocycloalkylene groups in which the heterocycloalkylene has one ring oxygen atom are oxetane-3,3-diyl and tetrahydro-2H-pyran-4,4-diyl. Examples of 4-7 membered heterocycloalkylene groups in which the heterocycloalkylene has one ring nitrogen atom are piperidine-4,4-diyl and azepane-4,4-diyl. The heterocycloalkylene group is unsubstituted or substituted as expressly defined.

[0049] The term "aryl", used alone or in combination, means phenyl or naphthyl, preferably phenyl, said aryl groups being unsubstituted or substituted as expressly defined.

[0050] The term "heteroaryl", whether used alone or in combination, unless a broader or narrower definition is expressly indicated, refers to a 5-10 membered monocyclic or bicyclic aromatic ring having from 1 to up to 4 heteroatoms, each of which is independently selected from oxygen, nitrogen and sulfur. Representative examples of such heteroaryl groups are 5-membered heteroaryl groups such as furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, etc.; 6-membered heteroaryl groups such as pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, etc.; and indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, and 8-10 membered bicyclic heteroaryl groups such as benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzoxadiazolyl, benzothiadiazolyl, thienopyridinyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrrolopyridinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrrolopyrazinyl, imidazopyridinyl, imidazopyridazinyl and imidazothiazolyl. The above heteroaryl groups are unsubstituted or substituted as expressly defined. The above heteroaryl groups are unsubstituted or substituted as expressly defined. The substituent R representing "5- or 6-membered heteroaryl" 2 In the context of the term this means in particular pyrazolyl, thiazolyl, pyridinyl or pyrimidinyl; especially 1H-pyrazol-4-yl, thiazol-5-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl; or in addition thiazol-2-yl. 2 In this respect, the term especially means indazolyl and 1H-benzo[d]imidazolyl; especially 1H-indazol-5-yl, 1H-indazol-6-yl and 1H-benzo[d]imidazol-5-yl.

[0051] The term "heteroarylene", whether used alone or in combination, refers to a heteroaryl group as defined above, bonded at two positions. Preferably, the attachment point of the linker A representing a 5-membered heteroarylene is in the 1,3-diyl configuration (which 1,3-diyl configuration is intended to mean the "meta" configuration, including the respective 1,4- or 3,5-diyl configurations, when the numbering is adapted to the nomenclature of the particular heteroarylene ring). Examples of A representing a 5-membered heteroarylene are 1,2,3-triazole-1,4-diyl and isoxazole-3,5-diyl; and, in addition, imidazole-1,4-diyl and isothiazole-3,5-diyl; in particular, isoxazole-3,5-diyl and 1,2,3-triazole-1,4-diyl.

[0052] For the avoidance of any doubt, when the linker A represents a two-bonded heteroaryl or heterocycloalkyl group, the substituent R 2 The attachment points of may be at both available positions of the heteroarylene or heterocycloalkylene biradical. For example, when A represents isoxazol-3,5-diyl, the substituent R 2 may be attached at the 3-position or at the 5-position of the isoxazole; thus representing the following possible structures:

[0053] [ka] R 2 The structure is

[0054] [ka] When it represents the formula:

[0055] [ka] "Structure (R 2-B ) group:

[0056] [ka] (Ring (B) represents a non-aromatic 5-membered ring fused to the phenyl group, Ring (B) has two heteroatoms independently selected from nitrogen and oxygen; Ring (B) is independently substituted with 1 or 2 substituents, one of which is oxo, and the other substituent, if present, is C 1-3 -alkyl. Examples of "are especially the groups 2,3-dihydro-1H-benzo[d]imidazol-5-yl, 2,3-dihydro-1H-benzo[d]imidazol-6-yl, 2,3-dihydrobenzo[d]oxazol-5-yl and 2,3-dihydrobenzo[d]oxazol-6-yl, which are independently substituted by one or two substituents in the fragment corresponding to ring (B) as defined above. Specific examples are 1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl or 2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl.

[0057] The term "cyano" refers to the group --CN.

[0058] The term "oxo" refers, for example, to a carbonyl group -(CO)- (or a sulfonyl group -(SO 2 )-) means the group =O, attached preferably to a chain or ring carbon or sulfur atom.

[0059] Whenever the word "between" is used to describe a range of numerical values, it is intended that the endpoints of the stated range are expressly included in that range. This means, for example, that when a temperature range is described as being between 40° C. and 80° C., the endpoints 40° C. and 80° C. are included in the range; or, when a variable is defined as an integer between 1 and 4, it means that the variable is the integer 1, 2, 3, or 4.

[0060] When not used in reference to temperature, the term "about" placed before a numerical value "X" in this application refers to between 10% of XX and 10% of X+X, preferably between 5% of XX and 5% of X+X. In the specific case of temperatures, the term "about" placed before a temperature "Y" in this application refers to a temperature between Y-10°C and Y+10°C, preferably between Y-5°C and Y+5°C. Furthermore, the term "room temperature" as used herein refers to a temperature of about 25°C.

[0061] Further aspects of the invention are described below: 2) The second embodiment is Ar 1 represents phenyl substituted by 1, 2 or 3 substituents, said substituents being independently selected from halogen, methyl, cyano, methoxy, trifluoromethyl and ethynyl (in particular from halogen, methyl, cyano and methoxy); at least one of the substituents is attached at the meta and / or para position of the phenyl, and if a para substituent is present, the para substituent is preferably selected from halogen, methyl, cyano, methoxy, trifluoromethyl and ethynyl (most preferably halogen, methyl, cyano and methoxy); - if a meta-substituent is present, said meta-substituent is preferably halogen; It relates to compounds according to embodiment 1).

[0062] 3) In another embodiment, Ar 1 represents phenyl substituted by 1, 2 or 3 substituents; one of the substituents is attached at the meta position of the phenyl and the substituent is halogen; the remaining substituents, if present, are halogen (especially fluoro); or - one of the substituents is attached at the para position of the phenyl, and the substituents are independently selected from methyl, cyano, and methoxy; Any remaining substituents, if present, are halogen (especially fluoro); It relates to compounds according to embodiment 1).

[0063] 4) In another embodiment, Ar 1 The structure:

[0064] [ka] (In the formula, - R m2 represents hydrogen or fluoro; and R p independently represent halogen (especially fluoro or chloro), methyl, cyano or methoxy (especially R p represents fluoro, chloro or methyl; or - R m2 represents hydrogen or fluoro; and R p represents hydrogen. ); It relates to compounds according to embodiment 1), in which

[0065] 5) In another embodiment, Ar 1 The structure:

[0066] [ka] (In the formula, - R m2 represents halogen (especially fluoro); - R p represents hydrogen, halogen (especially fluoro or chloro), methyl, cyano or methoxy (especially R p represents fluoro, chloro or methyl. It relates to compounds according to embodiment 1), in which

[0067] 6) In another embodiment, Ar 1 but:

[0068] [ka] relates to compounds according to embodiment 1),

[0069] In a subembodiment of embodiment 6), Ar 1 represents 3,4,5-trifluorophenyl.

[0070] 7) In another embodiment, R 1 but, - Hydroxy; - Methoxy; - -O-CO-C 1-3 -Alkyl (especially -O-CO-methyl); - -O-CH 2 -HET 1 (H.E.T. 1 represents a 5-membered heteroaryl (particularly oxazolyl, thiazolyl or imidazolyl), which 5-membered heteroaryl is independently unsubstituted or substituted by one methyl; or - -O-CH 2 -CO-R 1X (R 1X teeth, -- -hydroxy; --Methoxy; --morpholin-4-yl; or

[0071] [ka] represents ); represents; relating to a compound according to any one of embodiments 1) to 6).

[0072] 8) In another aspect, R 1 represents hydroxy; relates to compounds according to any one of embodiments 1) to 6).

[0073] 9) In another aspect, R 1 represents methoxy; relates to compounds according to any one of embodiments 1) to 6).

[0074] 10) Another embodiment is where A is 1,2,3-triazole-1,4-diyl or isoxazole-3,5-diyl (particularly isoxazole-3,5-diyl, especially R2 isoxazole-3,5-diyl or R 2 represents isoxazole-3,5-diyl) attached at the 5-position; relates to a compound according to any one of embodiments 1) to 9).

[0075] 11) Another embodiment is where A is isoxazole-3,5-diyl (particularly R 2 isoxazole-3,5-diyl or R 2 represents isoxazole-3,5-diyl) attached at the 5-position; relates to a compound according to any one of embodiments 1) to 9).

[0076] 12) Another embodiment relates to compounds according to any one of embodiments 1) to 9), in which A represents 4,5-dihydroisoxazole-3,5-diyl.

[0077] 13) In another aspect, R 2 but, - C 1-6 - alkyl (especially tert-butyl); - C 1-6 -Alkyl(C 1-6 -Alkyl has one C 1-3 -Alkoxy (especially methoxy, ethoxy), -CO-C 1-4 -Alkoxy, -NH 2 or -NH-CO-C 1-4 - substituted by alkoxy; - C 1-4 -fluoroalkyl; - C 3-6 -Cycloalkyl(C 3-6 -cycloalkyl is independently unsubstituted or substituted with 1 or 2 substituents, the substituents being oxo, fluoro, -NH-CO-C 1-4 -Alkoxy, C 1-3 -Alkyl (especially methyl), C 1-3 -Alkoxy (especially methoxy), C 1 -Fluoroalkyl, cyano, -CH 2 -CN and -NH-CO-C 1-4 -Alkyl(C1-4 -Alkyl is one -NH 2 or -NH-CO-C 1-4 -substituted by alkoxy; - 4-6 membered heterocycloalkyl, wherein the heterocycloalkyl has one ring oxygen atom and the 4-6 membered heterocycloalkyl is independently unsubstituted or has one C 1-4 - substituted by alkyl (especially methyl or ethyl); - 4-6 membered heterocycloalkyl, which has one ring sulfur atom (especially tetrahydro-2H-thiopyranyl) and the sulfur atom is unsubstituted or substituted by one oxo (=O); or the sulfur atom is substituted by two substituents, one of which is oxo (=O) and the other of which is oxo (=O), imido (=NH), C 1-3 -Alkyl imide (=NC 1-3 -alkyl), 4,4-difluorocyclohexyl imide and benzylimide (=N-benzyl) (i.e., sulfinyl, sulfonyl, sulfonimidoyl, N-alkylsulfonimidoyl Forming an N-(4,4-difluorocyclohexyl)-sulfonimidoyl or N-benzylsulfonimidoyl group. - 4-6 membered heterocycloalkyl having one ring nitrogen atom which is unsubstituted or has one -- C 1-6 -alkyl; -- -CO-C 1-6 -Alkyl; -CO-C 4-6 -Cycloalkyl; -CO-C 1-3 -Fluoroalkyl; -CO-C 1-4 -Alkoxy; -CO-NH-C 1-4 -alkyl; --SO 2 -C 1-4 -alkyl; -- -CH 2 -C 3-6 -cycloalkyl; -- -CO-C1-6 -alkyl (above C 1-6 - alkyl is substituted with one amino; -- -CH 2 -Oxetanyl; -- Thiazol-2-yl; oxazol-2-yl; benzo[d]thiazol-2-yl; ---CO-benzyloxy; -- -CO-NH-C 3-6 -cycloalkyl; -- -CO-NR N31 R N32 (R N31 and R N32 are each independently 1-3 - alkyl (in particular methyl or ethyl); -- -CO-NR N41 R N42 (R N41 and R N42 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl (particularly a pyrrolidinyl, piperidinyl or piperazinyl ring), which 5- or 6-membered heterocycloalkyl is independently unsubstituted or 1-3 - substituted by alkyl (especially methyl); -- -SO-C 1-6 -alkyl; --SO 2 -C 1-3 -fluoroalkyl; --SO 2 -NR N51 R N52 (R N51 and R N52 are each independently 1-3 - alkyl (especially methyl); --SO 2 -NR N61 R N62 (R N61 and R N62together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl (particularly a pyrrolidinyl or piperidinyl or morpholinyl ring), which 5- or 6-membered heterocycloalkyl is independently unsubstituted or substituted by 2 fluoro; --SO 2 -phenyl, which is substituted by one methyl; -- -SO(NH)-C 1-6 -alkyl; or -SO(NC 1-3 -alkyl)-C 1-6 -alkyl; Replaced by; The 4- to 7-membered heterocycloalkyl may bear no further substituents in addition to the substituents on the ring nitrogen atoms, or may be C 1-4 - carrying one further substituent which is alkyl (especially methyl) (this C 1-4 -Alkyl is attached to a ring carbon atom. );-L-OH (L is -- C 1-6 -alkylene; -- Chloro-C 2-6 -alkylene; 1-phenyl-ethane-1,1-diyl or 1-(2-fluorophenyl)-ethane-1,1-diyl; -- (cyclopropyl)-(pyridin-2-yl)-methylene; -- C 4-6 -Cycloalkylene (the C 4-6 -cycloalkylene is independently unsubstituted or substituted with two substituents, the substituents being independently methyl or fluoro; -- Cyclopropylene-(CH 2 ) n - * (n represents an integer of 0 or 1, and the asterisk indicates the bond connecting to the -OH group); -- 4- to 6-membered heterocycloalkylene (the heterocycloalkylene has one ring oxygen ; or -- 4- to 6-membered heterocycloalkylene, the heterocycloalkylene having one ring nitrogen atom, the nitrogen atom being unsubstituted or having one --CO-C 1-4 -Alkyl or -CO-C 1-4 - substituted by alkoxy; represents ); - 5- or 6-membered heteroaryl (especially pyrazolyl, thiazolyl, pyridinyl, pyrimidinyl), which 5- or 6-membered heteroaryl are independently unsubstituted or substituted by one substituent, which substituents are independently selected from the group consisting of C 1-4 -Alkyl (especially methyl), C 1-3 -fluoroalkyl, halogen (especially bromo) or C 1-4 -alkoxy (especially methoxy); - 2-oxo-1,2-dihydropyridin-4-yl, 6-oxo-1,6-dihydropyridin-3-yl or 1-methyl-2-oxo-1,2-dihydropyridin-4-yl;

[0078] [ka] (m and p each independently represent an integer of 1 or 2; R N81 is hydrogen or C 1-4 - alkyl (especially methyl); - C 0-3 -Alkylene-phenyl (especially phenyl or -CH(CH 3 )-phenyl; wherein the phenyl is independently unsubstituted or substituted with 1, 2 or 3 substituents, the substituents being independently selected from the group consisting of: 1-4 -Alkyl, C 1-3 -fluoroalkyl, halogen (especially fluoro or chloro), hydroxy, C 1-4 -alkoxy (especially methoxy) or C 1-4 -fluoroalkoxy (especially difluoromethoxy);

[0079] [ka] (R N91is hydrogen or -CO-C 1-4 -alkoxy (especially -CO-tert-butoxy); represents; - or R 2 However, the structure (R 2-B ) group:

[0080] [ka] (Ring (B) represents a non-aromatic 5-membered ring fused to the phenyl group, Ring (B) has two heteroatoms independently selected from nitrogen and oxygen; Ring (B) is independently substituted with 1 or 2 substituents, one of which is oxo, and the other substituent, if present, is C 1-3 -alkyl (especially methyl); [especially the above groups, (R 2-B ) is 1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl or 2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl. ]; The compound according to any one of the embodiments 1) to 12).

[0081] 14) In another aspect, R 2 but, - C 1-6 - alkyl (especially tert-butyl); - C 1-6 -Alkyl(C 1-6 -Alkyl has one C 1-3 -Alkoxy (especially methoxy, ethoxy), -CO-C 1-4 -Alkoxy, -NH 2 or -NH-CO-C 1-4 - substituted by alkoxy; - C 1-4 -fluoroalkyl; - C 3-6 -Cycloalkyl(C 3-6 -cycloalkyl is independently unsubstituted or substituted with 1 or 2 substituents, the substituents being oxo, fluoro, -NH-CO-C 1-4 -Alkoxy, C1-3 -Alkyl (especially methyl), C 1-3 -Alkoxy (especially methoxy), C 1 -Fluoroalkyl, cyano, -CH 2 -CN and -NH-CO-C 1-4 -Alkyl(C 1-4 -Alkyl is one -NH 2 or -NH-CO-C 1-4 -substituted by alkoxy; - 4-6 membered heterocycloalkyl, wherein the heterocycloalkyl has one ring oxygen atom and the 4-6 membered heterocycloalkyl is independently unsubstituted or has one C 1-4 - substituted by alkyl (especially methyl or ethyl); - 4-6 membered heterocycloalkyl, which has one ring sulfur atom (especially tetrahydro-2H-thiopyranyl) and the sulfur atom is unsubstituted or substituted by one oxo (=O); or the sulfur atom is substituted by two substituents, one of which is oxo (=O) and the other of which is oxo (=O), imido (=NH), C 1-3 -Alkyl imide (=NC 1-3 -alkyl), 4,4-difluorocyclohexylimide and benzylimide (=N-benzyl) (thus forming sulfinyl, sulfonyl, sulfonimidoyl, N-alkylsulfonimidoyl N-(4,4-difluorocyclohexyl)-sulfonimidoyl or N-benzylsulfonimidoyl groups); - 4-6 membered heterocycloalkyl, which has one ring nitrogen atom, which is unsubstituted or has one -- C 1-6 -alkyl; -- -CO-C 1-6 -Alkyl; -CO-C 4-6 -Cycloalkyl; -CO-C 1-3 -Fluoroalkyl; -CO-C 1-4 -Alkoxy; -CO-NH-C 1-4 -alkyl; --SO 2 -C 1-4 -alkyl; -- -CH 2 -C 3-6 -cycloalkyl; -- Thiazol-2-yl; oxazol-2-yl; benzo[d]thiazol-2-yl; ---CO-benzyloxy; -- -CO-NH-C 3-6 -cycloalkyl; -- -CO-NR N31 R N32 (R N31 and R N32 are each independently 1-3 - alkyl (in particular methyl or ethyl); -- -CO-NR N41 R N42 (R N41 and R N42 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl (particularly a pyrrolidinyl, piperidinyl or piperazinyl ring), which 5- or 6-membered heterocycloalkyl is independently unsubstituted or 1-3 - substituted by alkyl (especially methyl); -- -SO-C 1-6 -alkyl; --SO 2 -C 1-3 -fluoroalkyl; --SO 2 -NR N51 R N52 (R N51 and R N52 are each independently 1-3 - alkyl (especially methyl); --SO 2 -NR N61 R N62 (R N61 and R N62together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl (particularly a pyrrolidinyl or piperidinyl or morpholinyl ring), which 5- or 6-membered heterocycloalkyl is independently unsubstituted or substituted by 2 fluoro; --SO 2 -phenyl, which is substituted by one methyl; -- -SO(NH)-C 1-6 -alkyl; or -SO(NC 1-3 -alkyl)-C 1-6 -alkyl; Replaced by; The 4- to 7-membered heterocycloalkyl may bear no further substituents in addition to the substituents on the ring nitrogen atoms, or may be C 1-4 - carrying one further substituent which is alkyl (especially methyl) (this C 1-4 -Alkyl is attached to a ring carbon atom. );-L-OH (L is -- C 1-6 -alkylene; -- Chloro-C 2-6 -alkylene; 1-phenyl-ethane-1,1-diyl or 1-(2-fluorophenyl)-ethane-1,1-diyl; -- C 4-6 -Cycloalkylene (the C 4-6 -cycloalkylene is independently unsubstituted or substituted with two substituents, the substituents being independently methyl or fluoro; -- Cyclopropylene-(CH 2 ) n - * (n represents an integer of 0 or 1, and the asterisk indicates the bond connecting to the -OH group); -- 4- to 6-membered heterocycloalkylene, the heterocycloalkylene having one ring oxygen atom; or -- 4- to 6-membered heterocycloalkylene, the heterocycloalkylene having one ring nitrogen atom, the nitrogen atom being unsubstituted or having one --CO-C 1-4-Alkyl or -CO-C 1-4 - substituted by alkoxy; represents ); - 2-oxo-1,2-dihydropyridin-4-yl, 6-oxo-1,6-dihydropyridin-3-yl or 1-methyl-2-oxo-1,2-dihydropyridin-4-yl;

[0082] [ka] (m and p each independently represent an integer of 1 or 2; R N81 is hydrogen or C 1-4 - alkyl (especially methyl); - -CH(CH 3 )-phenyl);

[0083] [ka] (R N91 is hydrogen or -CO-C 1-4 -alkoxy (especially -CO-tert-butoxy); represents; - or R 2 However, the structure (R 2-B ) group:

[0084] [ka] (Ring (B) represents a non-aromatic 5-membered ring fused to the phenyl group, Ring (B) has two heteroatoms independently selected from nitrogen and oxygen; Ring (B) is independently substituted with 1 or 2 substituents, one of which is oxo, and the other substituent, if present, is C 1-3 -alkyl (especially methyl). 2-B ) is 1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl or 2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl. ]; The compound according to any one of the embodiments 1) to 12).

[0085] 15) In another aspect, R 2 but, - C 1-6 - alkyl (especially tert-butyl); - C 1-6 -Alkyl(C 1-6 -Alkyl has one C 1-3 -Alkoxy (especially methoxy, ethoxy), -CO-C 1-4 -Alkoxy, -NH 2 or -NH-CO-C 1-4 - substituted by alkoxy; - C 1-4 -fluoroalkyl; - C 3-6 -Cycloalkyl(C 3-6 -cycloalkyl is independently unsubstituted or substituted with 1 or 2 substituents, the substituents being oxo, fluoro, -NH-CO-C 1-4 -Alkoxy, C 1-3 -Alkyl (especially methyl), C 1-3 -Alkoxy (especially methoxy), C 1 -fluoroalkyl, cyano and -CH 2 -CN has been selected as an independent will be selected. ); - 4-6 membered heterocycloalkyl, wherein the heterocycloalkyl has one ring oxygen atom and the 4-6 membered heterocycloalkyl is independently unsubstituted or has one C 1-4 - substituted by alkyl (especially methyl or ethyl); - L-OH (L is -- C 1-6 -alkylene; -- C 4-6 -Cycloalkylene (the C 4-6 -cycloalkylene is independently unsubstituted or substituted with two substituents, each of which is independently methyl or fluoro; or -- Cyclopropylene-(CH 2 ) n -* (n represents an integer of 0 or 1, and the asterisk indicates the bond connecting to the -OH group); ); or - -CH(CH 3 )-phenyl); represents; relating to a compound according to any one of embodiments 1) to 12).

[0086] 16) In another aspect, R 2 but, - C 1-6 - alkyl (especially tert-butyl); - C 1-6 -Alkyl(C 1-6 -Alkyl has one C 1-3 - substituted by alkoxy (especially methoxy, ethoxy); - C 1-4 -fluoroalkyl; or - L-OH (L is -- C 1-6 -alkylene; -- C 4-6 -Cycloalkylene (the C 4-6 -cycloalkylene is independently unsubstituted; or -- Cyclopropylene-(CH 2 ) n - * (n represents an integer of 0 or 1, and the asterisk indicates the bond connecting to the -OH group); represents ); represents; relating to a compound according to any one of embodiments 1) to 12).

[0087] 17) In another aspect, R 2 but, - C 1-6 - alkyl (especially tert-butyl); - cyclobutyl or cyclopentyl; - cyclohexyl, substituted by one or two substituents, the substituents being independently oxo, fluoro or -NH-CO-C 1-4 -Alkoxy, cyclohexyl; - 4-6 membered heterocycloalkyl, which has one ring oxygen atom; - 4-7 membered heterocycloalkyl, which has one ring nitrogen atom, which is unsubstituted or has one C 1-6 -Alkyl, -CO-C 1-6 -Alkyl, -CO-C 4-6 -Cycloalkyl, -CO-C 1-3 -Fluoroalkyl, -CO-C 1-4 -Alkoxy, -CO-NH-C 1-4 -Alkyl, -SO 2 -C 1-4 -Alkyl, -SO 2 -NH-C 1-4 -Alkyl, -CH 2 -C 3-6 -Cycloalkyl, -CO-C 1-6 -alkyl (above C 1-6 -Alkyl is substituted with one amino. 2 -substituted by oxetanyl, thiazol-2-yl, oxazol-2-yl or benzo[d]thiazol-2-yl; - L-OH (L is -- C 4-6 -Cycloalkylene (the C 4-6 -cycloalkylene is independently unsubstituted or substituted with 1 or 2 substituents, the substituents being independently methyl or fluoro; -- 4- to 7-membered heterocycloalkylene (the heterocycloalkylene has one ring oxygen ; or -- 4- to 7-membered heterocycloalkylene, the heterocycloalkylene having one ring nitrogen atom, the nitrogen atom being unsubstituted or having one --CO-C 1-4 -Alkyl or -CO-C 1-4 - substituted by alkoxy; represents ); represents; - or R 2 However, the structure (R 2-B ) group:

[0088] [ka] (Ring (B) represents a non-aromatic 5-membered ring fused to the phenyl group, Ring (B) has two heteroatoms independently selected from nitrogen and oxygen; Ring (B) is independently substituted with 1 or 2 substituents, one of which is oxo, and the other substituent, if present, is C 1-3 -alkyl (especially methyl). 2-B ) is 1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl or 2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl. ]; The compound according to any one of the embodiments 1) to 12).

[0089] 18) In another aspect, R 2 but, - tert-butyl; - cyclobutyl or cyclopentyl; - cyclohexyl, substituted by one or two substituents, the substituents being independently oxo, fluoro or -NH-CO-C 1-4 -Alkoxy, cyclohexyl; - 4-6 membered heterocycloalkyl, which has one ring oxygen atom; - 4-7 membered heterocycloalkyl, which has one ring nitrogen atom, which is unsubstituted or has one C 1-6 -Alkyl, -CO-C 1-6 -Alkyl, -CO-C 4-6 -Cycloalkyl, -CO-C 1-3 -Fluoroalkyl, -CO-C 1-4 -Alkoxy, -CO-NH-C 1-4 -Alkyl, -SO 2 -C 1-4 -Alkyl, -CH 2 -C 3-6-cycloalkyl, thiazol-2-yl, oxazol-2-yl or benzo[d]thiazol-2-yl; ;-L-OH, where L is -- C 4-6 -Cycloalkylene (the C 4-6 -cycloalkylene is independently unsubstituted; or -- 4- to 7-membered heterocycloalkylene, the heterocycloalkylene having one ring nitrogen atom, the nitrogen atom being unsubstituted or having one --CO-C 1-4 - substituted by alkoxy; ); or - 2-oxo-1,2-dihydropyridin-4-yl; represents; relating to a compound according to any one of embodiments 1) to 12).

[0090] 19) Another aspect is R 2 C 1-6 -alkyl (in particular tert-butyl); relates to compounds according to any one of embodiments 1) to 12).

[0091] 20) The present invention thus relates to compounds of formula (I) as defined in embodiment 1) or such compounds further defined by the features of any one of embodiments 2) to 19) according to their respective subdivisions; pharma- ceutically acceptable salts thereof; and uses of such compounds as further described below. For the avoidance of any doubt, the following embodiments in particular are possible and contemplated with respect to compounds of formula (I) and are specifically disclosed herein as individual forms: 1、2+1、3+1、4+1、5+1、6+1、7+1、7+2+1、7+3+1、7+4+1、7+5+1、7+6+1、8+1、8+2+1、8+3+1、8+4+1、8+5+1、8+6+1、9+1、9+2+1、9+3+1、9+4+1、9+5+1、9+6+1、10+1、10+2+1、10+3+1、10+4+1、10+5+1、10+6+1、10+7+1、10+7+2+1、10+7+3+1、10+7+4+1、10+7+5+1、10+7+6+1、10+8+1、10+8+2+1、10+8+3+1、10+8+4+1、10+8+5+1、10+8+6+1、10+9+1、10+9+2+1、10+9+3+1、10+9+4+1、10+9+5+1、10+9+6+1、11+1、11+2+1、11+3+1、11+4+1、11+5+1、11+6+1、11+7+1、11+7+2+1、11+7+3+1、11+7+4+1、11+7+5+1、11+7+6+1、11+8+1、11+8+2+1、11+8+3+1、11+8+4+1、11+8+5+1、11+8+6+1、11+9+1、11+9+2+1、11+9+3+1、11+9+4+1、11+9+5+1、11+9+6+1、12+1、12+2+1、12+3+1、12+4+1、12+5+1、12+6+1、12+7+1、12+7+2+1、12+7+3+1、12+7+4+1、12+7+5+1、12+7+6+1、12+8+1、12+8+2+1、12+8+3+1、12+8+4+1、12+8+5+1、12+8+6+1、12+9+1、12+9+2+1、12+9+3+1、12+9+4+1、12+9+5+1、12+9+6+1、13+1、13+2+1、13+3+1、13+4+1、13+5+1、13+6+1、13+7+1、13+7+2+1、13+7+3+1、13+7+4+1、13+7+5+1、13+7+6+1、13+8+1、13+8+2+1、13+8+3+1、13+8+4+1、13+8+5+1、13+8+6+1、13+9+1、13+9+2+1、13+9+3+1、13+9+4+1、13+9+5+1、13+9+6+1、13+10+1、13+10+2+1、13+10+3+1、13+10+4+1、13+10+5+1、13+10+6+1、13+10+7+1、13+10+7+2+1、13+10+7+3+1、13+10+7+4+1、13+10+7+5+1、13+10+7+6+1、13+10+8+1、13+10+8+2+1、13+10+8+3+1、13+10+8+4+1、13+10+8+5+1、13+10+8+6+1、13+10+9+1、13+10+9+2+1、13+10+9+3+1、13+10+9+4+1、13+10+9+5+1、13+10+9+6+1、13+11+1、13+11+2+1、13+11+3+1、13+11+4+1、13+11+5+1、13+11+6+1、13+11+7+1、13+11+7+2+1、13+11+7+3+1、13+11+7+4+1、13+11+7+5+1、13+11+7+6+1、13+11+8+1、13+11+8+2+1、13+11+8+3+1、13+11+8+4+1、13+11+8+5+1、13+11+8+6+1、13+11+9+1、13+11+9+2+1、13+11+9+3+1、13+11+9+4+1、13+11+9+5+1、13+11+9+6+1、13+12+1、13+12+2+1、13+12+3+1、13+12+4+1、13+12+5+1、13+12+6+1、13+12+7+1、13+12+7+2+1、13+12+7+3+1、13+12+7+4+1、13+12+7+5+1、13+12+7+6+1、13+12+8+1、13+12+8+2+1、13+12+8+3+1、13+12+8+4+1、13+12+8+5+1、13+12+8+6+1、13+12+9+1、13+12+9+2+1、13+12+9+3+1、13+12+9+4+1、13+12+9+5+1、13+12+9+6+1、 14+1、14+2+1、14+3+1、14+4+1、14+5+1、14+6+1、14+7+1、14+7+2+1、14+7+3+1、14+7+4+1、14+7+5+1、14+7+6+1、14+8+1、14+8+2+1、14+8+3+1、14+8+4+1、14+8+5+1、14+8+6+1、14+9+1、14+9+2+1、14+9+3+1、14+9+4+1、14+9+5+1、14+9+6+1、14+10+1、14+10+2+1、14+10+3+1、14+10+4+1、14+10+5+1、14+10+6+1、14+10+7+1、14+10+7+2+1、14+10+7+3+1、14+10+7+4+1、14+10+7+5+1、14+10+7+6+1、14+10+8+1、14+10+8+2+1、14+10+8+3+1、14+10+8+4+1、14+10+8+5+1、14+10+8+6+1、14+10+9+1、14+10+9+2+1、14+10+9+3+1、14+10+9+4+1、14+10+9+5+1、14+10+9+6+1、14+11+1、14+11+2+1、14+11+3+1、14+11+4+1、14+11+5+1、14+11+6+1、14+11+7+1、14+11+7+2+1、14+11+7+3+1、14+11+7+4+1、14+11+7+5+1、14+11+7+6+1、14+11+8+1、14+11+8+2+1、14+11+8+3+1、14+11+8+4+1、14+11+8+5+1、14+11+8+6+1、14+11+9+1、14+11+9+2+1、14+11+9+3+1、14+11+9+4+1、14+11+9+5+1、14+11+9+6+1、14+12+1、14+12+2+1、14+12+3+1、14+12+4+1、14+12+5+1、14+12+6+1、14+12+7+1、14+12+7+2+1、14+12+7+3+1、14+12+7+4+1、14+12+7+5+1、14+12+7+6+1、14+12+8+1、14+12+8+2+1、14+12+8+3+1、14+12+8+4+1、14+12+8+5+1、14+12+8+6+1、14+12+9+1、14+12+9+2+1、14+12+9+3+1、14+12+9+4+1、14+12+9+5+1、14+12+9+6+1、15+1、15+2+1、15+3+1、15+4+1、15+5+1、15+6+1、15+7+1、15+7+2+1、15+7+3+1、15+7+4+1、15+7+5+1、15+7+6+1、15+8+1、15+8+2+1、15+8+3+1、15+8+4+1、15+8+5+1、15+8+6+1、15+9+1、15+9+2+1、15+9+3+1、15+9+4+1、15+9+5+1、15+9+6+1、15+10+1、15+10+2+1、15+10+3+1、15+10+4+1、15+10+5+1、15+10+6+1、15+10+7+1、15+10+7+2+1、15+10+7+3+1、15+10+7+4+1、15+10+7+5+1、15+10+7+6+1、15+10+8+1、15+10+8+2+1、15+10+8+3+1、15+10+8+4+1、15+10+8+5+1、15+10+8+6+1、15+10+9+1、15+10+9+2+1、15+10+9+3+1、15+10+9+4+1、15+10+9+5+1、15+10+9+6+1、15+11+1、15+11+2+1、15+11+3+1、15+11+4+1、15+11+5+1、15+11+6+1、15+11+7+1、15+11+7+2+1、15+11+7+3+1、15+11+7+4+1、15+11+7+5+1、15+11+7+6+1、15+11+8+1、15+11+8+2+1、15+11+8+3+1、15+11+8+4+1、15+11+8+5+1、15+11+8+6+1、15+11+9+1、15+11+9+2+1、15+11+9+3+1、15+11+9+4+1、15+11+9+5+1、15+11+9+6+1、15+12+1、15+12+2+1、15+12+3+1、15+12+4+1、15+12+5+1、15+12+6+1、15+12+7+1、15+12+7+2+1、15+12+7+3+1、15+12+7+4+1、15+12+7+5+1、15+12+7+6+1、15+12+8+1、15+12+8+2+1、15+12+8+3+1、15+12+8+4+1、15+12+8+5+1、15+12+8+6+1、15+12+9+1、15+12+9+2+1、15+12+9+3+1、15+12+9+4+1、15+12+9+5+1、15+12+9+6+1、16+1、16+2+1、16+3+1、16+4+1、16+5+1、16+6+1、16+7+1、16+7+2+1、16+7+3+1、16+7+4+1、16+7+5+1、16+7+6+1、16+8+1、16+8+2+1、16+8+3+1、16+8+4+1、16+8+5+1、16+8+6+1、16+9+1、16+9+2+1、16+9+3+1、16+9+4+1、16+9+5+1、16+9+6+1、16+10+1、16+10+2+1、16+10+3+1、16+10+4+1、16+10+5+1、16+10+6+1、16+10+7+1、16+10+7+2+1、16+10+7+3+1、16+10+7+4+1、16+10+7+5+1、16+10+7+6+1、16+10+8+1、16+10+8+2+1、16+10+8+3+1、16+10+8+4+1、16+10+8+5+1、16+10+8+6+1、16+10+9+1、16+10+9+2+1、16+10+9+3+1、16+10+9+4+1、16+10+9+5+1、16+10+9+6+1、16+11+1、16+11+2+1、16+11+3+1、16+11+4+1、16+11+5+1、16+11+6+1、16+11+7+1、16+11+7+2+1、16+11+7+3+1、16+11+7+4+1、16+11+7+5+1、16+11+7+6+1、16+11+8+1、16+11+8+2+1、16+11+8+3+1、16+11+8+4+1、16+11+8+5+1、16+11+8+6+1、16+11+9+1、16+11+9+2+1、16+11+9+3+1、16+11+9+4+1、16+11+9+5+1、16+11+9+6+1、16+12+1、16+12+2+1、16+12+3+1、16+12+4+1、16+12+5+1、16+12+6+1、16+12+7+1、16+12+7+2+1、16+12+7+3+1、16+12+7+4+1、16+12+7+5+1、16+12+7+6+1、16+12+8+1、16+12+8+2+1、16+12+8+3+1、16+12+8+4+1、16+12+8+5+1、16+12+8+6+1、16+12+9+1、16+12+9+2+1、16+12+9+3+1、16+12+9+4+1、16+12+9+5+1、16+12+9+6+1、17+1、17+2+1、17+3+1、17+4+1、17+5+1、17+6+1、17+7+1、17+7+2+1、17+7+3+1、17+7+4+1、17+7+5+1、17+7+6+1、17+8+1、17+8+2+1、17+8+3+1、17+8+4+1、17+8+5+1、17+8+6+1、17+9+1、17+9+2+1、17+9+3+1、17+9+4+1、17+9+5+1、17+9+6+1、17+10+1、17+10+2+1、17+10+3+1、17+10+4+1、17+10+5+1、17+10+6+1、17+10+7+1、17+10+7+2+1、17+10+7+3+1、17+10+7+4+1、17+10+7+5+1、17+10+7+6+1、17+10+8+1、17+10+8+2+1、17+10+8+3+1、17+10+8+4+1、17+10+8+5+1、17+10+8+6+1、17+10+9+1、17+10+9+2+1、17+10+9+3+1、17+10+9+4+1、17+10+9+5+1、17+10+9+6+1、17+11+1、17+11+2+1、17+11+3+1、17+11+4+1、17+11+5+1、17+11+6+1、17+11+7+1、17+11+7+2+1、17+11+7+3+1、17+11+7+4+1、17+11+7+5+1、17+11+7+6+1、17+11+8+1、17+11+8+2+1、17+11+8+3+1、17+11+8+4+1、17+11+8+5+1、17+11+8+6+1、17+11+9+1、17+11+9+2+1、17+11+9+3+1、17+11+9+4+1、17+11+9+5+1、17+11+9+6+1、17+12+1、17+12+2+1、17+12+3+1、17+12+4+1、17+12+5+1、17+12+6+1、17+12+7+1、17+12+7+2+1、17+12+7+3+1、17+12+7+4+1、17+12+7+5+1、17+12+7+6+1、17+12+8+1、17+12+8+2+1、17+12+8+3+1、17+12+8+4+1、17+12+8+5+1、17+12+8+6+1、17+12+9+1、17+12+9+2+1、17+12+9+3+1、17+12+9+4+1、17+12+9+5+1、17+12+9+6+1、18+1、18+2+1、18+3+1、18+4+1、18+5+1、18+6+1、18+7+1、18+7+2+1、18+7+3+1、18+7+4+1、18+7+5+1、18+7+6+1、18+8+1、18+8+2+1、18+8+3+1、18+8+4+1、18+8+5+1、18+8+6+1、18+9+1、18+9+2+1、18+9+3+1、18+9+4+1、18+9+5+1、18+9+6+1、18+10+1、18+10+2+1、18+10+3+1、18+10+4+1、18+10+5+1、18+10+6+1、18+10+7+1、18+10+7+2+1、18+10+7+3+1、18+10+7+4+1、18+10+7+5+1、18+10+7+6+1、18+10+8+1、18+10+8+2+1、18+10+8+3+1、18+10+8+4+1、18+10+8+5+1、18+10+8+6+1、18+10+9+1、18+10+9+2+1、18+10+9+3+1、18+10+9+4+1、18+10+9+5+1、18+10+9+6+1、18+11+1、18+11+2+1、18+11+3+1、18+11+4+1、18+11+5+1、18+11+6+1、18+11+7+1、18+11+7+2+1、18+11+7+3+1、18+11+7+4+1、18+11+7+5+1、18+11+7+6+1、18+11+8+1、18+11+8+2+1、18+11+8+3+1、18+11+8+4+1、18+11+8+5+1、18+11+8+6+1、18+11+9+1、18+11+9+2+1、18+11+9+3+1、18+11+9+4+1、18+11+9+5+1、18+11+9+6+1、18+12+1、18+12+2+1、18+12+3+1、18+12+4+1、18+12+5+1、18+12+6+1、18+12+7+1、18+12+7+2+1、18+12+7+3+1、18+12+7+4+1、18+12+7+5+1、18+12+7+6+1、18+12+8+1、18+12+8+2+1、18+12+8+3+1、18+12+8+4+1、18+12+8+5+1、18+12+8+6+1、18+12+9+1、18+12+9+2+1、18+12+9+3+1、18+12+9+4+1、18+12+9+5+1、18+12+9+6+1、19+1、19+2+1、19+3+1、19+4+1、19+5+1、19+6+1、19+7+1、19+7+2+1、19+7+3+1、19+7+4+1、19+7+5+1、19+7+6+1、19+8+1、19+8+2+1、19+8+3+1、19+8+4+1、19+8+5+1、19+8+6+1、19+9+1、19+9+2+1、19+9+3+1、19+9+4+1、19+9+5+1、19+9+6+1、19+10+1、19+10+2+1、19+10+3+1、19+10+4+1、19+10+5+1、19+10+6+1、19+10+7+1、19+10+7+2+1、19+10+7+3+1、19+10+7+4+1、19+10+7+5+1、19+10+7+6+1、19+10+8+1、19+10+8+2+1、19+10+8+3+1、19+10+8+4+1、19+10+8+5+1、19+10+8+6+1、19+10+9+1、19+10+9+2+1、19+10+9+3+1、19+10+9+4+1、19+10+9+5+1、19+10+9+6+1、19+11+1、19+11+2+1、19+11+3+1、19+11+4+1、19+11+5+1、19+11+6+1、19+11+7+1、19+11+7+2+1、19+11+7+3+1、19+11+7+4+1、19+11+7+5+1、19+11+7+6+1、19+11+8+1、19+11+8+2+1、19+11+8+3+1、19+11+8+4+1、19+11+8+5+1、19+11+8+6+1、19+11+9+1、19+11+9+2+1、19+11+9+3+1、19+11+9+4+1、19+11+9+5+1、19+11+9+6+1、19+12+1、19+12+2+1、19+12+3+1、19+12+4+1、19+12+5+1、19+12+6+1、19+12+7+1、19+12+7+2+1、19+12+7+3+1、19+12+7+4+1、19+12+7+5+1、19+12+7+6+1、19+12+8+1、19+12+8+2+1、19+12+8+3+1、19+12+8+4+1、19+12+8+5+1、19+12+8+6+1、19+12+9+1、19+12+9+2+1、19+12+9+3+1、19+12+9+4+1、19+12+9+5+1、19+12+9+6+1。、

[0092] In the above list, the numbers refer to the embodiments according to the above numbers, and "+" indicates a dependency from another embodiment. The various embodiments are individually separated by commas. In other words, for example, "14+10+6+1" means embodiment 14) which is dependent on embodiment 10) which is dependent on embodiment 6) which is dependent on embodiment 1), i.e. embodiment "14+10+6+1" corresponds to a compound of formula (I) according to embodiment 1) further limited by all the features of embodiments 6), 10) and 14).

[0093] 21) Another aspect of the present invention is a compound represented by the formula (I P ) which is also a compound of formula (I) according to embodiment 1):

[0094] [ka] (In the formula, Ar 1 represents aryl substituted with 1, 2, 3 or 4 substituents, said substituents being independently selected from halogen, methyl, cyano and methoxy; [In particular, at least one of the substituents is attached at the meta or para position of the phenyl; if a para substituent is present, said para substituent is preferably selected from halogen, methyl, cyano and methoxy; if a meta substituent is present, said meta substituent is preferably halogen.]; R 1 is hydroxy, C 1-4 -Alkoxy, -O-CO-C 1-3 -Alkyl or -O-CH 2 -COOH; A represents a 5-membered heterocycloalkylene or a 5-membered heteroarylene; the heterocycloalkylene or heteroarylene is 1H-1,2,3-triazole-1,4-diyl, isoxazole-3,5-diyl, or 4,5-dihydroisoxazole-3,5-diyl; R 2 teeth, - C 1-6- alkyl (especially tert-butyl); - C 3-6 -Cycloalkyl(C 3-6 -cycloalkyl is independently unsubstituted or substituted with 1 or 2 substituents, the substituents being independently oxo, fluoro or -NH-CO-C 1-4 -alkoxy; or 3-6 -Cycloalkyl forms a spiro-compound together with 1,3-dioxolane-2,2-diyl; - 4-6 membered heterocycloalkyl, which has one ring oxygen atom; - 4-7 membered heterocycloalkyl, which has one ring nitrogen atom, which is unsubstituted or has one C 1-6 -Alkyl, -CO-C 1-6 -Alkyl, -CO-C 4-6 -Cycloalkyl, -CO-C 1-3 -Fluoroalkyl, -CO-C 1-4 -Alkoxy, -CO-NH-C 1-4 -Alkyl, -SO 2 -C 1-4 -Alkyl, -SO 2 -NH-C 1-4 -Alkyl, -CH 2 -C 3-6 -Cycloalkyl, -CO-C 1-6 -alkyl (above C 1-6 -Alkyl is bound to one amino group substituted.), -CH 2 -substituted by oxetanyl, thiazol-2-yl, oxazol-2-yl or benzo[d]thiazol-2-yl; - L-OH (L is -- C 1-6 -alkylene; -- C 4-6 -Cycloalkylene (the C 4-6 -cycloalkylene is independently unsubstituted or substituted with 1 or 2 substituents, the substituents being independently methyl, fluoro or -CO-R O2 (R O2is hydroxy or C 1-4 -alkoxy.) ); -- 4- to 7-membered heterocycloalkylene, the heterocycloalkylene having one ring oxygen atom; -- 4- to 7-membered heterocycloalkylene, the heterocycloalkylene having one ring nitrogen atom, the nitrogen atom being unsubstituted or having one --CO-C 1-4 -Alkyl or -CO-C 1-4 - substituted by alkoxy; represents ); - 5- or 6-membered heteroaryl (in particular 1H-pyrazolyl, thiazolyl, pyridinyl, pyrimidinyl), wherein the 5- or 6-membered heteroaryl is independently unsubstituted or substituted by one substituent, the substituent being independently selected from the group consisting of C 1-4 -Alkyl (especially methyl), C 1-3 -Fluoroalkyl, halogen, C 1-4 -alkoxy (especially methoxy) or C 1-4 -fluoroalkoxy; - 2-oxo-1,2-dihydropyridin-4-yl; - phenyl, substituted by 1 or 2 substituents, said substituents being independently selected from the group consisting of: 1-4 -Alkyl, C 1-3 -Fluoroalkyl, halogen, hydroxy, C 1-4 -alkoxy (especially methoxy) or C 1-4 -fluoroalkoxy, phenyl; - Benzyl; - 9-membered heteroaryl (especially indazolyl and 1H-benzo[d]imidazolyl); represents; - or R 2 is the structure (R 2-B ) group:

[0095] [ka] (Ring (B) represents a non-aromatic 5-membered ring fused to the phenyl group, Ring (B) has two heteroatoms independently selected from nitrogen and oxygen; Ring (B) is independently substituted with 1 or 2 substituents, one of which is oxo, and the other substituent, if present, is C 1-3 - alkyl (especially methyl); [In particular, the above groups, (R 2-B ) is 1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl or 2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl]. ); The features disclosed in embodiments 2) to 20) can be, mutatis mutandis, combined with the formula (I P ) is also intended to apply to compounds of

[0096] 22) Another embodiment relates to compounds of formula (I) according to embodiment 1), which are selected from the following compounds: 6-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)benzo[d]oxazol-2(3H)-one; 6-((RS)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)benzo[d]oxazol-2(3H)-one; 6-((S)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)benzo[d]oxazol-2(3H)-one; tert-Butyl 4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-3-acetoxy-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((S)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-3-acetoxy-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate;(2R,3R,4R,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)- (fluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; tert-Butyl (RS)-3-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; tert-Butyl 4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-4-hydroxypiperidine-1-carboxylate; tert-Butyl 4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidine-1-carboxylate;(2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclopentylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-hydroxycyclohexyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclobutylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(4,4-difluorocyclohexyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-butyl ((1R,4R)-4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclohexyl)carbamate; tert-Butyl ((1S,4S)-4-(3-(((2R,3R,4R,5R,6R )-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclohexyl)carbamate; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((5-(1-(oxazol-2-yl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-2-((5-(1-(benzo[d]thiazol-2-yl)piperidin-4-yl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((5-(1-(thiazol-2-yl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; 5-((RS)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one; 4-((S)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one; 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one; 4-((S)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one; 4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclohexan-1-one; (2R,3R,4R,5R,6R)-2-((5-(4-hydroxycyclohexyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-2-((5-((1R,4R)-4-hydroxycyclohexyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(propionyloxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxamide Boxylate; (2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl propionate; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-3-ethoxy-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate;(2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl propionate; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-propoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; 2-(((2R,3R,4S,5R,6R)-2-((5-(1-(tert-butoxycarbonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(isobutyryloxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-(((RS)-3-(piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; 1-(4-((RS)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidin-1-yl)ethan-1-one; 1-(4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidin-1-yl)ethan-1-one; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-(((S)-3-(piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; 1-(4-((S)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidin-1-yl)ethan-1-one; 1-(4-((S)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidin-1-yl)ethan-1-one; (2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl acetate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 1-(4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-((RS)-3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-((S)-3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; (2R,3R,4S,5R,6R)-2-((5-(1-acetylpiperidin-4-yl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl acetate; (2R,3R,4S,5R,6R)-2-(((RS)-5-(1-acetylpiperidin-4-yl)-4,5-dihydroisoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl acetate; (2R,3R,4S,5R,6R)-2-(((S)-5-(1-acetylpiperidin-4-yl)-4,5-dihydroisoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl acetate; Ethyl 4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; 4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-N-ethylpiperidine-1-carboxamide; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((5-(1-methylpiperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; 1-(4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)-2,2-dimethylpropan-1-one; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Methyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; 1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)-2-methylpropan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)-2,2-dimethylpropan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)butan-1-one; N-ethyl-4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxamide; 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl) Isoxazol-5-yl)-N-isopropylpiperidine-1-carboxamide; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-methylpiperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((5-(1-isobutylpiperidin-4-yl)isoxazol-3-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-(3,3-dimethylbutyl)piperidin-4-yl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-(cyclopropylmethyl)piperidin-4-yl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(propylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((5-(1-(isopropylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)-3-methylbutan-1-one; Cyclopentyl(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)methanone; Cyclobutyl(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)methanone; 3,3,3-trifluoro-1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)propan-1-one; N-(tert-butyl)-4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H- Pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxamide; (RS)-1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)-2-methylbutan-1-one; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((1-(tetrahydro-2H-pyran-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 1-(4-(1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)piperidin-1-yl)ethan-1-one; tert-Butyl 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate; 1-(4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidin-1-yl)ethan-1-one; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((1-(1-(methylsulfonyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; N-(tert-butyl)-4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxamide; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((1-(1-(propylsulfonyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; and (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((1-(1-(isopropylsulfonyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol.

[0097] 23) In addition to the compounds described in embodiment 22), further compounds according to embodiment 1) are selected from the following compounds: tert-Butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazole -1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(3,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(3,4-difluoro-5-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(4-chloro-3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; (RS)-5-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidin-2-one; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-1-methylpyridin-2(1H)-one; (2R,3R,4S,5R,6R)-6-((3-cyclohexylisoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate;tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; tert-Butyl 4-(5-(((2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy -6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-(5-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidine-1-carboxylate;tert-Butyl 4-(5-(((2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidine-1-carboxylate;tert-Butyl 4-(5-(((2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-6-((5-(4-bromothiazol-2-yl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-(((S)-5-cyclohexyl-4,5-dihydroisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-Butyl (4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)bicyclo[2.2.2]octan-1-yl)carbamate; (2R,3R,4S,5R,6R)-6-((5-(4-aminobicyclo[2.2.2]octan-1-yl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol formate; tert-Butyl 4-hydroxy-4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-4-ol formate; tert-Butyl ((1R,4r)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclohexyl)carbamate; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl) Piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-((S)-1-(N-methylpropan-2-ylsulfonimidoyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-((R)-1-(N-methylpropan-2-ylsulfonimidoyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-(((RS)-3-(piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol formate; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-(((RS)-3-(piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol formate;tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-(((RS)-3-(piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol formate; (1R,4r)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-1-(isopropylimino)hexahydro-1l6-thiopyran 1-oxide; (1S,4s)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-1-(isopropylimino)hexahydro-1l6-thiopyran 1-oxide; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-trifluorophenyl) riazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5- Hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one;1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5- Hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one;1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl) nyl)-1H-1,2,3-triazol-1-yl)-6-((5-cyclohexylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclohexylisoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy Tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((5-(1-(N-isopropylpropan-2-ylsulfonimidoyl)piperidin-4-yl)isoxazol-3-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate; (2R,3R,4R,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; Ethyl 3-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-3-methylbutanoate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methoxycyclopentyl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methoxycyclohexyl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(3-methyloxetan-3-yl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(3-ethyloxetan-3-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-fluorocyclopropyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-(difluoromethyl)cyclopropyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(2-aminopropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4- (4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one;Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-cyclopentylisoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclobutylisoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclobutylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-cyclobutylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((5-(2-hydroxypropan-2-yl)isoxazol-3-yl)methyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-hydroxycyclohexyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-hydroxycyclopentyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclopentylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-hydroxycyclobutyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((5-(2-hydroxypropan-2-yl)isoxazol-3-yl)methyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclohexyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclopentyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclopentylisoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclobutyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((5-(2-hydroxypropan-2-yl)isoxazol-3-yl)methyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclohexyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclopentyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-cyclopentylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclobutyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy -6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(3-methyloxetan-3-yl)isoxazol-5-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(3-methyloxetan-3-yl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(3-methyloxetan-3-yl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-chloro-3-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-chloro-3-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol;(2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1- Chloro-3-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol;(2R,3R,4S,5R,6R)-6-(((RS)-3-(tert-butyl)-4,5-dihydroisoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-(((RS)-3-(tert-butyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; 4-(1-((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-4-yl)-1H-1,2,3-triazol-4-yl)-2,3-difluorobenzonitrile; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-methylcyclopentyl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-methylcyclopentyl)isoxazol-3-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5 -Methoxy-6-((5-(1-methylcyclopentyl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-methylcyclopentyl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; 1-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclopentane-1-carbonitrile; 1-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclopentane-1-carbonitrile; 1-(3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclopentane-1-carbonitrile; 1-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclopentane-1-carbonitrile; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-(((RS)-3-(1-hydroxy-2-methylpropan-2-yl)-4,5-dihydroisoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-5-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopentyl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopentyl)isoxazol-5-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl ) tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopentyl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopentyl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; 1-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclopentane-1-carbonitrile; 1-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclopentane-1-carbonitrile; 1-(5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclopentane-1-carbonitrile; 1-(5-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclopentane-1-carbonitrile; (2R,3R,4R,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4S,5R,6R)-6-((3-(1,1-difluoro-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((3-isopropylisoxazol-5-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-hydroxycyclopentyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 2-(1-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclopropyl)acetonitrile; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methoxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-Butyl (2-(5-(((2R,3R,4S,5R,6R)-5-hydroxy si-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-2-methylpropyl)carbamate; (2R,3R,4S,5R,6R)-6-((3-(1-amino-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((RS)-1-hydroxy-1-phenylethyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclopropyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(3-methyloxetan-3-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((5-(1-(hydroxymethyl)cyclopropyl)isoxazol-3-yl)methyl)-5-methoxytetrahydro-2H-pyran-3-ol; Ethyl 4-(5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-4-methylpiperidine-1-carboxylate; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxycyclopentyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(2-ethoxypropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methoxy-2-methylpropan-2-yl)isoxazol-2-yl) (5-phenyl-5-yl)methyl)tetrahydro-2H-pyran-3-ol; tert-Butyl (2-(5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-2-methylpropyl)carbamate; 2-(1-(5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclopropyl)acetonitrile; (2R,3R,4R,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((3-(3-methyloxetan-3-yl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4S,5R,6R)-6-((3-(1-amino-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (RS)-5-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)azepan-2-one; 4-(1-((2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-4-yl)-1H-1,2,3-triazol-4-yl)-2,3-difluorobenzonitrile; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((R)-1-hydroxy-1-phenylethyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; 5-(((4aR,6R,7R,8R,8aR)-8-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)-3-((RS)-1-phenylethyl)isoxazole; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((1RS,2RS)-2-hydroxycyclobutyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-((5-((1RS,2RS)-2-hydroxycyclopentyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate to; (RS)-5-(5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-1-methylazepan-2-one; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((1S,2S)-2-hydroxycyclobutyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((1R,2R)-2-hydroxycyclobutyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (RS)-5-(5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)azepan-2-one; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((1S,2R)-2-hydroxycyclopropyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((1R,2R)-2-hydroxycyclopropyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (RS)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-1-methylpiperidin-2-one; (RS)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidin-2-one; (RS)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)pyrrolidin-2-one; tert-Butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(4-chloro-2,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-isopropoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-3-(2,2-difluoroethoxy)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-5-(2,2-difluoroethoxy)-2-(hydroxymethyl)-6-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-morpholinoethan-1-one; tert-Butyl ((S)-1-(((1R,4S)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclohexyl)amino)-3-methyl-1-oxobutan-2-yl ) carbamate;(S)-2-amino-N-((1R,4S)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclohexyl)-3-methylbutanamide; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-3-ethoxy-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; 2-(((2R,3R,4S,5R,6R)-2-(((RS)-3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(2-(methylamino)-2-oxoeto oxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(2-morpholino-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; 2-(((2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-N-methylacetamide; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-((R)-3-hydroxypyrrolidin-1-yl)ethan-1-one; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-(3-hydroxyazetidin-1-yl)ethan-1-one; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-(4-hydroxypiperidin-1-yl)ethan-1-one; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-((S)-3-hydroxypyrrolidin-1-yl)ethan-1-one; 2-(((2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; 2-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; (2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl carbamate; 2-(((2R,3R,4S,5R,6R)-5-hydroxy-2-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-6- (hydroxymethyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(4-ethynyl-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4R,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-6-(hydroxymethyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl ethylcarbamate; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-((1-methyl-1H-imidazol-2-yl)methoxy)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-(thiazol-2-ylmethoxy)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-(thiazol-4-ylmethoxy)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-(oxazol-5-ylmethoxy)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxycyclobutyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxycyclobutyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxy Cyclobutyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((3-(2-hydroxypropan-2-yl)isoxazol-5-yl)methyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((3-(2-hydroxypropan-2-yl)isoxazol-5-yl)methyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((3-(2-hydroxypropan-2-yl)isoxazol-5-yl)methyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-((S)-tert-butylsulfinyl)piperidin-4-yl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(2-methylpropan-2-ylsulfonimidoyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(N-methylpropan-2-ylsulfonimidoyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-N,N-dimethylpiperidine-1-sulfonamide; N-cyclopropyl-4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxamide;(2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-(((S)-3-(1-(isopropylsulfonyl)piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(morpholinosulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(piperidin-1-ylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(pyrrolidin-1-ylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-((4,4-difluoropiperidin-1-yl)sulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)(piperidin-1-yl)methanone; (4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)(pyrrolidin-1-yl)methanone; N-ethyl-4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-N-methylpiperidine-1-carboxamide; 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-N,N-dimethylpiperidine-1-carboxamide; (4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)(4-methylpiperazin-1-yl)methanone; benzyl 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((1-(tetrahydro-2H-thiopyran-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-thiopyran 1-oxide; 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl) -1H-1,2,3-triazol-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide; 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-iminohexahydro-11-6-thiopyran 1-oxide; 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-(methylimino)hexahydro-116-thiopyran 1-oxide; (2R,3R,4S,5R,6R)-6-((1-(1-((S)-tert-butylsulfinyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; benzyl 4-(1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((1-(1-(2-methylpropan-2-ylsulfonimidoyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((4-(1-(isopropylsulfonyl)piperidin-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((4-(1-tosylpiperidin-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 1-(Ethylimino)-4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)hexahydro-11-6-thiopyran 1-oxide; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((4-(1-(N-methylpropan-2-ylsulfonimidoyl)piperidin-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 4-(1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)-N,N-dimethylpiperidine-1-sulfonyl Sulfonamide; N-(tert-butyl)-4-(1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxamide; 1-(Benzylimino)-4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)hexahydro-1l6-thiopyran 1-oxide; (2R,3R,4S,5R,6R)-6-((1-cyclohexyl-1H-1,2,3-triazol-4-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-(isopropylimino)hexahydro-11-6-thiopyran 1-oxide; N-cyclopropyl-4-(1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxamide; 1-((4,4-difluorocyclohexyl)imino)-4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)hexahydro-11-6-thiopyran 1-oxide; benzyl 4-(4-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate; benzyl 4-(4-(((2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate; benzyl 4-(4-(((2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate; benzyl 4-(4-(((2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-6-((4-(tert-butyl)-1H-1,2 ,3-triazol-1-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; Ethyl 4-(1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((4-(tetrahydro-2H-pyran-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((4-(2-hydroxypropan-2-yl)-1H-1,2,3-triazol-1-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((4-cyclopentyl-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((4-(1-methylcyclopentyl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((4-(4-methyltetrahydro-2H-pyran-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((4-(tert-butyl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((4-(tert-butyl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(4-chloro-2,3-difluoro (1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (RS)-3-(1-acetylpiperidin-4-yl)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)oxazolidin-2-one; (RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-(methylsulfonyl)piperidin-4-yl)oxazolidin-2-one; (S)-3-(1-acetylpiperidin-4-yl)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)oxazolidin-2-one; (S)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-(methylsulfonyl)piperidin-4-yl)oxazolidin-2-one; (R)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-(methylsulfonyl)piperidin-4-yl)oxazolidin-2-one; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidin-3-yl)piperidine-1-carboxylate; (RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-isobutyrylpiperidin-4-yl)oxazolidin-2-one; 4-((RS)_5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidin-3-yl)-N,N-dimethylpiperidine-1-carboxamide; (S)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-isobutyrylpiperidin-4-yl)oxazolidin-2-one; tert-Butyl 4-((R)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidin-3-yl)piperidine-1-carboxylate; (RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H -1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(tetrahydro-2H-pyran-4-yl)oxazolidin-2-one; (RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-(isobutylsulfonyl)piperidin-4-yl)oxazolidin-2-one; (RS)-3-(1-(3,3-dimethylbutanoyl)piperidin-4-yl)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)oxazolidin-2-one; (RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)oxazolidin-2-one; (RS)-3-(1-(tert-butylsulfonyl)piperidin-4-yl)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)oxazolidin-2-one; (RS)-3-cyclohexyl-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)oxazolidin-2-one; tert-Butyl 4-((RS)-3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidin-5-yl)piperidine-1-carboxylate; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isothiazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(piperidin-4-yl)isothiazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((4-(tert-butyl)-1H-imidazol-1-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-phenyloxazol-2(3H)-one; 3-Cyclohexyl-1-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran -2-yl)methyl)imidazolidin-4-one; 1-(1-acetylpiperidin-4-yl)-3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)imidazolidin-4-one; 3-(1-acetylpiperidin-4-yl)-1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)imidazolidin-4-one; 3-Cyclohexyl-1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)imidazolidin-4-one; 1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(tetrahydro-2H-pyran-4-yl)imidazolidin-4-one; and Ethyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-5-oxoimidazolidin-1-yl)piperidine-1-carboxylate.

[0098] The compounds of formula (I) according to embodiments 1) to 23) and their pharma- ceutically acceptable salts can be used as medicaments, for example in the form of pharmaceutical compositions for enteral (such as, in particular orally, for example in the form of tablets or capsules) or parenteral (including topical application or inhalation) administration.

[0099] The preparation of pharmaceutical compositions can be carried out in a manner well known to any person skilled in the art (see, for example, Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams & Wilkins]) by combining the above-mentioned compounds of formula (I) or pharma- ceutical acceptable salts thereof, optionally with other therapeutically valuable substances, with suitable non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if necessary, with conventional pharmaceutical adjuvants, to form a pharmaceutical dosage form.

[0100] The present invention also relates to a method for the prevention or treatment of a disease or disorder described herein, comprising administering to a subject a pharma- ceutically effective amount of a compound of formula (I) according to embodiments 1) to 23). In a subembodiment of the invention, the dosage is comprised between 1 mg and 1000 mg per day.

[0101] For the avoidance of any doubt, where a compound is described as being useful for the prevention or treatment of a disease, such compound is also suitable for use in the manufacture of a medicament for the prevention or treatment of that disease.Similarly, such compound is also suitable in a method for the prevention or treatment of such disease, comprising administering an effective amount of such compound to a subject (mammal, particularly a human) in need thereof.

[0102] 24) Another embodiment relates to compounds of formula (I) as defined in any one of embodiments 1) to 23), useful for the prevention or treatment of diseases and disorders in which the binding of galectin-3 to its natural ligand is involved.

[0103] Such diseases and disorders involving binding of Gal-3 to its natural ligands are particularly These include diseases and disorders in which inhibition of the biological activity of Gal-3 is beneficial, such as diseases in which the Gal-3 receptor is involved and is implicated in the etiology or pathology of the disease, or is otherwise implicated in at least one symptom of the disease.

[0104] Diseases and disorders in which the binding of galectin-3 to its natural ligands is implicated may be defined as including, in particular: - fibrosis of an organ: -- all forms of fibrotic interstitial lung disease, including in particular idiopathic pulmonary fibrosis (also known as cryptogenic fibrosing alveolitis); pulmonary fibrosis secondary to systemic inflammatory diseases such as rheumatoid arthritis, scleroderma (systemic sclerosis, SSc), lupus (systemic lupus erythematosus, SLE), polymyositis or mixed connective tissue disease (MCTD); pulmonary fibrosis secondary to sarcoidosis; iatrogenic pulmonary fibrosis, including radiation-induced fibrosis; silicosis-induced pulmonary fibrosis; asbestos-induced pulmonary fibrosis; and pleural fibrosis; -- renal / kidney fibrosis, including chronic kidney disease (CKD), renal failure (acute or chronic), tubulointerstitial nephritis and / or chronic nephropathy such as (primary) glomerulonephritis and glomerulonephritis secondary to systemic inflammatory diseases such as SLE and SSc, diabetes, focal segmental glomerulosclerosis, IgA nephropathy, hypertension, renal transplantation and renal fibrosis due to / associated with Alport syndrome; -- all forms of liver / hepatic fibrosis (whether or not associated with portal hypertension), including cirrhosis, alcohol-induced liver fibrosis, non-alcoholic steatohepatitis, bile duct injury, primary biliary cirrhosis (also known as primary biliary cholangitis), infectious or virally induced liver fibrosis (e.g. chronic HCV infection) and autoimmune hepatitis; -- Cardiovascular disease, heart failure, Fabry disease, CKD; all forms of heart / cardiac fibrosis, including cardiac fibrosis associated with diabetes, hypertension or hypercholesterolemia; --gut fibrosis, including gastrointestinal fibrosis secondary to SSc and radiation-induced gastrointestinal fibrosis; -- Skin fibrosis, including SSc and skin scarring; --Head and neck fibrosis, including radiation-induced head and neck fibrosis; -- ocular / corneal fibrosis, including scarring (e.g., sequelae of laser-assisted in situ keratomileusis or trabeculectomy); -- Hypertrophic scars and keloids, including burn-induced or surgical hypertrophic scars and keloids; -- fibrotic sequelae of organ transplants (including corneal transplants); -- and other fibrotic diseases, including endometriosis, spinal fibrosis, myelofibrosis, perivascular and arterial fibrosis; as well as scar tissue formation, Peyronie's disease, abdominal or intestinal adhesions, bladder fibrosis, nasal fibrosis and fibrosis mediated by fibroblasts; fibrosis of organs, including; - (acute or chronic) liver diseases and disorders (acute and chronic viral hepatitis; cirrhosis due to / associated with arthritis and vasculitis; metabolic liver diseases due to / associated with arthritis, myocarditis, diabetes or neurological conditions; cholestatic diseases due to / associated with hyperlipidemia, inflammatory bowel disease (IBD) or ulcerative colitis; liver tumors; autoimmune hepatitis and cirrhosis due to / associated with celiac disease, autoimmune hemolytic anemia, IBD, autoimmune thyroiditis, ulcerative colitis, diabetes, glomerulonephritis, pericarditis, autoimmune thyroiditis, hyperthyroidism, polymyositis, Sjögren's syndrome, panniculitis, alveolitis or alcoholic steatosis; cirrhosis associated with dementia; cirrhosis associated with peripheral neuropathy; cirrhosis due to / associated with oral or esophageal cancer; cirrhosis due to / associated with obesity, metabolic syndrome or type 2 diabetes Non-alcoholic fatty liver disease (particularly non-alcoholic steatohepatitis); hepatic vascular disorders (including Budd-Chiari syndrome, portal vein thrombosis, sinusoidal obstruction syndrome); acute and chronic liver failure (with or without associated portal hypertension); hepatic insufficiency; - acute kidney injury and chronic kidney disease (CKD) caused by / associated with heart disease (also called cardiorenal syndrome types 1 and 2), or caused by / associated with hypertension, or caused by / associated with diabetes (also called diabetic nephropathy (DKD) including DKD associated with hypertension), in particular diabetes mellitus type 1 or 2), or caused by / associated with inflammatory diseases and disorders (such as glomerulonephritis and glomerulonephritis secondary to systemic inflammatory diseases such as SLE or SSc, tubulointerstitial nephritis, vasculitis, sepsis, urinary tract infections), or caused by / associated with polycystic kidney disease, or caused by / associated with obstructive nephropathy (including stones, benign prostatic hyperplasia, prostate cancer, retroperitoneal pelvic tumors), or caused by / associated with neurogenic bladder disease-related symptoms) [in particular the Kidney Disease Improving Global stages 1 to 5 CKD as defined by the Kidney Disease Outcomes (KDIGO) Guidelines], especially (particularly) these stages of CKD; and acute and chronic renal failure; - Cardiovascular diseases and disorders (atherosclerosis caused / related to hypertension, hypercholesterolemia, diabetes, inflammation, obesity, elderly / age; peripheral arterial disease caused / related to hypertension, hypercholesterolemia, diabetes, elderly / age; deep vein thrombosis; pulmonary embolism caused / related to obesity or cancer; aortic aneurysm and dissection caused / related to elderly, hypertension, Marfan syndrome, congenital heart defects, inflammatory or infectious disorders; cerebrovascular disease caused / related to hypertension, atrial fibrillation, hypercholesterolemia, diabetes, elderly / age; hypertension, hypercholesterolemia, diabetes, elderly / age or CKD, in particular Kidney Disease Improving coronary heart disease due to / associated with CKD (stages 1-5 as defined by the Cardiovascular Outcomes and Global Outcomes (KDIGO) Guidelines); rheumatic heart disease due to / associated with bacterial infection; cardiac and vascular tumors; cardiomyopathies and arrhythmias; valvular heart disease (including valvular calcification and degenerative aortic stenosis); inflammatory heart disease due to / associated with infection, carditis, glomerulonephritis, cancer; heart failure (HF) defined as including congestive HF, particularly including systolic HF / HF with reduced ejection fraction (HFrEF) and diastolic HF / HF with preserved ejection fraction (HFpEF); - Interstitial lung diseases and disorders (including smoking-related interstitial lung disease; interstitial lung disease due to / associated with chronic obstructive pulmonary disease; interstitial pneumonia (including ordinary interstitial pneumonia) associated with collagen vascular disease, or pneumonia); - Cell proliferative disorders and cancer (including solid tumors, solid tumor metastases, carcinomas, sarcomas, myeloma (and multiple myeloma), leukemia, lymphoma, mixed cancers, angiofibroma, Kaposi's sarcoma, chronic lymphocytic leukemia (CLL), spinal tumors and invasive metastases of cancer cells); - inflammatory and autoimmune diseases and disorders (including chronic and acute inflammatory and autoimmune diseases and disorders, in particular inflammatory renal / kidney diseases such as sepsis, Q fever, asthma, rheumatoid arthritis, multiple sclerosis, SLE, SSc, polymyositis, plaque psoriasis (including psoriasis caused / associated with NASH), atopic dermatitis, nephropathy (including diabetic nephropathy, glomerulonephritis, tubulointerstitial nephritis), inflammatory cardiac / heart diseases, inflammatory lung / lung-related diseases; inflammatory liver / liver-related diseases; diabetes (type 1 or type 2) and diabetes-related diseases such as diabetic vasculopathy, diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy or skin-related diseases; viral encephalitis; and COVID-19 and its sequelae); - Digestive diseases and disorders (including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastritis and abnormal pancreatic secretions); - Pancreatic diseases and disorders (including, for example, pancreatitis associated with cystic fibrosis); - Diseases and disorders associated with abnormal angiogenesis (including arterial occlusive disease); - Brain-related diseases and disorders (including stroke and cerebral hemorrhage); - Neuropathic pain and peripheral neuropathy; - Eye diseases and disorders (including dry eye, age-related macular degeneration (AMD), diabetes-related diseases (diabetic retinopathy), proliferative vitreous retinopathy (PVR), cicatricial pemphigoid and glaucoma (including ocular scarring after glaucoma filtration surgery and glaucoma associated with elevated intraocular pressure) and corneal angiogenesis / neovascularization); and - Transplant rejection (including rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea and skin; graft-versus-host disease resulting from hematopoietic stem cell transplantation; chronic allograft rejection and chronic allograft vasculopathy); and sequelae of such transplant rejection.

[0105] 25) A further embodiment relates to a compound of formula (I) for use according to embodiment 24), wherein the compound is for use in the prevention or treatment of organ fibrosis, including liver / hepatic fibrosis, renal / kidney fibrosis, lung / pulmonary fibrosis, heart / cardiac fibrosis, ocular / corneal fibrosis and skin fibrosis; and gastrointestinal fibrosis, head and neck fibrosis, hypertrophic scars and keloids; and fibrotic sequelae of organ transplantation.

[0106] 26) A further embodiment relates to compounds of formula (I) for use according to embodiment 24), wherein the compounds are for use in the prevention or treatment of cardiovascular diseases and disorders.

[0107] 27) A further embodiment relates to compounds of formula (I) for use according to embodiment 24), wherein the compounds are for use in the prevention or treatment of acute kidney injury and chronic kidney disease (CKD).

[0108] 28) A further embodiment relates to compounds of formula (I) for use according to embodiment 24), wherein the compounds are for use in the prevention or treatment of (acute or chronic) liver diseases and disorders.

[0109] 29) A further embodiment relates to compounds of formula (I) for use according to embodiment 24), wherein the compounds are for use in the prevention or treatment of interstitial lung diseases and disorders.

[0110] 30) A further embodiment relates to a compound of formula (I) for use according to embodiment 24), wherein the compound is for use in the prevention or treatment of eye diseases and disorders.

[0111] 31) A further embodiment relates to compounds of formula (I) for use according to embodiment 24), wherein the compounds are for use in the prevention or treatment of cell proliferative disorders and cancer.

[0112] 32) A further embodiment relates to compounds of formula (I) for use according to embodiment 24), wherein the compounds are for use in the prevention or treatment of chronic and acute inflammatory and autoimmune diseases and disorders.

[0113] 33) A further embodiment relates to compounds of formula (I) for use according to embodiment 24), wherein the compounds are for use in the prevention or treatment of gastrointestinal diseases and disorders.

[0114] 34) A further embodiment relates to a compound of formula (I) for use according to embodiment 24), wherein the compound is for use in the prevention or treatment of pancreatic diseases and disorders.

[0115] 35) A further embodiment relates to compounds of formula (I) for use according to embodiment 24), wherein the compounds are for use in the prevention or treatment of diseases and disorders associated with abnormal angiogenesis.

[0116] 36) A further embodiment relates to compounds of formula (I) for use according to embodiment 24), wherein the compounds are for use in the prevention or treatment of brain-related diseases and disorders.

[0117] 37) A further embodiment relates to compounds of formula (I) for use according to embodiment 24), wherein the compounds are for use in the prevention or treatment of neuropathic pain and peripheral neuropathy.

[0118] 38) A further embodiment relates to a compound of formula (I) for use according to embodiment 24), wherein the compound is for use in the treatment of transplant rejection.

[0119] Preparation of Compounds of Formula (I) Compounds of formula (I) can be prepared by well-known literature methods, by the following methods, by the methods described in the experimental section below, or by analogous methods. Optimum reaction conditions will vary with the specific reactants or solvents used, but such conditions can be determined by one skilled in the art by routine optimization procedures. In some cases, the reaction schemes below and / or the order of carrying out the reaction steps may be modified to facilitate the reaction or to avoid unwanted reaction products. In the general reaction sequences outlined below, the generic group, R 1 , R 2 , A and Ar 1 is as defined for formula (I). Other abbreviations used herein are either explicitly defined or as defined in the experimental section. In some cases, the generic group, R 1 , R 2 , A and Ar 1may not be compatible with the preparation illustrated in the scheme below and would require the use of a protecting group (Pg). The use of protecting groups is well known in the art (see, for example, "Protective Groups in Organic Synthesis", TW Greene, PG M Huts, Wiley-Interscience, 1999). For this purpose, it is assumed that such protecting groups have been introduced as necessary. In some cases, the final product may be further modified, for example by manipulating the substituents to give new final products. Such manipulations include, but are not limited to, reduction, oxidation, alkylation, acylation, hydrolysis and transition metal catalyzed cross-coupling reactions well known to those skilled in the art. The resulting compounds may be converted into salts, particularly pharma- ceutically acceptable salts, by methods known in the art.

[0120] The compounds of formula (I) of the present invention may be prepared according to the general reaction sequences outlined below: Only a few of the synthetic possibilities which lead to compounds of formula (I) are described.

[0121] [ka] The compounds of formula (I) may be prepared by reacting R with H, a suitable protecting group such as acetyl, trimethylsilyl, TBDMS, or R as defined in formula (I). 1 The compound is prepared by deprotecting a compound of structure I, which represents

[0122] Compounds of structure 1, in which A represents a 3,5-disubstituted isoxazole or a 4,5-dihydroisoxazole (structure 1a or structure 1b), are synthesized by 1,3-dipolar cycloaddition of nitrile oxides with dipolarophiles such as alkynes and alkenes of structures 2a, 2b, 5 or 6, as shown below. Oximes such as structures 3a or 4 are the precursors of nitrile oxides, which are oxidized in situ with N-chlorosuccinimide and then oxidized with NEt in a suitable solvent such as DCM or DMF at temperatures ranging from rt to 50° C. 3or a tertiary amine base such as DIPEA. Alternatively, the nitrile oxide is generated by dehydration of an aliphatic nitro compound of structure 3b using an aryl isocyanate and a catalytic amount of base (Mukaiyama conditions, T. Mukaiyama and T. Hoshino, J. Am. Chem. Soc., 1960, 82, 5339-5342).

[0123] [ka] Compounds of structure 1, in which A represents a 1,4-disubstituted 1,2,3-triazole (structure 9a or structure 9b), can be synthesized by the copper-catalyzed 1,3-dipolar cycloaddition of alkynes of structure 2b or 6 with azides of structure 7 or 8 (Click Chemistry in Glycoscience: New Development and Strategies, 1st edition, 2013, The reaction can be carried out according to a batch procedure by John Wiley & Sons, or the reaction can be carried out in a commercially available continuous-flow reactor using a copper coil in a solvent such as THF as shown below. This can be done using a Vapourtec reactor.

[0124] [ka] Compounds of structure 1, where A represents a 3,5-disubstituted oxazolidin-2-one (structure 10a or 10b), can be obtained by cyclization of the corresponding amino alcohols 11a or 11b with carbonic acid derivatives such as CDI or phosgene. The required amino alcohols can also be obtained by cyclization of the appropriate epoxide intermediates (12a or 12b) with primary amines (13a or 13b) as shown in the diagram below. 2 NR 2 The resulting diastereomeric mixture can be separated by chiral preparative HPLC. Alternatively, chiral epoxides can be used in this synthesis, which are prepared from alkene precursors according to methods known to those skilled in the art.

[0125] [ka] Compounds of structure 1, in which A represents a 1,3-disubstituted imidazolidin-4-one (structure 14a or 14b), can be obtained by cyclization of the corresponding amino acid amides 15a or 15b with formaldehyde. The required amino acid amides 15a can be obtained by alkylation with the corresponding chloroacetamides of structure 16 or by reductive amination with glyoxalamide derivatives of structure 17. The amino acid amides of structure 15b can be obtained by reaction of chloroacetamide derivatives of structure 18 (obtained by acylation of amines of structure 13 with chloroacetyl chloride) with primary amines, as shown in the diagram below.

[0126] [ka] Experimental section The following examples illustrate the invention but do not in any way limit its scope.

[0127] All temperatures are given in °C. Commercially available starting materials were used as received without further purification. All reactions were carried out under a nitrogen or argon atmosphere unless otherwise noted. Compounds were purified by flash chromatography on silica gel (Biotage) using preparative TLC (Merck TLC plates, Silica gel 60 F 254 ) or by preparative HPLC. The compounds described in this invention were 1 H-NMR (400 MHz or 500 MHz Bruker; chemical shifts are given in ppm relative to the solvent used; multiplicities: s=singlet, d=doublet, t=triplet, q=quartet, quint=quintet, hex=sexlet, hept=septet, m=multiplet, br=broad; coupling constants are given in Hz) and / or LC-MS (retention times t Rare given in min; molecular weights obtained from mass spectrometry are given in g / mol.) using the conditions described below.

[0128] Qualitative analysis methods used LC-MS retention times were obtained using the following elution conditions: A) LC-MS(A): Zorbax RRHD SB-Aq, 1.8 μm, 2.1×50 mm column, thermostated at 40° C. The two elution solvents were: Solvent A=water+0.04% TFA; Solvent B=acetonitrile. The eluent flow rate was 0.8 mL / min and the characteristics of the proportion of the eluted mixture related to the time t from the start of the elution are summarized in the table below (a linear gradient is used between two successive time points):

[0129] [Table 1] B) LC-MS(B): Waters BEH C18, 1.8 μm, 1.2x50 mm column thermostated at 40° C. The two elution solvents were as follows: Solvent A = water + 13 mM NH 4 OH; solvent B = acetonitrile. The eluent flow rate was 0.8 mL / min and the characteristics of the proportions of the eluted mixture related to the time t from the start of the elution are summarized in the table below (a linear gradient is used between two successive time points):

[0130] [Table 2] Purification by preparative LC-MS was carried out using the conditions described below.

[0131] C) Preparative LC-MS(I): A Waters column (Waters XBridge C18, 10 μm OBD, 30x75 mm) was used. The two elution solvents were as follows: Solvent A = water + 0.5% of 25% NH 4OH in water; solvent B = acetonitrile. The eluent flow rate was 75 mL / min and the characteristics of the proportions of the eluted mixture related to the time t from the start of the elution are summarized in the following table (a linear gradient is used between two successive time points):

[0132] [Table 3] D) Preparative LC-MS(II): A Waters column (Waters XBridge C18, 10 μm OBD, 30×75 mm) was used. The two elution solvents were: Solvent A=water+HCOOH 0.5%; Solvent B=acetonitrile. The eluent flow rate was 75 mL / min and the characteristics of the proportion of the eluted mixture related to the time t from the start of the elution are summarized in the following table (a linear gradient is used between two successive time points):

[0133] [Table 4] E) Preparative LC-MS (III): A Waters column (Zorbax SB-AQ 30x75mm, 5μm) was used. The two elution solvents were as follows: Solvent A = water + HCOOH 0.5%; Solvent B = a The eluent flow rate was 75 mL / min and the characteristics of the proportions of the eluted mixture related to the time t from the start of the elution are summarized in the following table (a linear gradient is used between two successive time points):

[0134] [Table 5] Chiral preparative HPLC method used: Separation of the epimers was achieved by preparative chiral column chromatography using the conditions described below. Separation was performed either at the final stage or with the protecting groups still present.

[0135] Chiral Preparative HPLC(I): A ChiralPack IC, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=DCM / MeOH / DEA 50:50:0.1. The eluent flow rate was 160 mL / min. Elution was performed with 60% Solvent A and 40% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Example 1.03 / 1.04 (protected)).

[0136] Chiral Preparative HPLC (II): A ChiralPack IC, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=DCM / MeOH 1:1. The eluent flow rate was 160 mL / min. Elution was performed with 65% Solvent A and 35% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Example 1.06 / 1.07 (acetate protected)).

[0137] Chiral Preparative HPLC (III): A ChiralPack IC, 5 μm, 30x250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=EtOH. The eluent flow rate was 160 mL / min. Elution was performed with 65% Solvent A and 35% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (example 2.04 / 2.05).

[0138] Chiral Preparative HPLC (IV): A ChiralPack IH, 5 μm, 30x250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=EtOH. The eluent flow rate was 160 mL / min. Elution was performed with 65% Solvent A and 35% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Example 1.09 / 1.10 (protected)).

[0139] Chiral Preparative HPLC(V): A ChiralPack AD-H, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=MeCN / EtOH 1:1. The eluent flow rate was 160 mL / min. Elution was performed with 65% Solvent A and 35% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Example 1.128 / 1.129 (protected)).

[0140] Chiral Preparative HPLC (VI): A ChiralPack AD-H, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=MeCN / EtOH / DEA 50:50:0.1. The eluent flow rate was 160 mL / min. Elution was performed with 65% Solvent A and 35% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Example 1.138 / 1.139).

[0141] Chiral Preparative HPLC (VII): A ChiralPack IE, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=ACN / EtOH / DEA 50:50:0.1. The eluent flow rate was 160 mL / min. Elution was performed with 55% Solvent A and 45% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Example 1.147 / 1.148).

[0142] Chiral Preparative HPLC (VIII): ChiralCel OD-H, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=EtOH / . The eluent flow rate was 160 mL / min. Elution was performed with 65% Solvent A and 35% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Example 1.339 / 1.340).

[0143] Chiral Preparative HPLC (IX): A ChiralPack AD-H, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=EtOH. The eluent flow rate was 160 mL / min. Elution was performed with 65% Solvent A and 35% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (example 1.47 / 1.48).

[0144] Chiral Preparative HPLC(X): A ChiralPack IC, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=MeCN / EtOH / DEA 50:50:0.1. The eluent flow rate was 160 mL / min. Elution was performed with 60% Solvent A and 40% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Examples 3.06 / 3.07 (protected); 3.10 / 3.11 (protected); 3.12 / 3.13 (protected)).

[0145] Chiral Preparative HPLC (XI): A ChiralPack IB, 5 μm, 30x250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=EtOH. The eluent flow rate was 160 mL / min. Elution was performed with 65% Solvent A and 35% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Example 3.19 / 3.20 (protected)).

[0146] Chiral Preparative HPLC (XII): A ChiralPack IE, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=EtOH. The eluent flow rate was 160 mL / min. Elution was performed with 55% Solvent A and 45% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (examples 3.24 / 3.25, Chiral Preparative HPLC (XIII): A ChiralPack IB, 5 μm, 30 x 250 mm was used, and the column was heated to 40°C. The temperature was controlled. The two elution solvents were as follows: Solvent A = CO2; Solvent B = MeCN / EtOH 1:1. The eluent flow rate was 160 mL / min. Elution was performed with 75% Solvent A and 25% Solvent B. Injection V = 1.0 mL, 10 mg / mL EtOH (Examples 3.60 / 3.61 (protected); 5.14 / 5.15).

[0147] Chiral Preparative HPLC (XIV): A ChiralPack IE, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=ACN / MeOH 50:50. The eluent flow rate was 160 mL / min. Elution was performed with 55% Solvent A and 45% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Example 5.05 / 5.06).

[0148] Chiral Preparative HPLC (XV): ChiralCel OJ-H, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=ACN / MeOH 50:50. The eluent flow rate was 160 mL / min. Elution was performed with 55% Solvent A and 45% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Example 5.07 / 5.08).

[0149] Chiral Preparative HPLC (XVI): A ChiralPack ID, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=ACN / EtOH / DEA 50:50:0.1. The eluent flow rate was 160 mL / min. Elution was performed with 55% Solvent A and 45% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Example 512 / 513 (precursor)).

[0150] Chiral Preparative HPLC (XVII): A ChiralPack IH, 5 μm, 30×250 mm was used and the column was thermostated at 40° C. The two elution solvents were as follows: Solvent A=CO2; Solvent B=MeCN / EtOH / DEA 50:50:0.1. The eluent flow rate was 160 mL / min. Elution was performed with 55% Solvent A and 45% Solvent B. Injection V=1.0 mL, 10 mg / mL EtOH (Example 2.07a / 2.07b (protected)).

[0151] NMR: 1H-NMR spectra were recorded on a Bruker Avance II, 400 MHz Ultra ShieldTM or a Brooker Avance III HD, Ascend 500 MHz; chemical shifts are given in ppm relative to the solvent used; multiplicities: s=singlet, d=doublet, t=triplet, q=quartet, quint=quintet, hex=sexet, hept=septet, m=multiplet, br=broad; coupling constants are given in Hz.

[0152] Abbreviations (as used herein): Ac 2 O Acetic anhydride AcOH Acetic acid aq. aqueous solution BB Building Blocks BF 3 OEt 2 Boron trifluoride diethyl etherate Boc tert-butoxycarbonyl BOP Benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate Bu (in nBuLi = n-butyl lithium, etc.) CC Silica Column Chromatography Concentrated CSA (+)-Camphor-10-sulfonic acid DCM Dichloromethane dil. Dilution DIPEA N-Ethyldiisopropylamine DMAP 4-Dimethylaminopyridine DMF Dimethylformamide DMSO Dimethyl sulfoxide EA Ethyl acetate EDC HCl N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide Hydrochloride eq (mol) equivalent Et Ethyl EtOH Ethanol Et 2 O Diethyl ether FC Flash Chromatography h time HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate Hept Heptane HOBt 1-Hydroxybenzotriazole hydrate HPLC High Performance Liquid Chromatography M Molar concentration [mol L -1 ] mCPBA 3-Chloroperbenzoic Acid Me Methyl MeCN Acetonitrile MeOH Methanol Ms Methanesulfonyl MS mass spectrometry min. N normality NaOAc Sodium Acetate NaOMe Sodium methoxide NaOtBu Sodium tert.(tertiary)butoxide NBS N-Bromosuccinimide NCS N-chlorosuccinimide NEt 3 Triethylamine o / n overnight org.organic Pg protecting group Ph Phenyl PTSA p-Toluenesulfonic acid rt room temperature sat. saturation TBME tert-Butyl methyl ether TBTU O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate tBu tert-butyl = tertiary butyl TFA Trifluoroacetic acid THF Tetrahydrofuran TMEDA Tetramethylethylenediamine TMSCl Chlorotrimethylsilane T3P Propylphosphonic anhydride t R retention time

[0153] A. Preparation of precursors and intermediates

[0154] [ka] Intermediate 1: (3R,4S,5R,6R)-6-(acetoxymethyl)-4-azidotetrahydro-2H-pyran-2,3,5-triyl triacetate (3R,4S,5R,6R)-6-(acetoxymethyl)-4-azidotetrahydro-2H-pyran-2,3,5-triyl triacetate is synthesized from (3aR,5S,6S,6aR)-5-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-ol according to the literature procedure from Ref: Carbohydrate Research 1994, 251, 33-67 and references cited therein.

[0155] Intermediate 2: (2R,3R,4R,5R,6R)-2-(acetoxymethyl)-6-allyl-4-azidotetrahydro-2H-pyran-3,5-diyl diacetate A solution of intermediate 1 (10 g, 26.8 mmol, 1 eq) in MeCN (100 mL) is cooled to 0 °C and allyltrimethylsilane 98% (13 mL, 80.4 mmol, 3 eq) and trimethylsilyl trifluoromethanesulfonate 99% (2.45 mL, 13.4 mmol, 0.5 eq) are added dropwise (non-exothermic). The ice bath is removed and the mixture is stirred at rt for 72 h. The mixture is cooled to 0 °C and cooled to 0 °C. 3 The solution is poured into a 100 ml ethanol bath and extracted with TBME. The organic phase is washed with brine and MgSO 4 The crude material is dried over SiO 2 Purification by filtration with (DCM / TBME 9:1) affords the title intermediate (as a 9:1 mixture of alpha / beta isomers) as a colourless oil which is used in the next step without further purification.

[0156] Major isomers: 1 H NMR (500MHz, DMSO) δ:5.70-5.78(m, 2H), 5.31(dd, J 1 = 1.6Hz, J 2 =3.4Hz, 1H), 5.06-5.14(m, 2H), 4.98-5.04(m, 1H), 4.39(dd, J 1 = 3.4Hz, J 2 =10.6Hz, 1H), 4.15(m, 1H), 3.91-4.09(m, 4H), 2.56-2.65(m, 1H), 2.22-2.28(m, 1H), 2.11(s, 3H), 2.09(s, 3H), 1.99(s, 3H)

[0157] Intermediate 3a: (2R,3R,4R,5R,6R)-2-(acetoxymethyl)-6-allyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyl diacetate To a solution of intermediate 2 (15 g, 42.5 mmol, 1 eq) in DMF (160 mL), -ethynyl-1,2,3-trifluorobenzene (9950 mg, 63.7 mmol, 1.5 eq), copper(I) iodide (809 mg, 4.25 mmol, 0.1 eq) and NEt3 (17.8 mL, 127 mmol, 3 eq) is added and stirred o / n at rt. The mixture is diluted with EA and dil.HCl. The organic phase is washed with water and brine and treated with MgSO 4 Dry with 500 t, concentrate and crystallize the crude material from EA (20 mL) and TBME (200 mL) to give the desired pure alpha isomer as a colorless solid. LCMS (A): R =1.02min;[M+H] + =512.15 1 H NMR (500MHz, DMSO-d6) δ:8.78(s, 1H), 7.83-7.88(m, 2H), 5.75-5.84(m, 1H), 5.70-5.74(m, 2H), 5.36(s, 1H), 5.1 8-5.21(m, 1H), 5.10-5.14(m, 1H), 4.41(m, 1H), 4.35(m, 1H), 4.00-4.04(m, 1H), 3.94(dd, J 1 = 7.1Hz, J 2 =11.3Hz, 1H), 2.84-2.91(m, 1H), 2.30-2.35(m, 1H), 2.02(s, 3H), 1.98(s, 3H), 1.86(s, 3H)

[0158] Intermediate 3b (Reference Example (Ref. Ex.)): (2R,3R,4R,5R,6S)-2-(acetoxymethyl)-6-allyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyl diacetate This intermediate is isolated (from the mother liquor) as a by-product in the synthesis of intermediate 3a. LCMS (A): R =1.04min;[M+H] + =512.15 1H NMR (500MHz, DMSO-d6) δ:8.76-8.79(m, 1H), 7.85(m, 2H), 5.86(m, 1H), 5.57(dd, J 1 = 3.2Hz, J 2=11.0Hz, 1H), 5.47(m, 1H), 5.39-5.41(m, 1H), 5.08-5.15(m, 2H), 4.28(m, 1H), 4.03(m, 2H) , 3.82(m, 1H), 2.35-2.40(m, 1H), 2.21-2.27(m, 1H), 2.08(s, 3H), 2.00(s, 3H), 1.83(s, 3H)

[0159] [ka] Intermediate 4a: (2R,3R,4R,5R,6R)-2-allyl-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol To a solution of intermediate 3a (12 g, 23.5 mmol, 1 eq) in methanol (240 mL), 2 CO 3 (324 mg, 2.35 mmol, 0.1 eq) is added. The reaction mixture is stirred at rt for 2 h. The mixture is concentrated under vacuum to give a beige foam. The crude compound is purified by FC (DCM / MeOH 9:1) to give the desired product as a colourless solid. LCMS (A):t R =0.7min;[M+H] + =385.76 1 H NMR (500MHz, DMSO-d6) δ:8.72(s, 1H), 7.82-7.87(m, 2H), 5.88(m, 1H), 5.26(d, J=5.7Hz, 1H), 5.14-5.19(m, 2H), 5.05-5.07(m, 1H), 4.90(dd, J 1 = 2.9Hz, J 2 =11.4Hz, 1H), 4.58(t, J=5.5Hz, 1H), 4.52(m, 1H), 4.02(m, 1H), 3.93(dd, J 1 =2.6 Hz, J 2 =6.4Hz, 1H), 3.78(t, J=6.2Hz, 1H), 3.49(m, 1H), 3.42(m, 1H), 2.68-2.75(m, 1H), 2.33-2.38(m, 1H)

[0160] Intermediate 5a: (4aR,6R,7R,8R,8aR)-6-allyl-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-ol A solution of intermediate 4a (15 g, 38.9 mmol, 1 eq) in THF (180 mL) is treated with 2,2-dimethoxypropane (19.1 mL, 156 mmol, 4 eq) and PTSA monohydrate (0.378 g, 1.95 mmol, 0.05 eq) and the light yellow solution is stirred o / n at rt. The mixture is diluted with EA and the organic layer is washed with sat.NaHCO 3 The solution was washed with water and brine, and then with MgSO 4 Dry at 40° C., filter and concentrate under reduced pressure to obtain the title intermediate as a colorless solid. LCMS (A): t R =0.93min;[M+H] + =426.13 1 H NMR (500MHz, DMSO-d6) δ:8.72(s, 0H), 8.58-8.64(m, 1H), 7.80-7.94(m, 2H), 5.81-5.90(m, 1H), 5.33-5.38(m, 1H) ), 5.11-5.20(m, 1H), 5.00-5.11(m, 2H), 4.41-4.52(m, 1H), 4.26-4.31(m, 1H), 4.12(ddd, J 1 =11.5Hz, J 2 = 5.7Hz, J 3 =3.2Hz, 1H), 4.01(dd, J 1 =12.7Hz, J 2 =2.0Hz, 1H), 3.66-3.71(m, 1H), 3.57-3.65(m, 1H), 2.64-2.72(m, 1H), 2.34-2.41(m, 1H), 1.32(s, 3H), 1.20(s, 3H)

[0161] Intermediate 6a: 1-((4aR,6R,7R,8R,8aR)-6-allyl-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl)-4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazole. To a solution of intermediate 5a (7.3 g, 17.2 mmol, 1 eq) in dry THF (50 mL) cooled to 0° C., dimethyl sulfate (2 mL, 20.6 mmol, 1.2 eq) is added, followed by portionwise addition of NaH [55% dispersion in paraffin] (824 mg, 20.6 mmol, 1.2 eq). The mixture is stirred at 0° C. for 3 h. The mixture is then cooled to 0° C. with sat. NH 4 Quench with Cl and extract twice with TBME. Combine the organic layers, wash with brine and MgSO 4 Dry at 40° C., filter and concentrate under reduced pressure to give a colorless solid. LCMS(A):t R =1.03min;[M+H] + =440.22 1 H NMR (500MHz, DMSO-d6) δ:8.71(s, 1H), 7.68-7.98(m, 2H), 5.70-5.97(m, 1H), 5.14-5.21(m, 2H), 5.09(m, 1H), 4.48(ddd, J 1 = 3.5Hz, J 2 = 5.5Hz, J 3 =11.4Hz, 1H), 4.30(d, J=2.9Hz, 1H), 4.22(dd, J 1 = 5.7Hz, J 2 =11.5Hz, 1H), 3.93-4.10(m, 1H), 3.56-3.74(m, 2H), 3.21(s, 3H), 2.70-2.78(m, 1H), 2.20-2.31(m, 1H), 1.32(s, 3H), 1.20(s, 3H)

[0162] Intermediate 6b: (4aR,6R,7R,8S,8aR)-6-allyl-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl acetate Intermediate 5a (725 mg, 1.7 mmol, 1 eq) was dissolved in DCM (10 mL) and 2 2H2O (0.193 mL, 2.05 mmol, 1.2 eq), DIPEA (0.438 mL, 2.56 mmol, 1.5 eq) and DMAP (10.4 mg, 0.0852 mmol, 0.05 eq) are added. The mixture is stirred at rt for 1 h. The mixture is diluted with EA and NaH CO 3 Partition between the solutions. The organic phase is washed with sat NH 4 Cl and brine, and then washed with MgSO 4 Dry and concentrate. Purification by FC (hept / EA 2:1, 1:1, 1:2) gives the title intermediate as a colourless foam. LCMS (A): R =1.04min;[M+H]+=467.98 1 H NMR (500MHz, DMSO-d6) δ:8.63(s, 1H), 7.89(m, 2H), 5.81(m, 1H), 5.59(dd, J 1 = 5.7Hz, J 2 =11.4Hz, 1H), 5.47(dd, J 1 = 3.2Hz, J 2 =11.4Hz, 1H), 5.19(dd, J 1= 1.9Hz, J 2 =17.2Hz, 1H), 5.09(m, 1H), 4.36-4.41(m, 2H), 4.03-4.06(m, 1H), 3.76(d, J=1.0Hz, 1H), 3.66(dd, J 1 = 1.7Hz, J 2 =12.8Hz, 1H), 2.80(m, 1H), 2.28-2.33(m, 1H), 1.84(s, 3H), 1.38(s, 3H), 1.25(s, 3H)

[0163] Intermediate 6c: ((2R,3R,4R,5R,6R)-3-acetoxy-6-allyl-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl acetate Step 1: (2R,3R,4S,5R,6R)-6-allyl-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol To a mixture of intermediate 6a (3050 mg, 6.94 mmol, 1 eq) in water (15 mL) was added acetic acid (30 mL) and the suspension was stirred at 55° C. for 3 h. The solution was concentrated under reduced pressure and the residue was dried under HV o / n. The crude (light yellow solid) was used in the next step without further purification.

[0164] Step 2: The intermediate of step 1 (3340 mg, 8.36 mmol, 1 eq) and Et 3 A solution of N (6.99 mL, 50.2 mmol, 6 eq) in DCM (40 mL) was added to N at 0 °C. 2 Lower, Ac 2 O (2.42 mL, 25.1 mmol, 3 eq) was added and the solution was stirred o / n at rt. Water was added and the mixture was extracted with DCM. The organic layer was washed with MgSO 4 Drying at rt and then concentration under reduced pressure afforded the title intermediate as a colourless solid. LCMS(A):t R =1.03min;[M+H]+=484.20

[0165] [ka] Intermediate 7a: 2-((4aR,6R,7R,8R,8aR)-7-Methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)acetaldehyde Intermediate 6a (4270 mg, 9.72 mmol, 1 eq) is suspended in 1,4-dioxane (50 mL) and water (15 mL). 2,6-lutidine (1.24 mL, 10.6 mmol, 3 eq) and sodium periodate (6235 mg, 29.2 mmol, 3 eq) are added, followed by potassium osmate dihydrate (15 mg, 0.0408 mmol, 0.0042 eq). The suspension is vigorously stirred o / n at rt. The mixture is diluted with water and EA and carefully adjusted to pH 2-3 with HCl (1N). The two layers are separated and the organic layer is washed with brine and MgSO 4 The crude material is purified by filtration using a CombiFlash (40 g SiO 2 Purification by FC using a column; gradient: 0-100% EA in hept) gives the desired aldehyde as a colorless solid. LCMS (A): R =0.91min;[M+H] + =442.12 1 H NMR (500MHz, DMSO-d6) δ:9.72(m, 1H), 8.73(s, 1H), 7.87(dd, J 1 = 9.0Hz, J 2 =6.8Hz, 2H), 5.11-5.18(m, 2H), 4.24-4.30(m, 2H), 4.01-4.04(m, 1H), 3.57-3.69(m, 2H), 3.32(s), 3.20(s, 3H), 2.98(ddd, J 1 =16.2Hz, J 2 = 9.2Hz, J 3 =3.0Hz, 1H), 2.83(ddd, J 1 =16.2Hz, J 2 = 5.0Hz, J 3 =1.4Hz, 1H), 1.18-1.33(m, 6H)

[0166] Intermediate 7b: (4aR,6R,7R,8S,8aR)-2,2-dimethyl-6-(2-oxoethyl)-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl acetate Prepared similarly to intermediate 7a starting from intermediate 6b. LCMS(A):t R =0.92min;[M+H] + =469.96 Intermediate 7c: (2R,3R,4R,5R,6R)-2-(acetoxymethyl)-6-(2-oxoethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyl diacetate Prepared similarly to intermediate 7a starting from intermediate 3a. LCMS(A):t R =0.93min;[M+H] + =514.10

[0167] Intermediate 8a: 2-((4aR,6R,7R,8R,8aR)-7-Methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)acetaldehyde oxime Intermediate 7a (1390 mg, 3.15 mmol, 1 eq), hydroxylamine HCl (328 mg, 4.72 mmol, 1.5 eq) and NaOAc (775 mg, 9.45 mmol, 3 eq) were placed in a flask and diluted with EtOH (5 mL) and H 2 The mixture is suspended in 20O (5 mL). THF (5 mL) is added and the mixture is stirred at rt for 1.5 h. The mixture is partitioned between EA and water. The organic layer is washed with brine and MgSO 4 Dry at rt and concentrate under reduced pressure. Triturate the crude with TBME and hept 3 / 1 (20 mL), sonicate, filter the off-white crystals and dry under hv.

[0168] The desired oxime (E / Z mixture) is isolated as an off-white solid. LCMS (A): R =0.88min;[M+H] + =457.16

[0169] Intermediate 8b: (4aR,6R,7R,8S,8aR)-6-(2-(hydroxyimino)ethyl)-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl acetate Prepared similarly to intermediate 8a starting from intermediate 7b. LCMS(A):t R =0.90min;[M+H] + =485.18

[0170] Intermediate 8c: (2R,3R,4R,5R,6R)-2-(acetoxymethyl)-6-(2-(hydroxyimino)ethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyl diacetate Prepared similarly to intermediate 8a starting from intermediate 7c. LCMS(A):t R =0.89min;[M+H] + =529.05

[0171] Intermediate 9a: 1-((4aR,6R,7R,8R,8aR)-7-Methoxy-2,2-dimethyl-6-(prop-2-yn-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-8-yl)-4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazole Intermediate 7a (750 mg, 1.7 mmol, 1 eq) was suspended in MeOH (15 mL) and treated with dimethyl (1-diazo-2-oxopropyl)phosphonate (10% solution in MeCN) (4.61 mL, 2.04 mmol, 1.2 eq) followed by K 2 CO 3 (470 mg, 3.4 mmol, 2 eq) is added. The mixture is stirred at rt for 3 h. The mixture is diluted with DCM and sat.NH 4 Partition between Cl solution. Extract the aqueous phase once more with DCM. Combine the organic phases and add MgSO 4Dry at 40° C. and concentrate. The crude product is purified by FC (CombiFlash 24 g cartridge, 30-100% EA in hept) to give the desired intermediate as a colourless solid. LCMS (A): R =0.99min;[M+H] + =437.91 1 H NMR (500MHz, DMSO-d6) δ: 8.71(s, 1H), 7.86(dd, J 1 = 6.8Hz, J 2 =9.0Hz, 2H), 5.19-5.21(m, 1 H), 4.59(m, 1H), 4.27(d, J=3.4Hz, 1H), 4.23(dd, J 1 = 5.7Hz, J 2 =11.4Hz, 1H), 4.06(d, J=11.0Hz, 1H), 3.67-3.70(m, 2H), 3.22(s, 3H), 2.95(ddd, J 1 = 2.5Hz, J 2 = 10.8Hz, J 3 =17.6Hz, 1H), 2.84(t, J=2.6Hz, 1H), 2.45(m, 1H), 1.32(s, 3H), 1.20(s, 3H)

[0172] Intermediate 9b (Reference Example): 1-((4aR,6S,7R,8R,8aR)-7-Methoxy-2,2-dimethyl-6-(prop-2-yn-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-8-yl)-4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazole The title intermediate was isolated in small amounts in the synthesis of intermediate 9a. LCMS(A):t R =1.00min;[M+H] + =437.91 1 H NMR (500MHz, DMSO-d6) δ:8.77(s, 1H), 7.92(dd, J 1 = 9.0Hz, J 2= 6.8Hz, 2H), 5.11(dd, J 1 = 10.6Hz, J 2 =3.2Hz, 1H), 4.33(d, J=2.9Hz, 1H), 4.01(dd, J1 =12.7Hz, J 2 =1.7Hz, 1H), 3.90(m, 1H), 3.75(dd, J 1 =12.8Hz, J 2 =1.4Hz, 1H), 3.61-3.65(m, 2H), 3.06(s, 3H), 2.91(t, J=2.6Hz, 1H), 1.31(d, J=69.7Hz, 7H)

[0173] [ka]

[0174] Intermediate 21: (2R,3R,4R,5R,6R)-2-(acetoxymethyl)-4-azido-6-(propa-1,2-dien-1-yl)tetrahydro-2H-pyran-3,5-diyl diacetate Intermediate 1 (3733 mg, 10 mmol, 1 eq) is dissolved in MeCN (20 mL) and cooled to 3° C. Trimethyl(propargyl)silane (3.73 mL, 25 mmol, 2.5 eq) is added followed by BF 3 OEt 2 (3.7 mL, 30 mmol, 3 eq) and trimethylsilyl trifluoromethanesulfonate (3.66 mL, 20 mmol, 2 eq) are added dropwise. The mixture is stirred at 0 °C for 1.5 h and at rt for 1 h. The mixture is diluted with TBME and sat NaHCO 3 The organic phase is washed with brine and MgSO 4 The crude product is purified by FC (hept / EA 2:1) to give the desired The allene intermediate of formula (I) is obtained as a yellowish oil.

[0175] 1 H NMR (500MHz, DMSO-D6) δ:5.56(q, J=6.7Hz, 1H), 5.35(d, J=2.2Hz, 1H), 4.98-5.05(m, 3H), 4.74(m, 1H), 4.35(dd, J 1 = 3.3Hz, J 2=11.2Hz, 1H), 4.20-4.23(m, 1H), 4.00-4.03(m, 1H), 3.90(dd, J 1 = 7.0Hz, J 2 =11.4Hz, 1H), 2.12(s, 3H), 2.09(s, 3H), 2.00-2.02(m, 4H)

[0176] Intermediate 22a: (2R,3R,4R,5R,6R)-2-(acetoxymethyl)-6-(propa-1,2-dien-1-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyl diacetate The title compound is prepared analogously to intermediate 3a starting from intermediate 21. LCMS(A):t R =1.02min;[M+H] + =510.24 1 H NMR (500MHz, DMSO-d6) δ:8.81(s, 1H), 7.82-7.86(m, 2H), 5.80(q, J=6.8Hz, 1H), 5.65-5.72(m, 2H), 5.40(d, J=1.5Hz, 1H), 5.06(dd, J 1 = 6.6Hz, J 2 =2.3Hz, 2H), 4.96-4.99(m, 1H), 4.50(t, J=6.3Hz, 1H), 4.01(m, 2H), 2.00-2.04(m, 6H), 1.87(s, 3H)

[0177] Intermediate 23a: 1-((4aR,6R,7R,8R,8aR)-7-Methoxy-2,2-dimethyl-6-(propa-1,2-dien-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-8-yl)-4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazole The title intermediate is prepared starting from intermediate 22a by following the procedures for intermediates 4a, 5a and 6a. LCMS(A): R =1.02min;[M+H] + =438.21 1H NMR (500MHz, DMSO-d6) δ:8.71(s, 1H), 7.87(dd, J 1 = 6.8Hz, J 2 =9.0Hz, 2H), 5.75(m, 1H), 5.13(dd, J 1 = 3.3Hz, J 2 =11.4Hz, 1H), 5.07(m, 1H), 4.98(m, 2H), 4.34-4.34(m, 1H), 4.26(dd, J 1 = 5.6Hz, J 2 =11.5Hz, 1H), 4.04(dd, J 1 = 2.0Hz, J 2 =12.9Hz, 1H), 3.82(d, J=0.7Hz, 1H), 3.68(dd, J 1 = 1.5Hz, J 2 =12.9Hz, 1H), 3.22(s, 3H), 1.32(s, 3H), 1.21(s, 3H)

[0178] Intermediate 24a: ((4aR,6R,7R,8R,8aR)-7-Methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methanol Intermediate 23a (1000 mg, 2.29 mmol, 1 eq) is dissolved in DCM / MeOH 4:1 (60 mL) and cooled to -70 °C. Ozone is bubbled through the solution in the scrubber until the KI solution turns brown (~60 min). 2 The excess O was removed by aeration for 10 min. 3 Purge NaBH 4 (86.5 mg, 2.29 mmol, 1 eq) is added at -78 °C, the dry ice bath is removed and the mixture is allowed to warm to rt within 1 h. The mixture is then carefully quenched with water (25 mL), the layers are separated and the organic layer is washed with MgSO 4 Dry at 40° C. and concentrate under reduced pressure.

[0179] The crude solid was purified by CombiFlash (24 g SiO 2 Column: hept in 20 min / EA 2 / 1 to 100% EA gradient) to give the title intermediate as a colourless solid. LCMS (A): R =0.84min;[M+H] + =430.29 1 H NMR (500MHz, DMSO-d6) δ:8.69(s, 1H), 7.86(m, 2H), 5.29(dd, J 1 =11.4Hz, J 2 =3.4Hz, 1H), 4.80(t, J=5.5Hz, 1H), 4.34(m, 2H), 4.24(dd, J 1 =11.4Hz, J 2 =6.1Hz, 1H), 3.96-4.07(m, 2H), 3.91(s, 1H), 3.71(dd, J 1 =12.7Hz, J 2 =1.4Hz, 1H), 3.63(ddd, J 1 =12.3Hz, J 2 = 5.8Hz, J 3 =2.9Hz, 1H), 3.23(s, 3H), 1.32(s, 3H), 1.20(s, 3H)

[0180] Intermediate 25a: ((4aR,6R,7R,8R,8aR)-7-Methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl methanesulfonate Intermediate 24a (400 mg, 0.932 mmol, 1 eq) is dissolved in DCM (8 mL) and cooled to 0° C. At this temperature, MsCl (0.0736 mL, 0.932 mmol, 1 eq) and DIPEA (0.191 mL, 1.12 mmol, 1.2 eq) are added and the mixture is stirred at 0° C. for 30 min. MsCl (0.0144 mL, 0.186 mmol, 0.2 eq) is further added and the mixture is stirred at 0° C. for another 30 min. The mixture is diluted with DCM and washed with water. The organic layer is dried over a phase separator and concentrated under reduced pressure. The crude foam is purified by elution with CombiFlash (12 g SiO 2Purification by FC using a column; gradient from hept to hept / EA 1 / 2 in 16 min) gives the desired intermediate as a colourless solid. LCMS (A): R =0.96min;[M+H] + =508.14 1 H NMR (500MHz, DMSO-d6) δ:8.72-8.74(m, 1H), 7.83-7.90(m, 2H), 5.18-5.27(m, 1H), 4.89-4.98(m, 1H), 4 .75-4.84(m, 1H), 4.27-4.37(m, 3H), 4.06-4.09(m, 1H), 3.83(s, 1H), 3.73(dd, J 1 =12.9Hz, J 2 =1.5Hz, 1H), 3.26(d, J=6.1Hz, 6H), 1.34(s, 3H), 1.22(s, 3H)

[0181] Intermediate 26a: 1-((4aR,6R,7R,8R,8aR)-6-(azidomethyl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl)-4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazole To a solution of intermediate 25a (409 mg, 0.806 mmol, 1 eq) in dry DMF (10 mL), 2 Sodium azide (62.9 mg, 0.967 mmol, 1.2 eq) is added under reduced pressure. The reaction mixture is heated at 70 °C for 5 h. The temperature is increased to 80 °C and the mixture is stirred at this temperature until the reaction is complete. The mixture is cooled to rt, diluted with EA and water and the layers are separated. The aqueous layer is extracted once more with EA. The combined organic layers are washed twice with water, brine and diluted with MgSO 4 The crude colorless solid is purified by elution with CombiFlash (12 g SiO 2 Purification by FC using a column; gradient from hept to hept / EA 1 / 1 in 17 min) gives the desired intermediate as a colourless solid. LCMS (A): R =1.01min;[M+H] + =455.19 1H NMR (500MHz, DMSO) δ:8.68-8.74(m, 1H), 7.82-7.91(m, 2H), 5.13-5.23(m, 1H), 4.67-4.74(m, 1H), 4.27-4.33(m, 2H), 4.17-4.2 5(m, 1H), 4.05-4.12(m, 1H), 3.78-3.86(m, 1H), 3.66-3.74(m, 1H), 3.23-3.26(m, 1H), 3.22(s, 3H), 1.34(s, 3H), 1.23(s, 3H)

[0182] Intermediate 27a: ((4aR,6R,7R,8R,8aR)-7-Methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methanamine To a solution of intermediate 26a (500 mg, 1.1 mmol, 1 eq) in THF (7.5 mL) was added PPh 3 (583 mg, 2.2 mmol, 2 eq) and water (1.5 mL) were added. The resulting mixture was then heated under reduced pressure in a nitrogen 2 The mixture was heated at 60° C. under reduced pressure for 3 h. The mixture was diluted with EA and then extracted with 10% citric acid (3 times) until all amine was removed from the organic phase. The aqueous layers were combined and extracted once more with EA, then with aq.sat.NaHCO 3 The basic aqueous layer was extracted twice with EA. The organic layers were combined and diluted with MgSO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure. It was used as is. LCMS(A):t R =0.72min;[M+H] + =429.09 1 H NMR (500MHz, DMSO) δ:8.42-8.90(m, 1H), 7.77-7.89(m, 2H), 5.09(dd, J 1 =11.4Hz, J 2 =3.4Hz, 1H), 4.27-4.31(m, 2H), 4.23(m, 1H), 3.99-4.03(m, 1H), 3.74(dd, J 1 = 1.5Hz, J 2=12.8Hz, 1H), 3.68(s, 1H), 3.21(s, 3H), 3.11(dd, J 1 =13.8Hz, J 2 =10.5Hz, 1H), 2.67(dd, J 1 =13.8Hz, J 2 =3.4Hz, 1H), 1.32(s, 3H) Different Ar 1 All further analogs of intermediates 3-27 bearing -substituents were prepared similarly to the procedures described above starting from known or commercially available substituted arylacetylenes.

[0183] Namely, the following most important analogues of intermediates 6, 8, 9, 26 and 27 were prepared and used in the synthesis of the final examples:

[0184] [Table 6]

[0185] [Table 7]

[0186] [Table 8]

[0187] [Table 9]

[0188] Production of other non-commercial intermediates: The following intermediates were prepared according to the procedure for intermediate 8a:

[0189] [Table 10]

[0190] Intermediate 33: 2-(4-ethynylpiperidin-1-yl)oxazole 4-Ethynylpiperidine hydrochloride (118 mg, 0.81 mmol, 1 eq) and 2-bromo-1,3-oxazole (126 mg, 0.81 mmol, 1 eq) were dissolved in DMF (2 mL) and the Cs 2 CO 3 (660 mg, 2.03 mmol, 2.5 eq) is added at rt. The mixture is stirred at rt for 2 h and at 100 °C for 1 h. The mixture is diluted with water and extracted twice with EA. After washing the organic layers with brine, they are combined and diluted with MgSO 4 Dry at 40° C., filter and evaporate. The product is purified by FC (CombiFlash, 4 g redisep column, 0-100% EA in hept) to give the desired intermediate as a pinkish oil. LCMS (A): R =0.47min;[M+H] + =177.33

[0191] Intermediate 34: 2-(4-ethynylpiperidin-1-yl)benzo[d]thiazole This intermediate is prepared analogously to intermediate 33. LCMS(A):t R =0.78min;[M+H] + =243.12

[0192] Intermediate 35: 2-(4-ethynylpiperidin-1-yl)thiazole This intermediate is prepared analogously to intermediate 33. LCMS(A):t R =0.50min;[M+H] + =193.25

[0193] Intermediate 36: Benzyl 4-azidopiperidine-1-carboxylate This intermediate is prepared analogously to a literature procedure (WO2017007689). LCMS (A): R =0.96min;[M+H] + =261.15

[0194] Intermediate 38: 1-(Isopropylimino)hexahydro-1l6-thiopyran-4-carbaldehyde 1-oxide oxime A solution of tetrahydrothiopyran-4-carbaldehyde (1 eq) in EtOH (1 mL / mmol) and CSA (spatula tip amount) is stirred in a sealed flask until the reaction is complete.

[0195] The ethyl acetal intermediate is oxidized according to general procedure N.

[0196] The sulfoxide intermediate is oxidized according to general procedure M.

[0197] The sulfoximine intermediate is alkylated according to general procedure J.

[0198] The acetal is deprotected according to general procedure C.

[0199] 1 H NMR (500MHz, DMSO) δ:9.33-9.72(m, 1H), 3.44-3.62(m, 2H), 3.18-3.23(m, 2H), 3.02-3.08(m, 1H), 2.62-2.67(m, 1H), 2.16-2.20(m, 2H), 1. 73-1.81(m, 2H), 1.05-1.07(m, 6H) The aldehyde is converted to the title oxime analogously to intermediate 8a and used without purification.

[0200] Intermediate 39: Ethyl 4-ethynylpiperidine-1-carboxylate This intermediate is prepared from 4-ethynylpiperidine hydrochloride following general procedure G. LCMS (A): R =0.80;[M+H] + =182.32.

[0201] Intermediate 40: 4-ethynyl-1-(N-isopropylpropan-2-ylsulfonimidoyl)piperidine Sulfuryl chloride (3 eq) is slowly added to a solution of diisopropyl disulfide (1 eq) in acetic acid (2 eq) cooled to −40° C. The reaction mixture is stirred at rt until the reaction is complete, concentrated and used directly in the next step.

[0202] The sulfinamide is prepared according to general procedure H.

[0203] The sulfonimidamides are prepared according to general procedure M.

[0204] The sulfonimidamide is alkylated according to general procedure J. LCMS(A):t R =0.67;[M+H] + =257.24.

[0205] Intermediate 41: Trimethyl(prop-1,2-dien-1-yl)silane The desired intermediate was prepared according to a literature procedure (OL 2009, 11, 5458).

[0206] 1 H NMR (500MHz, CDCl3) δ:0.13(s, 11H), 4.33(d, J=7.1Hz, 2H), 4.90(t, J=7.1Hz, 1H)

[0207] Intermediate 42: 1-Ethynylcyclopentane-1-carbonitrile A solution of 1-formylcyclopentane-1-carbonitrile (1 eq) in MeOH (5 mL / mmol) was added to 2 CO 3 (2 eq) and 1-diazo-1-dimethoxyphosphoryl-propan-2-one (1.1 eq) are added. The suspension is stirred at rt for 2 h. Aqueous workup (saturated NaHCO 3 / pentane) the crude product is dried and used without further purification.

[0208] 1H NMR (500MHz, DMSO) δ:1.70-1.88(m, 4H), 2.03-2.12(m, 2H), 2.17-2.32(m, 2H), 3.58-3.64(m, 1H)

[0209] Intermediate 43: N-Cyclohexyl-2,2-dihydroxyacetamide Step 1: (2R,3R)-N1,N4-dicyclohexyl-2,3-dihydroxysuccinamide (+)-Dimethyl L-tartrate (1 eq) and cyclohexylamine (2.5 eq) are stirred in a sealed flask at 80° C. for 1 h. TBME is added and the suspension is filtered. The solid is dried. LCMS (A): R =0.71;[M+H] + =313.28.

[0210] Step 2: N-Cyclohexyl-2,2-dihydroxyacetamide The intermediate from step 1 (1 eq) was dissolved in dioxane / H 2 Dissolve in 0 5:1 (5 mL / mmol) and add sodium (meta)periodate (1.2 eq). Stir the reaction mixture o / n at rt. Filter the suspension and wash the solid with EA and dry. Use in the next step without purification. LCMS (A):t R =0.45;[M+H] + =174.25

[0211] Intermediate 44: N-(1-acetylpiperidin-4-yl)-2,2-dihydroxyacetamide Same as intermediate 43, except cyclohexylamine was replaced with 4-amino N-acetylpiperidine.

[0212] Intermediate 45: 2,2-Dihydroxy-N-(tetrahydro-2H-pyran-4-yl)acetamide Same as intermediate 43, except 4-aminotetrahydropyran was used instead of cyclohexylamine.

[0213] Intermediate 46: Ethyl 4-(2,2-dihydroxyacetamido)piperidine-1-carboxylate Same as intermediate 43, except ethyl 4-aminopiperidine-1-carboxylate was used instead of cyclohexylamine. LCMS(A):t R =0.45;[M+H] + =247.26

[0214] Intermediate 47: Trimethyl(1-(nitromethyl)cyclobutoxy)silane Step 1: 1-(Nitromethyl)cyclobutan-1-ol Nitromethane (2.75 mL, 50 mmol, 1 eq) was treated with 1,1,3,3-tetramethylguanidine (0.35 mL, 2.76 mmol, 0.05 eq) followed by the dropwise addition of cyclobutanone (3613 mg, 50 mmol, 1 eq) over 1 h. The mixture was stirred o / n at rt, diluted with EA, washed with water (twice) and brine, and diluted with MgSO 4 The crude product was used directly in the next step.

[0215] Step 2: Trimethyl(1-(nitromethyl)cyclobutoxy)silane Imidazole (1744 mg, 25.6 mmol, 1.2 eq) was dissolved in DMF (5 mL) and chlorotrimethylsilane (2.98 mL, 23.5 mmol, 1.1 eq) was added. The intermediate from step 1 (2800 mg, 21.4 mmol, 1 eq) was added dropwise over 15 min. The mixture was stirred at rt for 3 h and partitioned between TBME and water. The organic phase was washed with water and brine and diluted with MgSO 4 Dry at rt and concentrate under reduced pressure (100 mbar, 40° C.) to give the desired intermediate as a liquid. 1 H NMR (500MHz, DMSO) δ:4.71(s, 2H), 3.08(s), 2.30(m, 2H), 2.16-2.23(m, 2H), 1.58-1.77(m, 2H), 1.11(s), 0.11(m, 9H)

[0216] Intermediate 48: 1-Cyclopropyl-1-(pyridin-2-yl)prop-2-yn-1-ol A solution of trimethylsilylacetylene (0.252 ml, 1.73 mmol) in THF (5 ml) was cooled to 0° C. and a solution of nBuLi (2.5 M in hexane) (0.676 mL, 1.18 eq) was added dropwise under Ar atmosphere. The clear solution was stirred at 0° C. for 1 h, after which a solution of cyclopropyl(2-pyridyl)methanone (250 mg, 1.65 mmol) in THF (1.5 ml) was added dropwise. The mixture was stirred at 0° C. for 1 h. The mixture was partitioned between water and DCM. The organic phase was diluted with MgSO 4 The crude intermediate was dissolved in MeOH (5 mL) and concentrated. 2 CO 3 (342 mg, 1.94 mmol) was added at rt and stirred until the reaction was complete. The product was isolated by prep HPLC (I) (yellowish foam).

[0217] 1 H NMR (500MHz, MeOD) δ:8.53(ddd, J 1 =0.9Hz, J 2 = 1.7Hz, J 3 =4.9Hz, 1H), 7.86(m, 1H), 7.78(m, 1H), 7.35(ddd, J 1 = 1.2Hz, J 2 = 4.9Hz, J 3 =7.4Hz, 1H), 2.98(s, 1H), 1.42(tt, J 1 = 5.1Hz, J 2 =8.2Hz, 1H), 0.68-0.78(m, 2H), 0.48-0.53(m, 2H). LCMS(A):t R =0.42;[M+H] + =174.13.

[0218] Intermediate 49: 3-Bromo-5-((3-ethynyloxetan-3-yl)oxy)pyridine This intermediate was prepared analogously to J. Med. Chem. 2011, 54, 8471-8489 (preparation of compound 22) starting from 3-ethynyloxetan-3-ol and 3-bromo-5-hydroxypyridine.

[0219] 1 H NMR (400MHz, MeOD) δ:8.36(d, J=1.8Hz, 1H), 8.21(d, J=2.5Hz, 1H), 7.57(dd, J 1 = 1.9Hz, J 2 =2.5Hz, 1H), 5.02(dd, J 1 =0.9Hz, J 2 =7.2Hz, 2H), 4.89-4.93(m, 5H), 3.58(s, 1H). LCMS(A):t R =0.79;[M+H] + =254.04

[0220] B. Preparation of Examples General procedure A: Cycloaddition of nitrile oxides with alkenes or alkynes: A solution of the oxime intermediate (1 eq) and NCS (1.5 eq) in DMF (5 mL / mmol) is stirred at rt until complete conversion to hydroximoyl chloride. Alkene or alkyne (1-3 eq) and DIPEA or 2,6-lutidine (3-4 eq) are added and the mixture is stirred at rt or 50° C. until complete conversion of the intermediate. After aqueous workup (dil.HCl / EA) the product is isolated and purified as described in the general method. Reaction with alkenes leads to the formation of diastereomers which can be separated by chiral preparative HPLC as described in the general method.

[0221] General procedure A': Cycloaddition of aldehydes and alkynes or alkenes in a one-pot procedure K 2 CO 3(3 eq) is added at rt to a solution of aldehyde (4 eq) and hydroxylamine HCl (4 eq) in DMF (5 ml / mmol). The mixture is stirred o / n at rt. NCS (5 eq) is added and the mixture is stirred at rt for a further 2 h. Alkyne or alkene (1 eq) and 2,6-lutidine (4 eq) are added and the mixture is stirred at 55° C. until the reaction is complete. After aqueous workup (dil.HCl / EA) the product is isolated and purified as described in the general method.

[0222] General procedure B: Copper-catalyzed cycloaddition of azides with alkynes (click chemistry) A mixture of azide (1 eq), alkyne (1 eq), CuI (0.1 eq) and DIPEA (3 eq) in DMF or THF (5 ml / mmol) is heated at 50° C. until complete conversion. After aqueous workup (dil.HCl / EA) the product is isolated and purified as described in general method.

[0223] General procedure C: Deprotection with aq.AcOH The protected intermediates (acetal and / or silyl Pg) (1 eq) were treated with AcOH / H until the reaction was complete. 2 O 1:1 or AcOH / H 2 Reflux in O / THF or dioxane 1:1:1 (5 mL / mmol) The product is purified as described in the general method.

[0224] General procedure D: K in MeOH 2 CO 3 Acetate deprotection by K 2 CO 3 (0.1 eq) to the acetate protected intermediate in MeOH (5 mL / mmol) (1 eq) and stir at rt until the reaction is complete. The product is purified as described in General Methods.

[0225] General procedure E: Boc deprotection with TFA TFA (10-20 eq) is added to a solution of the Boc-protected intermediate (1 eq) in DCM (5 ml / mmol). The mixture is stirred at rt until complete conversion. The volatiles are removed under reduced pressure and the residue is dissolved in DCM and dil.NH 4 Partition the organic phase between MgSO 4 Dry at rt and concentrate in vacuo. If necessary, the product is further purified as described in General Methods.

[0226] General procedure F: Boc deprotection with HCl A solution of the Boc-protected amine (1 eq) in dioxane (5 ml / mmol) is treated with a solution of HCl in dioxane (4 M, 10-20 eq) and the resulting mixture is stirred at rt until the reaction is complete. Volatiles are removed under reduced pressure and the crude product is isolated by trituration with TBME.

[0227] General procedure G: Schotten Baumann acylation Acyl chloride or anhydride (1.2 eq) was dissolved in 1 eq of amine (1 eq) in DCM (5 ml / mmol) and sat. NaHCO at 0 °C. 3 The solution (5 ml / mmol) is added to the biphasic mixture under vigorous stirring. The mixture is further stirred at rt until complete conversion. The phases are separated and the organic phase is washed with MgSO 4 Dry at 40° C. and concentrate. The product is purified as described in the general method.

[0228] General procedure H: Derivatization with sulfonyl chlorides, chloroformates, isocyanates, sulfinyl chlorides, sulfamoyl chlorides, or carbamoyl chlorides The electrophile (sulfonyl chloride, chloroformate, isocyanate, sulfinyl chloride, sulfamoyl chloride or carbamoyl chloride 1.1 eq) was added to a mixture of the starting amine (1 eq free base or as TFA or HCl salt) in DCM (5 ml / mmol) with DMF (1 ml / mmol) and base (NEt 3or DIPEA, 5 eq) with or without is added at 0° C. or rt. The mixture is stirred at rt until the reaction is complete. The product is purified as described in the general methods.

[0229] General Procedure I: Standard Amide Coupling A solution of acid BB (1.1 eq) and amine intermediate (1 eq) in DMF (5 ml / mmol) was treated with DIPEA (3-5 eq) and a coupling reagent (HATU, DCC, EDC HCl, BOP / HOBt or T 3 P (50% solution in EA) (1.5 eq) is added and the mixture is stirred at rt until complete conversion. After aqueous workup (EA / dil.HCl) the product is purified as described in the general method.

[0230] General Method J: Reductive Amination A mixture of the amine intermediate (1 eq) and the aldehyde BB or ketone (1-2 eq) in DCM is reacted with NaBH(OAc) 3 (3 eq) and stir the mixture at rt until complete conversion. 4 After reaction (OH) the desired product is isolated as described in the general method.

[0231] General method K: Acetal protection A mixture of the diol, 2,2-dimethoxypropane (3 eq) and pTsOH or CSA (0.05 eq) in THF is stirred at rt until the reaction is complete. 3 ) the crude product is used directly in the next step.

[0232] General Method L: O / N-Alkylation To a solution of hydroxy or amine intermediate (1 eq) and alkylating agent (chloride, bromide or mesylate) (1.2 eq) in DMF cooled to 0° C., sodium hydride (1.2 eq) is added. The mixture is stirred at 0° C. for 20 min and at rt until the reaction is complete. Aqueous workup (EA / sat NH 4After purification, the product is purified as described in the general methods.

[0233] General Procedure M: Formation of Sulfonimidamides or Sulfoximines A mixture of diacetoxyiodobenzene (3 eq), ammonium carbamate (4 eq) and sulfur derivative (1 eq) in MeOH is stirred at rt until the reaction is complete. Aqueous workup (EA / sat.NaHCO 3 ) the crude product is used directly in the next step.

[0234] General Method N: Oxidation (formation of sulfoxide) The sulfur derivative (1 eq) in MeOH and dioxane is cooled to 0°C. Sodium periodate (1.1 eq) is dissolved in H 2 A solution of 1H2O in 1H2O is added dropwise and the reaction mixture is stirred at rt until the reaction is complete. 2 After O) the product is purified as described in General Methods.

[0235] General Method O: Oxidation (formation of sulfone) A mixture of mCPBA (2.5 eq) and the sulfur derivative (1 eq) in DCM is stirred at rt until the reaction is complete. The mixture is used as is in the next step.

[0236] General manufacturing method P: Cbz deprotection The Cbz protected intermediate (1 eq) in MeOH (5 mL / mmol) is stirred with Pd / C 10% (0.1 eq) under hydrogen atmosphere (1 bar) until the reaction is complete. After filtration, the liquid is concentrated under reduced pressure and the crude product is used directly in the next step.

[0237] General Method Q: Saponification THF / H 2 O 1:1 or THF / MeOH / H 2 Ester (1 eq) and LiOH in O 3:2:1 (1 mL / mmol) . H 2O (1.5-3 eq) was added and stirred at rt until the reaction was complete. 2 After O) the product is purified as described in General Methods.

[0238] General process R: Epoxidation mCPBA (1.5 eq) in DCM (5 mL / mmol) was dissolved in MgSO 4 Dry with 500 cc and filter. Alkene (1 eq) in DCM (5 mL / mmol) is cooled to 0° C. and the mCPBA solution is added. The reaction mixture is stirred at rt until the reaction is complete. Aqueous workup (DCM / H 2 O or 10% Na 2 S 2 O 3 ) the crude product is purified as described in General Methods.

[0239] General Process S: Epoxide Ring Opening The amine (5 eq) is added to the epoxide (1 eq) in MeOH (5 mL / mmol). The mixture is stirred at 70° C. until the reaction is complete. Aqueous workup (EA / sat.NH 4 After purification, the product is purified as described in the general methods.

[0240] General Method S': Epoxide Ring Opening Add the amine (1 eq) to the epoxide (1 eq) in DMF (5 mL / mmol). Add a 1M solution of lithium tert-butoxide in THF (1.5-2 eq) and the reaction The mixture is stirred at rt until completion of the reaction. 2 After O) the product is purified as described in General Methods.

[0241] General procedure T: Cyclization with triphosgene or diphosgene DIPEA or NEt 3(4-10 eq) and triphosgene (0.4-0.8 eq) or 1 M solution of bis(trichloromethyl)carbonate (1 eq) are added dropwise to 1,2-aminoalcohol (1 eq) in DCM (5-10 ml / mmol) at 0° C. The reaction mixture is stirred at rt until the reaction is complete. Aqueous workup (DCM / sat.NaHCO 3 ) the product is purified as described in General Methods.

[0242] General procedure U: Dehydration of nitro derivatives to form nitrile oxides (Mukaiyama conditions) and cycloaddition with alkynes (J. Am. Chem. Soc., 1960, 82, 20, 5339-5342) A solution of the alkyne derivative (1 eq) and the alkyl nitro derivative (3 eq) in toluene (10 ml / mmol) was treated with phenyl isocyanate (2.5 eq) followed by 2,6-lutidine (3 eq) and NEt 3 (0.2 eq) is added. The mixture is stirred at 50-55° C. until the reaction is complete. After aqueous workup (water / EA) the product is purified as described in the general method.

[0243] The compounds of Examples 1.01 to 1.352 listed in Table 1 below are prepared by applying General Procedure A or A' to the appropriate intermediates or commercially available building blocks from the above sections, followed by deprotection according to General Procedure C or D to give the isoxazoles or isoxazolidines.

[0244] [Table 11]

[0245] [Table 12]

[0246] [Table 13]

[0247]

Table 14

[0248]

Table 15

[0249]

Table 16

[0250]

Table 17

[0251]

Table 18

[0252]

Table 19

[0253]

Table 20

[0254]

Table 21

[0255]

Table 22

[0256]

Table 23

[0257]

Table 24

[0258]

Table 25

[0259]

Table 26

[0260]

Table 27

[0261]

Table 28

[0262]

Table 29

[0263]

Table 30

[0264]

Table 31

[0265]

Table 32

[0266]

Table 33

[0267]

Table 34

[0268] [Table 35]

[0269] [Table 36]

[0270] [Table 37]

[0271] [Table 38]

[0272] [Table 39]

[0273] [Table 40]

[0274] Example 2.01: (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((3-(4-methoxyphenyl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol Step 1: To a mixture of (2R,3R,4R,5R,6R)-2-(acetoxymethyl)-6-(((RS)-3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyl diacetate (intermediate in the synthesis of Example 1.02, 270 mg, 0.409 mmol, 1 eq) in dry toluene (8 mL), manganese(IV) oxide (632 mg, 6.54 mmol, 16 eq) is added and the resulting suspension is heated to 100° C. and stirred o / n at this temperature. An additional amount of manganese(IV) oxide (355 mg, 4.09 mmol, 10 eq) is added and the black suspension is stirred at 100° C. for another 24 h. The black suspension is filtered, the solid is washed with EA and the filtrate is concentrated under reduced pressure. The crude is purified by prep. HPLC (LCMS III) to give the acetate protected title compound. LCMS (A):t R =1.09min;[M+H] + =659.20 Step 2: Deprotection following general procedure D gives the title compound. LCMS (A): tR=0.87 min; [M+H]+=533.24

[0275] Example 2.02 5-((RS)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridine-2( 1H)-On Step 1: To a solution of (2R,3R,4R,5R,6R)-2-(acetoxymethyl)-6-(((RS)-3-(6-methoxypyridin-3-yl)-4,5-dihydroisoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyl diacetate (intermediate in the synthesis of Example 1.23, 49 mg, 0.0741 mmol, 1 eq) in dry acetonitrile (1 mL) was added N 2 Chlorotrimethylsilane (0.047 mL, 0.37 mmol, 5 eq) and sodium iodide (55.5 mg, 0.37 mmol, 5 eq) are added under reduced pressure and the resulting yellow suspension is stirred for 2 h at 80° C. The suspension is diluted with EA and diluted with 10% Na 2 S 2 O 3 The organic layer is washed twice with aqueous solution, once with water, and once with brine. 4 Dry at 40° C., filter and concentrate under reduced pressure. LCMS(A):t R =0.90min;[M+H] + =648.11 Step 2: Deprotection according to general procedure D gives the title compound. LCMS (A):t R =0.64min;[M+H] + =522.15

[0276] Example 2.03: 4-((RS)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one Step 1: 4-((RS)-5-(((4aR,6R,7R,8R,8aR)-7-hydroxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one This intermediate is prepared analogously to Example 2.02, step 1, starting from the intermediate of Example 1.24. LCMS (A): R =0.83min;[M+H] + =561.91 Step 2: Deprotection according to general procedure C gives the title compound. LCMS (A):t R =0.65min;[M+H] + =522.15

[0277] Examples 2.04 and 2.05: The diastereomers of the compound of Example 2.03 are separated by chiral HPLC (chiral prep HPLC (III)). First eluting compound: S-isomer. Second eluting compound: R-isomer.

[0278] Both compounds are deprotected according to general procedure C to give the following compounds: Example 2.04 4-((R)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one LCMS(A):t R =0.65min;[M+H] + =522.15 1H NMR (500MHz, DMSO-d6) δ:11.54-11.71(m, 1H), 8.56-8.85(m, 1H), 7.83-7.87(m, 2H), 7.34-7.44(m, 1H), 6.37-6.61(m, 2H), 5.10-5.35(m, 2H), 4.83-5.04(m, 2) H), 4.49-4.65(m, 2H), 4.05-4.26(m, 1H), 3.82-3.92(m, 2H), 3.41-3.48(m, 3H), 3.16-3.21(m, 1H), 2.39-2.43(m, 1H), 1.74-2.02(m, 1H)

[0279] Example 2.05. 4-((S)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one LCMS(A):t R =0.66min;[M+H] + =522.14 1 H NMR (500MHz, DMSO-d6) δ:11.58-11.68(m, 1H), 8.72-8.76(m, 1H), 7.84(m, 2H), 7.38(d, J=6.8Hz, 1H), 6.28-6.6 7(m, 2H), 5.28(m, 2H), 4.85-4.93(m, 2H), 4.71(t, J=5.8Hz, 1H), 4.54(m, 1H), 4.23(ddd, J 1 =11.7Hz, J 2 = 6.1Hz, J 3 =2.4Hz, 1H), 3.81-3.90(m, 2H), 3.45-3.55(m, 3H), 3.12(dd, J 1 =17.3Hz, J 2 =7.9Hz, 1H), 2.25-2.31(m, 1H), 1.95(m, 1H)

[0280] Example 2.06: 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one The title example is prepared analogously to Example 2.03. LCMS(A):t R =0.75min;[M+H] + =536.14

[0281] Example 2.07a: 4-((S)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one The title example is prepared by chiral separation of Example 2.06. LCMS(A):t R =0.75min;[M+H] + =536.17 1 H NMR (500MHz, DMSO-d6) δ:11.57-11.70(m, 1H), 8.72-8.90(m, 1H), 7.73-7.94(m, 2H), 7.35-7.41(m, 1H), 6.46-6.53(m, 2H), 5.24-5.36(m, 1H), 4.84- 5.04(m, 2H), 4.74(m, 1H), 4.45-4.61(m, 1H), 4.25-4.31(m, 1H), 3.74-3.96(m, 2H), 3.45-3.56(m, 3H), 3.21(s, 3H), 3.14(dd, J 1 =17.3Hz, J 2 =8.2Hz, 1H), 2.37(m, 2H), 1.75-1.81(m, 1H)

[0282] Example 2.07b: 4-((R)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one The title example is obtained by chiral separation of Example 2.06. LCMS(A):t R =0.75min;[M+H] + =536.15

[0283] Example 2.08: (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-((RS)-pyrrolidin-3-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2, 3-Triazol-1-yl)tetrahydro-2H-pyran-3-ol The intermediate of Example 1.70 is deprotected using general procedure E. LCMS (A): R =0.66min;[M+H] + =510.14

[0284] Example 2.09: 1-((RS)-3-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)pyrrolidin-1-yl)ethan-1-one Example 2.08 is acylated with acetic anhydride according to general procedure G. LCMS (A): R =0.79min;[M+H] + =552.08

[0285] Example 2.10: 1-((RS)-4-hydroxy-4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)azepan-1-yl)ethan-1-one The title example is prepared starting from the intermediate of Example 1.76 following general procedures E and G. LCMS (A): R =0.76min;[M+H] + =596.11

[0286] Example 2.11: (1S,4s)-4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-4-hydroxycyclohexane-1-carboxylic acid Example 1.78 is saponified using general procedure Q.

[0287] LCMS(A):t R =0.63min;[M+H] + =569.01

[0288] Example 2.12: 4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclohexan-1-one The compound of Example 1.77 is deprotected using general procedure C. LCMS (A): R =0.76min;[M+H] + =523.04

[0289] Example 2.13: (2R,3R,4R,5R,6R)-2-((5-(4-hydroxycyclohexyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol (cis / trans mixture 1:1) A solution of Example 2.12 (25 mg, 0.0478 mmol, 1 eq) in MeOH (1.5 mL) is treated with sodium borohydride (1.83 mg, 0.0478 mmol, 1 eq) and the mixture is stirred at rt for 20 min. The product is recovered after aqueous workup as a mixture of isomers. LCMS (A): t R =0.72 / 0.73min;[M+H] + =525.05

[0290] Example 2.14: (2R,3R,4R,5R,6R)-2-((5-((1r,4r)-4-hydroxycyclohexyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2, 3-Triazol-1-yl)tetrahydro-2H-pyran-3,5-diol Example 2.13 is further purified by prep HPLC (Prep LC-MS III) to give the pure trans-configured compound. LCMS (A): t R =0.72min;[M+H] + =525.05 1 H NMR (500MHz, DMSO-d6) δ:8.76(s, 1H), 7.85(m, 2H), 6.34(d, 1H), 5.47(d, J=5.5Hz, 1H), 5.26(d, J=6.4Hz, 1H), 5.02(dd, J 1 =11.4Hz, J 2 =2.9Hz, 1H), 4.71(t, J=5.5Hz, 1H), 4.62(d, J=4.4Hz, 1H), 4.57(m, 1H), 4.17(ddd, J 1 =11.9Hz, J 2 = 6.0Hz, J 3 =2.6Hz, 1H), 3.93-3.98(m, 2H), 3.39-3.51(m, 3H), 3.27(dd, J 1 =15.2Hz, J 2 =12.0Hz, 1H), 2.93(dd, J 1 =15.2Hz, J 2 =2.6Hz, 1H), 2.65-2.72(m, 1H), 1.98-2.01(m, 2H), 1.90(dd, J 1 =12.9Hz, J 2 =3.3Hz, 2H), 1.37-1.45(m, 2H), 1.28(m, 3H)

[0291] Example 2.15: tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(propionyloxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate Step 1: tert-butyl 4-(3-(((4aR,6R,7R,8S,8aR)-7-acetoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate Intermediate 8b and 1-Boc-4-ethynylpiperidine are coupled according to general procedure A. LCMS (A): R =1.12min;[M+H] + =692.20 Step 2: tert-Butyl 4-(3-(((4aR,6R,7R,8R,8aR)-7-hydroxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate The acetate group of the step 1 intermediate is removed according to general procedure D. LCMS (A): R =1.05min;[M+H] + =650.19 Step 3: tert-butyl 4-(3-(((4aR,6R,7R,8S,8aR)-2,2-dimethyl-7-(propionyloxy)-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate Pyridine (0.17 mL, 0.215 mmol, 4 eq), DMAP (3.32 mg, 0.5 eq) and propionyl chloride (0.0057 mL, 1.2 eq) are added to a solution of the intermediate from step 2 (35 mg, 0.0539 mmol, 1 eq) in DCM (1 mL) and the mixture is stirred at rt for 2 days. The mixture is partitioned between DCM and water and the aqueous phase is extracted twice more with DCM. The organic phases are combined, washed with brine and diluted with MgSO 4 Dry at 40° C. and concentrate under reduced pressure. LCMS(A):t R = 1.14 min; [M+H] + =706.21 Step 4: tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(propionyloxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidinyl 1-carboxylate The intermediate of step 3 is deprotected according to general procedure C. LCMS (A): R =1.01min;[M+H] + =666.17

[0292] Example 2.16: (2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl propionate A small amount of the title compound is obtained in the synthesis of Example 2.15, Step 4. LCMS (A): R =0.71min;[M+H] + =566.16

[0293] Example 2.17: tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-3-ethoxy-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate Step 1: tert-butyl 4-(3-(((4aR,6R,7R,8R,8aR)-7-ethoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate Example 2.15 The intermediate from step 2 is alkylated using general procedure L. LCMS (A): t R = 1.14 min; [M+H] + =678.23 Step 2: The intermediate from step 1 is deprotected according to general procedure C. LCMS (A):t R =1.01min;[M+H] + =638.17

[0294] Example 2.18: (2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl propionate A small amount of the title compound is obtained in the synthesis of Example 2.17, Step 2. LCMS (A): R =0.71min;[M+H] + =538.18

[0295] Example 2.19: tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-propoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate This example is prepared analogously to Example 2.17 using 1-iodopropane instead of iodoethane. LCMS(A): R =1.04min;[M+H] + =652.20

[0296] Example 2.20: tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-3-butoxy-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate This example is prepared analogously to Example 2.17 using 1-iodobutane instead of iodoethane. LCMS(A): R =1.06min;[M+H] + =666.23

[0297] Example 2.21: 2-(((2R,3R,4S,5R,6R)-2-((5-(1-(tert-butoxycarbonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid This example is prepared analogously to Example 2.17, using iodoacetic acid instead of iodoethane. LCMS (A): R =0.89min;[M+H] + =668.13

[0298] Example 2.22: tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(isobutyryloxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate This example is prepared analogously to Example 2.15, steps 3-4, using isobutyryl chloride instead of propionyl chloride. LCMS (A): R =1.04min;[M+H] + =680.19

[0299] Example 2.23: tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-isopropoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate Step 1: tert-butyl 4-(3-(((4aR,6R,7R,8R,8aR)-7-hydroxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate Example 1.40 is protected according to general procedure K. LCMS(A):t R =1.05min;[M+H] + =650.18 Step 2: tert-Butyl 4-(3-(((4aR,6R,7R,8R,8aR)-7-isopropoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate The step 1 intermediate is alkylated with 2-iodopropane according to general procedure L. LCMS (A): R = 1.16 min; [M+H] + =692.30 Step 3: Deprotection according to general procedure C gives the title compound. LCMS (A):t R =1.03min;[M+H] + =652.17

[0300] Example 2.24: (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-isopropoxy-6-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol A small amount of the title compound is obtained in the synthesis of Example 2.23, Step 3. LCMS (A): R =0.73min;[M+H] + =552.16.

[0301] Example 2.25: tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-3-(2,2-difluoroethoxy)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazole-5 -yl)piperidine-1-carboxylate This example is prepared analogously to Example 2.23 using 2,2-difluoroethyl trifluoromethanesulfonate. LCMS (A): R =1.00min;[M+H] + =673.94

[0302] Example 2.26: (2R,3R,4S,5R,6R)-5-(2,2-difluoroethoxy)-2-(hydroxymethyl)-6-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol A small amount of the title compound is obtained in the synthesis of Example 2.25, Step 3. LCMS (A): R =0.72min;[M+H] + =574.15.

[0303] Example 2.27: 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid Step 1: (4aR,6R,7R,8R,8aR)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-8-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-7-ol Acetal Protection Hydrolysis of the acetate protecting group of Example 1.204 was carried out according to general procedure D. LCMS (A): R =1.04min;[M+H] + =519.29 Step 2: Methyl 2-(((4aR,6R,7R,8R,8aR)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-8-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-7-yl)oxy)acetate Alkylation of the intermediate in step 1 with methyl chloroacetate was carried out according to general procedure L. LCMS (A): t R =1.11min;[M+H] +=591.25 Step 3: 2-(((4aR,6R,7R,8R,8aR)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-8-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-7-yl)oxy)acetic acid Ester hydrolysis was carried out according to general procedure Q. LCMS(A):t R =1.01min;[M+H] + =577.22 Step 4: Deprotection according to general procedure C gives the title compound. LCMS (A):t R =0.84min;[M+H] + =537.22

[0304] Example 2.28: 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-morpholinoethan-1-one This example is prepared analogously to Example 2.27, steps 2 and 4, using 4-(chloroacetyl)morpholine instead of methyl chloroacetate. LCMS (A): R =0.86min;[M+H] + =610.247

[0305] Example 2.29: tert-Butyl ((S)-1-(((1R,4S)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3 -Triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclohexyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate Step 1: (2R,3R,4S,5R,6R)-6-((3-((1r,4R)-4-aminocyclohexyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol Example 1.134 is deprotected using general procedure E. LCMS (A): R =0.69min;[M+H] + =538.22 Step 2: tert-butyl ((S)-1-(((1R,4S)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclohexyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate The step 2 intermediate is coupled to Boc-Val-OH by HATU using general procedure I. LCMS (A): R =0.98min;[M+H] + =737.38

[0306] Example 2.30: (S)-2-amino-N-((1R,4S)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclohexyl)-3-methylbutanamide The Boc group of Example 2.29 is deprotected using general procedure E. LCMS (A): R =0.74min;[M+H] + =637.30

[0307] Example 2.31: tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-3-ethoxy-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate Step 1: tert-butyl 4-((RS)-5-(((4aR,6R,7R,8R,8aR)-7-hydroxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate Intermediate 5a and intermediate 37 are coupled using general procedure A. LCMS (A): R =1.01min;[M+H] + =652.27 Step 2: tert-Butyl 4-((RS)-5-(((4aR,6R,7R,8R,8aR)-7-ethoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate The intermediate from step 1 is alkylated with ethyl iodide according to general procedure L. LCMS(A):t R =1.12min;[M+H] + =680.30 Step 3: Deprotection according to general procedure C gives the title compound. LCMS (A):t R =0.98min;[M+H] + =640.30

[0308] Example 2.32: tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-3-(2,2-difluoroethoxy)-5-hydroxy-6-(hydro 4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate This example is prepared analogously to Example 2.31 using 2,2-difluoroethyl trifluoromethanesulfonate instead of ethyl iodide. LCMS (A): R =0.97min;[M+H] + =676.20

[0309] Example 2.33: tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(2-methoxy-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate This example is prepared analogously to Example 2.31 using methyl bromoacetate instead of ethyl iodide. LCMS (A): t R =0.95min;[M+H] + =684.30

[0310] Example 2.34: 2-(((2R,3R,4S,5R,6R)-2-(((RS)-3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid Step 1: tert-butyl 4-((RS)-5-(((4aR,6R,7R,8R,8aR)-7-(2-methoxy-2-oxoethoxy)-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate This intermediate is prepared analogously to Example 2.31, steps 1 and 2. LCMS (A): R =1.09min;[M+H] + =724.26 Step 2: 2-(((4aR,6R,7R,8R,8aR)-6-(((RS)-3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl)oxy)acetic acid The intermediate from step 1 is saponified using general procedure Q. LCMS(A):t R =1.02min;[M+H] + =710.33 Step 3: Deprotection according to general procedure C gives the title compound. LCMS (A):t R =0.86min;[M+H] + =670.29

[0311] Example 2.35: tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(2-(methylamino)-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate This example is prepared analogously to Example 2.31 using 2-bromo-N-methylacetamine instead of ethyl iodide. LCMS (A): R =0.87min;[M+H] + =683.32

[0312] Example 2.36: tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(2-morpholino-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1 ,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate This example is prepared analogously to Example 2.31 using 4-(chloroacetyl)-morpholine instead of ethyl iodide. LCMS (A): R =0.88min;[M+H] + =739.35

[0313] Example 2.37: 2-(((2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid This product is prepared analogously to Example 2.34, steps 1, 2 and 3, starting from intermediate 9g and pivalaldehyde oxime. LCMS (A): R =0.83min;[M+H] + =541.19

[0314] Example 2.38: 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-N-methylacetamide This product is prepared analogously to Example 2.27 starting from intermediate 8b using 2-bromo-N-methyl-acetamide. LCMS (A): R =0.85min;[M+H]+=554.23

[0315] Example 2.39: 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-((R)-3-hydroxypyrrolidin-1-yl)ethan-1-one Step 1: 2-(((4aR,6R,7R,8R,8aR)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl)oxy)acetic acid This intermediate is prepared analogously to Example 2.27 starting from intermediate 8b. LCMS(A):t R =1.00min;[M+H]+=581.16. Step 2: 2-(((4aR,6R,7R,8R,8aR)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl)oxy)-1-((R)-3-hydroxypyrrolidin-1-yl)ethan-1-one The intermediate from step 1 is coupled with (R)-3-piperidinol according to general procedure I. LCMS (A): R =0.98min;[M+H]+=650.30 Step 3: Deprotection according to general procedure C gives the title compound. LCMS (A):t R =0.80min;[M+H] + =610.24

[0316] Example 2.40: 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-(3-hydroxyazetidin-1-yl)ethan-1-one This product is prepared analogously to Example 2.39 using azetidin-3-ol. LCMS(A):t R =0.79min;[M+H]+=596.24.

[0317] Example 2.41: 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-(4-hydroxypiperidin-1-yl)ethan-1-one This product is prepared analogously to Example 2.39 using hydroxypiperidine. LCMS (A): R =0.81min;[M+H]+=624.25.

[0318] Example 2.42: 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-((S)-3-hydroxypyrrolidin-1-yl)ethan-1-one This product is prepared analogously to Example 2.39 using (S)-3-piperidinol. LCMS (A): R =0.80min;[M+H]+=610.26.

[0319] Example 2.43: 2-(((2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid This product is prepared starting from intermediate 9h using trimethylacetaldehyde according to General Procedure A', followed by alkylation with ethyl bromoacetate (General Procedure L), saponification (General Procedure Q) and deprotection (General Procedure C). LCMS (A): t R =0.82min;[M+H]+=541.23.

[0320] Example 2.44: 2-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid This product is prepared analogously to Example 2.43 starting from intermediate 9h and 1-methylcyclopropane-1-carbaldehyde. LCMS (A): t R =0.80min;[M+H]+=539.14.

[0321] Example 2.45: (2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl carbamate Step 1: (4aR,6R,7R,8R,8aR)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-8-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-7-ol Intermediate 9i is coupled with trimethylacetaldehyde using general procedure A'. LCMS (A): R =1.04min;[M+H] + =519.30.

[0322] Step 2: The intermediate from step 1 is coupled with trichloroacetyl isocyanate and deprotected using general procedures H, D and C. LCMS (A): R =0.83min;[M+H] + =522.19.

[0323] Example 2.46: 2-(((2R,3R,4S,5R,6R)-5-hydroxy-2-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-6-(hydroxymethyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid This product is prepared analogously to Example 2.43 starting from intermediate 9h and 3-hydroxy-2,2-dimethylpropanal. LCMS (A): t R =0.70min;[M+H]+=557.14.

[0324] Example 2.47: (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(4-ethynyl-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol Step 1: To a mixture of Example 1.191 (1 eq), CuI (0.1 eq) and bis(triphenylphosphine)palladium (0.1 eq) in 1,4-dioxane (5 ml / mmol) was added NEt 3 (5 eq) and trimethylsilylacetylene (5 eq) are added. The resulting mixture is heated to 80 °C and stirred at this temperature for 3 h. Trimethylsilylacetylene (5 eq), CuI (0.1 eq) and bis(triphenylphosphine)palladium (0.1 eq) are further added and the mixture is stirred o / n at 80 °C. EA is added, the suspension is filtered and the filtrate is washed with water. The organic layer is diluted with MgSO 4 Dry at 40° C., filter and concentrate under reduced pressure. The crude material is used without further purification. LCMS (A): t R = 1.13 min; [M+H] + =575.25 Step 2: Deprotection (TMS group) according to general procedure D gives the title compound. LCMS (A):t R = 0.97min;[M+H]+ = 503.25.

[0325] Example 2.48: (2R,3R,4R,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol Step 1: (2R,3R,4R,5R,6R)-2-(acetoxymethyl)-4-azido-6-(prop-2-yn-1-yl)tetrahydro-2H-pyran-3,5-diyl diacetate Intermediate 1 (1 eq) is dissolved in MeOH and cooled to 0° C. Intermediate 41 (2 eq) is then reacted with BF 3 OEt 2(3 eq) and trimethylsilyl trifluoromethanesulfonate (2 eq) are added. The reaction mixture is stirred at 0° C. for 1 h and at rt for 2 h. Aqueous workup (NaHCO 3 After purification (sat. / EA) the crude product is purified as described in the general methods.

[0326] 1 H NMR (500MHz, DMSO) δ:1.99-2.01(m, 3H), 2.09-2.11(m, 6H), 2.58(m, 1H), 2.73(ddd, J 1 =17.4Hz, J 2 = 9.4Hz, J 3 =2.6Hz, 1H), 2.90(t, J=2.6Hz, 1H), 3.99-4.07(m, 4H), 4.23(m, 1H), 4.40(dd, J 1 = 10.5Hz, J 2 =3.4Hz, 1H), 5.02(dd, J 1 = 10.5Hz, J 2 =5.6Hz, 1H), 5.29(dd, J 1 = 3.4Hz, J 2 =1.6Hz, 1H) Step 2: (2R,3R,4R,5R,6R)-2-(acetoxymethyl)-4-azido-6-((3-(tert-butyl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3,5-diyl diacetate The intermediate of step 1 is coupled with trimethylacetaldehyde using general method A'. LCMS(A):t R = 1.00min;[M+H]+ = 453.22.

[0327] Step 3: (2R,3R,4R,5R,6R)-2-(acetoxymethyl)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diyl diacetate The intermediate from step 2 is coupled with 3,4,5-trifluorophenylacetylene using general procedure B. LCMS (A): R = 1.10min;[M+H]+ = 609.02.

[0328] Step 4: Deprotection according to general procedure D gives the title compound. LCMS (A):t R =0.84min;[M+H]+=483.18.

[0329] Example 2.49: (2R,3R,4R,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-6-(hydroxymethyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol The product is prepared analogously to Example 2.48 using 2,3,4-trifluorophenylacetylene. LCMS (A): R =0.83min;[M+H]+=483.19.

[0330] Example 2.50: (2R,3R,4R,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol The product is prepared analogously to Example 2.48 using 1-ethynyl-2,3-difluoro-4-methyl-benzene. LCMS (A): R =0.85min;[M+H]+=479.21.

[0331] Example 2.51: (2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl ethylcarbamate This product is prepared analogously to Example 2.45 using ethyl isocyanate in step 2. LCMS (A): t R = 0.90min;[M+H]+ = 550.15.

[0332] Example 2.52: (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-((1-methyl-1H-imidazol-2-yl)methoxy)tetrahydro-2H-pyran-3-ol This product was prepared starting from Example 2.45, Step 1 and 2-(chloromethyl)-1-methyl-1H-imidazole following General Procedure L (alkylation) followed by deprotection (General Procedure C). R =0.69min;[M+H]+=573.22.

[0333] Example 2.53: (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-(thiazol-2-ylmethoxy)tetrahydro-2H-pyran-3-ol R This product was prepared starting from Example 2.45, Step 1 and 2-(bromomethyl)thiazole following General Procedure L (alkylation) followed by deprotection (General Procedure C). R =0.94min;[M+H]+=576.18.

[0334] Example 2.54: (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-(thiazol-4-ylmethoxy)tetrahydro-2H-pyran-3-ol This product was prepared starting from Example 2.45, Step 1 and 4-(chloromethyl)thiazole following General Procedure L (alkylation) followed by deprotection (General Procedure C). R =0.94min;[M+H]+=576.18.

[0335] Example 2.55: (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-(oxazol-5-ylmethoxy)tetrahydro-2H-pyran-3-ol This product was prepared starting from Example 2.45, Step 1 and 5-(bromomethyl)oxazole following General Procedure L (alkylation) followed by deprotection (General Procedure C). R =0.92min;[M+H]+=560.23.

[0336] Example 2.56: (2R,3R,4S,5R,6R)-6-((3-(1-hydroxycyclobutyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol This product was prepared starting from intermediates 9a and 47 according to general procedure U. Deprotection was carried out according to general procedure C. R =0.83min;[M+H]+=511.20.

[0337] Example 2.57: (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxycyclobutyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol [1-(1,3-di-deoxy-2-O-methyl-3-[4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl]-aD-galacto-pyranose)-1-(3-(1-hydroxycyclobutyl)1H-isoxazol-5-yl)-methane] This product was prepared according to general procedure U starting from intermediates 9h and 47. Deprotection was carried out according to general procedure C. R =0.81min;[M+H]+=511.19.

[0338] Example 2.58: (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxycyclobutyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol This product was prepared starting from intermediates 9l and 47 according to general procedure U. Deprotection was carried out according to general procedure C. R =0.83min;[M+H]+=507.22.

[0339] Example 2.59: (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxycyclobutyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol This product was prepared starting from intermediates 9k and 47 according to general procedure U. Deprotection was carried out according to general procedure C. R =0.85min;[M+H]+=527.13

[0340] Example 2.60: (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((3-(2-hydroxypropan-2-yl)isoxazol-5-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol This product was prepared starting from trimethyl((2-methyl-1-nitropropan-2-yl)oxy)silane according to general procedure U. Deprotection was carried out according to general procedure C. R =0.80min;[M+H]+=499.20

[0341] Example 2.61: (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((3-(2-hydroxypropan-2-yl)isoxazol-5-yl)methyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol This product was prepared starting from intermediate 9h and trimethyl((2-methyl-1-nitropropan-2-yl)oxy)silane according to general procedure U. Deprotection was carried out according to general procedure C. R =0.78min;[M+H]+=499.21

[0342] Example 2.62: (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((3-(2-hydroxypropan-2-yl)isoxazol-5-yl)methyl)-5-methoxytetrahydro-2H-pyran-3-ol This product was prepared starting from intermediate 9l and trimethyl((2-methyl-1-nitropropan-2-yl)oxy)silane according to general procedure U. Deprotection was carried out according to general procedure C. R =0.80min;[M+H]+=495.22

[0343] Example 2.63: (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((3-(2-hydroxypropan-2-yl)isoxazol-5-yl)methyl)-5-methoxytetrahydro-2H-pyran-3-ol This product was prepared starting from intermediate 9k and trimethyl((2-methyl-1-nitropropan-2-yl)oxy)silane according to general procedure U. Deprotection was carried out according to general procedure C. R =0.82min;[M+H]+=515.17.

[0344] [ka] The compounds of Examples 3.01-3.70 listed in Table 2 below are the same as those of the Examples of Table 1 except for the Boc-protected The compounds are prepared by subjecting the protective intermediate to either one of Processes E or F described above, followed by derivatization with an electrophilic reagent using Processes G, H, I, J and / or M.

[0345] [Table 41]

[0346] [Table 42]

[0347] [Table 43]

[0348] [Table 44]

[0349] [Table 45]

[0350] [Table 46]

[0351] [Table 47]

[0352] [Table 48]

[0353] The compounds of Examples 4.01-4.55 listed in Table 3 below are prepared by applying General Procedure B (click chemistry) to the appropriate azide and alkyne building blocks (either commercially available or listed as intermediates). The triazoles are then further deprotected (General Procedures C, D, E, F or P) and / or derivatized according to General Procedures G, H, I, J, M, N and / or O.

[0354] [Table 49]

[0355] [Table 50]

[0356] [Table 51]

[0357] [Table 52]

[0358] [Table 53]

[0359] [Table 54] The compounds of Examples 5.01-5.26 listed in Table 4 below are prepared by applying General Procedure R to Intermediate 6. The epoxide is then further opened with a suitable amine (either commercially available or listed as an intermediate) according to General Procedure S or S' and cyclized according to T. The heterocyclyl is then further deprotected (General Procedure C, F) and / or derivatized according to General Procedure G, H or O.

[0360] [Table 55]

[0361] [Table 56]

[0362] [Table 57]

[0363] Example 5.24: tert-Butyl 4-((RS)-3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidin-5-yl)piperidine-1-carboxylate This product is prepared starting from intermediate 27a using general procedures S, T and C. LCMS (A): R = 0.93min;[M+H]+ = 642.26.

[0364] Example 6.01: (2R,3R,4S,5R,6R)-6-((5-(4,4-difluorocyclohexyl)isothiazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol Step 1: 4-(4,4-difluorocyclohexyl)-1-((4aR,6R,7R,8R,8aR)-7-methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)but-3-yn-2-ol 4-Ethynyl-1,1-difluorocyclohexane (1.1 eq) in THF (5 mL / mmol) is cooled to -78 °C. nBuLi 1.6 M (1.1 eq) in hexane is added dropwise under nitrogen atmosphere. After stirring at -78 °C for 1 h, intermediate 7a (1 eq) in THF (5 mL / mmol) is added and the reaction mixture is stirred at -78 °C for 2 h. Aqueous workup (EA / NH 4 After elution with Cl sat., the crude product is used without further purification. LCMS (A): R = 1.04min;[M+H]+ = 586.15.

[0365] Step 2: 4-(4,4-difluorocyclohexyl)-1-((4aR,6R,7R,8R,8aR)-7-methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)but-3-yn-2-one To a solution of the intermediate from step 1 (1 eq) in acetone (5 mL / mmol) was added MnO 2 (5 eq) is added 8 times. The reaction mixture is stirred at rt until the reaction is complete. After filtration, the filtrate is concentrated under reduced pressure. The crude product is purified by FC (heptane / EA 7:3) to give the desired product as a white solid. LCMS (A):t R = 1.10min;[M+H]+ = 584.10.

[0366] Step 3: (2R,3R,4S,5R,6R)-6-((5-(4,4-difluorocyclohexyl)isothiazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol H of the intermediate (1eq) of step 2 2 To a solution cooled to 0 °C in 2H2O (5 mL / mmol) is added hydroxylamine-O-sulfonic acid (1 eq). The mixture is stirred o / n at rt. NaHCO 3 (1 eq) and sodium hydrogen sulfate (1.1 eq) are added twice and the mixture is stirred until the reaction is complete. 2 After O) the product is purified as described in the general method. LCMS (A): R =0.98min;[M+H]+=574.86.

[0367] Example 6.02: tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isothiazol-5-yl)piperidine-1-carboxylate The product is prepared analogously to Example 6.01, using tert-butyl 4-ethynylpiperidine-1-carboxylate instead of 4-ethynyl-1,1-difluorocyclohexane. LCMS (A): R = 1.01min;[M+H]+ = 639.92.

[0368] Example 6.03: (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(piperidin-4-yl)isothiazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol The Boc group of Example 6.02 is deprotected in step 3. LCMS (A): R =0.68min;[M+H] + =539.83.

[0369] Example 6.04: (2R,3R,4S,5R,6R)-6-((4-(tert-butyl)-1H-imidazol-1-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol To a solution of intermediate 27a in toluene (5 mL / mmol) is added 1-bromopinacolone (1 eq), paraformaldehyde (1 eq) and ammonium acetate (1.5 eq). The reaction mixture is stirred at 110° C. until the reaction is complete. After aqueous workup (EA / H2O) the crude product is purified as described in the general method. LCMS (A): t R =0.73min;[M+H] + =496.30.

[0370] Example 6.05: 5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl) 1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl-3-phenyloxazol-2(3H)-one Step 1: 1-((4aR,6R,7R,8R,8aR)-6-(3-bromoprop-2-yn-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-8-yl)-4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazole To a solution of intermediate 9a (1 eq) in acetone (5 mL / mmol) is added NBS (1.3 eq) and silver nitrate (0.05 eq). The reaction mixture is stirred at rt until the reaction is complete. Aqueous workup (EA, H 2 O), the crude product is used without further purification. LCMS (A): t R=1.06min;[M+H] + =517.67.

[0371] Step 2: tert-butyl (3-((4aR,6R,7R,8R,8aR)-7-methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)prop-1-yn-1-yl)(phenyl)carbamate To a solution of the intermediate from step 1 (1.2 eq) and tert-butyl phenylcarbamate (1 eq) in toluene (5 mL / mmol) was added CuSO 4 (0.3 eq), potassium phosphate (2.6 eq) and 1,10-phenanthroline monohydrate (0.66 eq) are added. The reaction mixture is stirred at 85° C. until the reaction is complete. Aqueous workup (EA / H 2 After O) the crude product is purified as described in the general method. LCMS (A): R = 1.18 min; [M+H] + =629.09.

[0372] Step 3: 5-(((4aR,6R,7R,8R,8aR)-7-Methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)-3-phenyloxazol-2(3H)-one To a solution of step 2 intermediate (1 eq) in DCM (5 mL / mmol) is added chloro(triphenylphosphine)gold(I) (0.08 eq) and silver(V) hexafluoroantimonate (0.08 eq). The reaction mixture is stirred o / n at 40° C. Aqueous workup (DCM / H 2 O), the crude product is used without further purification. LCMS (A): t R =1.06min;[M+H] + =573.13.

[0373] Step 4: 5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-phenyloxazol-2(3H)-one THF / H 2 The intermediate of step 3 (1 eq) in O 1:2 (5 mL / mmol) is stirred with TFA overnight. The crude mixture is purified as described in the general method. LCMS (A): R =0.91min;[M+H] + =533.13.

[0374] Example 6.06: 3-Cyclohexyl-1-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)imidazolidin-4-one Step 1: N-cyclohexyl-2-((((4aR,6R,7R,8R,8aR)-8-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)amino)acetamide A solution of intermediate 27b (1 eq) and intermediate 43 (1.5 eq) in AcOH (2 eq) and DCM / MeOH 4:1 (5 mL / mmol) was added with sodium cyanoborohydride. (1.5 eq) is added. The mixture is stirred at rt for 1.5 h. Aqueous workup (DCM / NH 4 After OH sat.) the crude product is purified by FC (DCM / MeOH 19:1). LCMS (A):t R =0.82min;[M+H] + =564.29.

[0375] Step 2: 3-cyclohexyl-1-(((4aR,6R,7R,8R,8aR)-8-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)imidazolidin-4-one To a solution of the intermediate from step 1 (1 eq) in EtOH (5 mL / mmol) is added a formaldehyde solution (37% in water, 10 eq). The mixture is stirred at 80° C. until the reaction is complete. Aqueous workup (EA / H 2 After elution, the crude product is purified by FC (DCM / MeOH 9:1). LCMS (A): R =0.93min;[M+H] + =576.23.

[0376] Step 3: Deprotection according to general procedure C gives the title compound. LCMS (A):t R =0.77min;[M+H] + =536.27.

[0377] Example 6.07: 1-(1-acetylpiperidin-4-yl)-3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)imidazolidin-4-one Step 1: 2-chloro-N-(((4aR,6R,7R,8R,8aR)-7-methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)acetamide This intermediate is prepared according to general procedure G starting from intermediate 27a. LCMS(A): R =0.92min;[M+H] + =505.13.

[0378] Step 2: 2-((1-acetylpiperidin-4-yl)amino)-N-(((4aR,6R,7R,8R,8aR)-7-methoxy-2,2-dimethyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)acetamide The intermediate from step 1 (1 eq) is dissolved in DMF (5 mL / mmol). 1-Acetylpiperidin-4-amine (1.1 eq) and DIPEA (5 eq) are added and the reaction mixture is stirred at 50° C. until the reaction is complete. Aqueous workup (EA / H 2 After elution, the crude product is purified by FC (DCM / MeOH 9:1). LCMS (A): R =0.73min;[M+H] + =611.11.

[0379] Step 3: The title compound is obtained according to steps 2 and 3 of Example 6.06. LCMS (A):t R =0.66min;[M+H] + =583.18.

[0380] Example 6.08: 3-(1-acetylpiperidin-4-yl)-1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)imidazolidin-4-one. This product is prepared analogously to Example 6.06, starting from intermediate 27a and intermediate 44. LCMS (A): t R =0.67min;[M+H] + =583.21.

[0381] Example 6.09: 3-Cyclohexyl-1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro -2H-pyran-2-yl)methyl)imidazolidin-4-one This product is prepared analogously to Example 6.06, starting from intermediate 27a and intermediate 43. LCMS (A): R =0.78min;[M+H] + =540.21.

[0382] Example 6.10: 1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(tetrahydro-2H-pyran-4-yl)imidazolidin-4-one This product is prepared analogously to Example 6.06, starting from intermediate 27a and intermediate 45. LCMS (A): t R =0.68min;[M+H] + =542.21.

[0383] Example 6.11: Ethyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-5-oxoimidazolidin-1-yl)piperidine-1-carboxylate This product is prepared analogously to Example 6.06, starting from intermediate 27a and intermediate 46. LCMS (A): t R =0.76min;[M+H] + =613.11.

[0384] II. Biological Testing Inhibitory activity of the compound (IC 50 ) Evaluation The inhibitory activity of the compounds is determined in a competitive binding test. This spectrophotometric assay measures the binding of biotin-labeled human Gal-3 (hGal-3) or human Gal-1 (hGal-1), respectively, to the glycoprotein asialofetuin (ASF) adsorbed on microplates (Proc Natl Acad Seis USA. 2013 Mar 26;110(13):5052-7). Alternatively and preferably, a version of human Gal-1 in which all six cysteines are replaced by serine may be used.

[0385] Briefly, compounds are serially diluted in DMSO (Test Diluent). Add 22.8 μL / well of biotinylated hGal-3 or hGal-1 in assay buffer (i.e., 300-1000 ng / ml biotinylated hGal-3 or hGal-1) to an ASF-coated 384-well plate, add 1.2 μL of compound test diluent and mix.

[0386] Plates are incubated for 3 h at 4 °C, then washed with cold assay buffer (3x50 μl), incubated with 25 μL / well of streptavidin-peroxidase solution (diluted to 80 ng / ml in assay buffer) for 1 h at 4 °C, then washed further with assay buffer (3x50 μl). Finally, 25 μL / well of ABTS substrate is added. OD (410 nm) is recorded after 30-45 min and IC 50 Calculate the value.

[0387] Calculated IC 50 Values ​​may vary with each day's assay run. This type of variation is known to those skilled in the art. IC values ​​obtained from several measurements 50 Values ​​are reported as average values.

[0388] [Table 58]

[0389] [Table 59]

[0390]

Table 60

[0391]

Table 61

[0392]

Table 62

[0393]

Table 63

[0394]

Table 64

[0395]

Table 65

Claims

1. A compound of formula (I) or a pharma- ceutically acceptable salt thereof: 【Chemistry 1】 (In the formula, Ar １ teeth, phenyl, which is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents, said substituents being independently selected from halogen, methyl, cyano, methoxy, trifluoromethyl, trifluoromethoxy and ethynyl; - a 5- or 6-membered heteroaryl, which is independently unsubstituted or substituted with 1 or 2 substituents, said substituents being independently selected from halogen, methyl, cyano and methoxy; or - 9- or 10-membered heteroaryl, which 9- or 10-membered heteroaryl is independently unsubstituted or substituted by one methyl; represents; R １ teeth, - hydroxy; - C １－４ -alkoxy; - -O-CO-C １－３ - alkyl; -O-CO-NH-R Ｎ１１ (R Ｎ１１ is hydrogen or C １－３ - represents alkyl; -O-CH ２ -C １ -fluoroalkyl; - -O-CH ２ -H.E.T. １ (H.E.T. １ represents a 5-membered heteroaryl, which is independently unsubstituted or substituted with one methyl; or - -O-CH ２ -CO-R １Ｘ (R １Ｘ は、 -- -hydroxy; -- C １－３ -alkoxy; --morpholin-4-yl; Or, -- -NR Ｎ２１ R Ｎ２２ (R Ｎ２１ and R Ｎ２２ each independently represents hydrogen or methyl; or R Ｎ２１ and R Ｎ２２ together with the nitrogen atom to which they are attached form a 4-6 membered heterocycloalkyl selected from azetidin-1-yl, pyrrolidin-1-yl, and piperidin-1-yl, said 4-6 membered heterocycloalkyl being substituted by one hydroxy; ) ; represents; A represents a 5-membered heterocycloalkylene or a 5-membered heteroarylene; the 5-membered heterocycloalkylene is selected from 4,5-dihydroisoxazole-3,5-diyl, imidazolidin-4-one-1,3-diyl, oxazol-2-one-3,5-diyl, and oxazolidine-2-one-3,5-diyl; the 5-membered heteroarylene is selected from 1,2,3-triazole-1,4-diyl, isoxazole-3,5-diyl, imidazol-1,4-diyl, and isothiazole-3,5-diyl; R ２ teeth, - C １－６ - alkyl; - C １－６ -Alkyl (the C １－６ -Alkyl is one C １－３ -alkoxy, -CO-C １－４ -Alkoxy, -NH ２ or -NH-CO-C １－４ - substituted by alkoxy; - C １－４ -fluoroalkyl; - C ３－６ -Cycloalkyl (the C ３－６ -cycloalkyl is independently unsubstituted or substituted with 1 or 2 substituents, the substituents being oxo, fluoro, -NH-CO-C １－４ -Alkoxy, C １－３ -Alkyl, C １－３ -Alkoxy, C １ -fluoroalkyl, cyano, -CH ２ -CN and -NH-CO-C １－４ -Alkyl (the C １－４ -Alkyl is one -NH ２ or -NH-CO-C １－４ -alkoxy; or ３－６ -cycloalkyl together with 1,3-dioxolane-2,2-diyl forms a spiro-bicyclic group; - 4-6 membered heterocycloalkyl, which has one ring oxygen atom and which is independently unsubstituted or has one C １－４ -substituted by alkyl; 4-6 membered heterocycloalkyl having one ring sulfur atom which is unsubstituted or substituted with one oxo (=O); or the sulfur atom is substituted with two substituents, one of which is oxo (=O) and the other of which is oxo (=O), imido (=NH), C １－３ -Alkyl imide (=N-C １－３ -alkyl), 4,4-difluorocyclohexyl imide and benzylimide (=N-benzyl); 4-7 membered heterocycloalkyl having one ring nitrogen atom which is unsubstituted or has one -- C １－６ - alkyl; -- --CO-C １－６ -alkyl; -CO-C ４－６ -cycloalkyl; -CO-C １ －３ -fluoroalkyl; -CO-C １－４ -Alkoxy; -CO-NH-C １－４ - alkyl; --SO ２ -C １－４ -Alkyl; -SO ２ -NH-C １－４ - alkyl; -- --CH ２ -C ３－６ -cycloalkyl; -- --CO-C １－６ -Alkyl (C １－６ - alkyl is substituted by one amino; -- --CH ２ -oxetanyl; --thiazol-2-yl; Oxazol-2-yl; Benzo[d]thiazol-2-yl; --CO-benzyloxy; -- --CO-NH ２ ;-CO-NH-C ３－６ -cycloalkyl; -- --CO-NR Ｎ３１ R Ｎ３２ (R Ｎ３１ and R Ｎ３２ Each of them is independently C １－３ - represents alkyl; -- --CO-NR Ｎ４１ R Ｎ４２ (R Ｎ４１ and R Ｎ４２ together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl, which 5- or 6-membered heterocycloalkyl is independently unsubstituted or １－３ -substituted by alkyl; ---SO-C １－６ - alkyl; --SO ２ -C １－３ -fluoroalkyl; -SO ２ -NH ２ ; --SO ２ -NR Ｎ５１ R Ｎ５２ (R Ｎ５１ and R Ｎ５２ Each of them is independently C １－３ - represents alkyl; --SO ２ -NR Ｎ６１ R Ｎ６２ (R Ｎ６１ and R Ｎ６２ together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl, which is independently unsubstituted or substituted with 2 fluoro; --SO ２ -phenyl, which is unsubstituted or substituted by one methyl; ----SO(NH)-C １－６ -alkyl; or -SO(N-C １－３ -alkyl)-C １－６ - alkyl; is replaced by; The 4- to 7-membered heterocycloalkyl may bear no further substituents in addition to those on the ring nitrogen atoms, or may be represented by the formula: １－４ -alkyl (this C １－４ - alkyl is intended to be attached to a ring carbon atom; 【Chemistry 2】 (R Ｎ７１ is hydrogen or -CO-C １－４ -represents alkoxy; - cyclopentenyl; -L-OH (L is -- C １－６ - alkylene; -- Chloro-C ２－６ - alkylene; -- 1-phenyl-ethane-1,1-diyl or 1-(2-fluorophenyl)-ethane-1,1-diyl; --(cyclopropyl)-(pyridin-2-yl)-methylene; -- C ４－６ -Cycloalkylene (the C ４－６ -cycloalkylene is independently unsubstituted or substituted with 1 or 2 substituents, said substituents being independently methyl, fluoro or -CO-R Ｏ２ (R Ｏ２ is hydroxy or C １－４ -alkoxy. --Cyclopropylene-(CH ２ ) ｎ - ＊ (n represents an integer of 0 or 1, and the asterisk indicates the bond connecting to the -OH group); -- 4-7 membered heterocycloalkylene, the heterocycloalkylene having one ring oxygen atom; or 4-7 membered heterocycloalkylene having one ring nitrogen atom which is unsubstituted or has one -CO-C １－４ -Alkyl or -CO-C １－４ - substituted by alkoxy; ) ; - 5- or 6-membered heteroaryl, which 5- or 6-membered heteroaryl is independently unsubstituted or substituted by one substituent, said substituent being independently selected from the group consisting of: １－４ -Alkyl, C １－３ -fluoroalkyl, halogen, C １－４ -Alkoxy or C １－４ -fluoroalkoxy; 2-oxo-1,2-dihydropyridin-4-yl, 6-oxo-1,6-dihydropyridin-3-yl or 1-methyl-2-oxo-1,2-dihydropyridin-4-yl; 【Chemistry 3】 (m and p each independently represent an integer of 1 or 2; R Ｎ８１ is hydrogen or C １－４ - represents alkyl; - C ０－３ -alkylene-phenyl; wherein the phenyl is independently unsubstituted or substituted by 1, 2 or 3 substituents, the substituents being independently selected from the group consisting of １－４ -Alkyl, C １－３ -fluoroalkyl, halogen, hydroxy, C １－４ -Alkoxy or C １－４ -fluoroalkoxy; - 9-membered heteroaryl; 【Chemistry 4】 (R Ｎ９１ is hydrogen or -CO-C １－４ -represents alkoxy; represents; - or R ２ is the structure (R ２－Ｂ ) group: 【Chemistry 5】 (Ring (B) represents a non-aromatic 5-membered ring fused to the phenyl group, and Ring (B) has two heteroatoms independently selected from nitrogen and oxygen; Ring (B) is independently substituted with 1 or 2 substituents, one of which is oxo, and if the other substituent is present, the other substituent is C １－３ -alkyl.) ; ).

2. Ar １ represents phenyl substituted by 1, 2 or 3 substituents independently selected from halogen, methyl, cyano, methoxy, trifluoromethyl and ethynyl; at least one of the substituents is attached at the meta and / or para position of the phenyl, and if a para substituent is present, the para substituent is selected from halogen, methyl, cyano, methoxy, trifluoromethyl, and ethynyl; - if a meta substituent is present, said meta substituent is halogen; 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

3. Ar １ The structure is: 【Chemistry 6】 (In the formula, - R ｍ２ represents a halogen; - R ｐ represents hydrogen, halogen, methyl, cyano or methoxy; represents a phenyl group; 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

4. Ar １ but: 【Chemistry 7】 Represents; 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

5. R １ A compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein: represents methoxy.

6. The compound according to any one of claims 1 to 5, wherein A represents 1,2,3-triazole-1,4-diyl or isoxazole-3,5-diyl; or a pharma- ceutically acceptable salt thereof.

7. R ２ but, - C １－６ - alkyl; - C １－６ -Alkyl (the C １－６ -Alkyl is one C １－３ -alkoxy, -CO-C １－４ -Alkoxy, -NH ２ or -NH-CO-C １－４ - substituted by alkoxy; - C １－４ -fluoroalkyl; - C ３－６ -Cycloalkyl (the C ３－６ -cycloalkyl is independently unsubstituted or substituted with 1 or 2 substituents, the substituents being oxo, fluoro, -NH-CO-C １－４ -Alkoxy, C １－３ -Alkyl, C １－３ -Alkoxy, C １ - Full Oroalkyl, cyano, -CH ２ -CN and -NH-CO-C １－４ -Alkyl (the C １－４ -Alkyl is one -NH ２ or -NH-CO-C １－４ -substituted by alkoxy; - 4-6 membered heterocycloalkyl, which has one ring oxygen atom and which is independently unsubstituted or has one C １－４ -substituted by alkyl; 4-6 membered heterocycloalkyl having one ring sulfur atom which is unsubstituted or substituted with one oxo (=O); or the sulfur atom is substituted with two substituents, one of which is oxo (=O) and the other of which is oxo (=O), imido (=NH), C １－３ -Alkyl imide (=N-C １－３ -alkyl), 4,4-difluorocyclohexyl imide and benzylimide (=N-benzyl); 4-6 membered heterocycloalkyl having one ring nitrogen atom which is unsubstituted or has one -- C １－６ - alkyl; -- --CO-C １－６ -alkyl; -CO-C ４－６ -cycloalkyl; -CO-C １－３ -fluoroalkyl; -CO-C １－４ -Alkoxy; -CO-NH-C １－４ - alkyl; --SO ２ -C １－４ - alkyl; -- --CH ２ -C ３－６ -cycloalkyl; --thiazol-2-yl; Oxazol-2-yl; Benzo[d]thiazol-2-yl; --CO-benzyloxy; -- -CO-NH-C ３－６ -cycloalkyl; -- --CO-NR Ｎ３１ R Ｎ３２ (R Ｎ３１ and R Ｎ３２ Each of them is independently C １－３ - represents alkyl; -- --CO-NR Ｎ４１ R Ｎ４２ (R Ｎ４１ and R Ｎ４２ together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl, which 5- or 6-membered heterocycloalkyl is independently unsubstituted or １－３ -substituted by alkyl; ---SO-C １－６ - alkyl; --SO ２ -C １－３ -fluoroalkyl; --SO ２ -NR Ｎ５１ R Ｎ５２ (R Ｎ５１ and R Ｎ５２ Each of them is independently C １－３ - represents alkyl; --SO ２ -NR Ｎ６１ R Ｎ６２ (R Ｎ６１ and R Ｎ６２ together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl, which is independently unsubstituted or substituted with 2 fluoro; --SO ２ -phenyl, which is substituted by one methyl; ----SO(NH)-C １－６ -alkyl; or -SO(N-C １－３ -alkyl)-C １－６ - alkyl; is replaced by; The 4- to 6-membered heterocycloalkyl may bear no further substituents in addition to those on the ring nitrogen atoms, or may be C １－４ -alkyl (this C １－４ - alkyl is intended to be attached to a ring carbon atom; -L-OH (L is -- C １－６ - alkylene; -- Chloro-C ２－６ - alkylene; -- 1-phenyl-ethane-1,1-diyl or 1-(2-fluorophenyl)-ethane-1,1-diyl; -- C ４－６ -Cycloalkylene (the C ４－６ -cycloalkylene is independently an unsubstituted or is substituted with two substituents, the substituents being independently methyl or fluoro; --Cyclopropylene-(CH ２ ) ｎ - ＊ (n represents an integer of 0 or 1, and the asterisk indicates the bond connecting to the -OH group); -- 4-6 membered heterocycloalkylene, the heterocycloalkylene having one ring oxygen atom; or 4-6 membered heterocycloalkylene, the heterocycloalkylene having one ring nitrogen atom which is unsubstituted or has one -CO-C １－４ -Alkyl or -CO-C １－４ - substituted by alkoxy; ) ; 2-oxo-1,2-dihydropyridin-4-yl, 6-oxo-1,6-dihydropyridin-3-yl or 1-methyl-2-oxo-1,2-dihydropyridin-4-yl; 【Chemistry 8】 (m and p each independently represent an integer of 1 or 2; R Ｎ８１ is hydrogen or C １－４ - represents alkyl; - -CH(CH ３ )-phenyl); 【Chemistry 9】 (R Ｎ９１ is hydrogen or -CO-C １－４ -represents alkoxy; represents; - or R ２ The structure (R ２－Ｂ ) group: 【Chemistry 10】 (Ring (B) represents a non-aromatic 5-membered ring fused to the phenyl group, and Ring (B) has two heteroatoms independently selected from nitrogen and oxygen; Ring (B) is independently substituted with 1 or 2 substituents, one of which is oxo, and if the other substituent is present, the other substituent is C １－３ -alkyl; The compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof.

8. R ２ but, - C １－６ - alkyl; - C １－６ -Alkyl (the C １－６ -Alkyl is one C １－３ - substituted by alkoxy; - C １－４ -fluoroalkyl; or -L-OH (L is -- C １－６ - alkylene; -- C ４－６ -Cycloalkylene (the C ４－６ -cycloalkylene is independently unsubstituted; or --Cyclopropylene-(CH ２ ) ｎ - ＊ (n represents an integer of 0 or 1, and the asterisk indicates the bond connecting to the -OH group); ) ; Represents; The compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof.

9. R ２ but, - C １－６ - alkyl; - cyclobutyl or cyclopentyl; - cyclohexyl, substituted by one or two substituents, the substituents being independently oxo, fluoro or -NH-CO-C １－４ -alkoxy, cyclohexyl; - 4-6 membered heterocycloalkyl, which has one ring oxygen atom; 4-7 membered heterocycloalkyl having one ring nitrogen atom, which is unsubstituted or has one C １－６ -Alkyl, -CO-C １－６ -Alkyl, -CO-C ４－６ -cycloalkyl, -CO-C １－３ -fluoroalkyl, -CO-C １－４ -Alkoxy, -CO-NH-C １－４ -Alkyl, -SO ２ -C １－４ -Alkyl, -SO ２ -NH-C １－４ -Alkyl, -CH ２ -C ３－６ -cycloalkyl, -CO-C １－６ -Alkyl (as above C １－６ -Alkyl is substituted by one amino.), -CH ２ -substituted by oxetanyl, thiazol-2-yl, oxazol-2-yl or benzo[d]thiazol-2-yl; -L-OH (L is -- C ４－６ -Cycloalkylene (the C ４－６ -cycloalkylene is independently unsubstituted or substituted with 1 or 2 substituents, said substituents being independently methyl or fluoro; -- 4-7 membered heterocycloalkylene, the heterocycloalkylene having one ring oxygen atom; or 4-7 membered heterocycloalkylene having one ring nitrogen atom which is unsubstituted or has one -CO-C １－４ -Alkyl or -CO-C １－４ - substituted by alkoxy; ) ; represents; - or R ２ The structure (R ２－Ｂ ) group: 【Chemistry 11】 (Ring (B) represents a non-aromatic 5-membered ring fused to the phenyl group, and Ring (B) has two heteroatoms independently selected from nitrogen and oxygen; Ring (B) is independently substituted with 1 or 2 substituents, one of which is oxo, and if the other substituent is present, the other substituent is C １－３ -alkyl; The compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof.

10. The compound is 6-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)benzo[d]oxazol-2(3H)-one; 6-((RS)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)benzo[d]oxazol-2(3H)-one; 6-((S)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)benzo[d]oxazol-2(3H)-one; tert-butyl 4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-3-acetoxy-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidinyl Din-1-carboxylate; tert-butyl 4-((S)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-butyl 4-(3-(((2R,3R,4S,5R,6R)-3-acetoxy-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4R,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; tert-butyl (RS)-3-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; tert-butyl 4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-4-hydroxypiperidine-1-carboxylate; tert-butyl 4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclopentylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-hydroxycyclohexyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclobutylisoxazole-3- yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(4,4-difluorocyclohexyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-butyl ((1R,4R)-4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclohexyl)carbamate; tert-butyl ((1S,4S)-4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclohexyl)carbamate; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((5-(1-(oxazol-2-yl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-2-((5-(1-(benzo[d]thiazol-2-yl)piperidin-4-yl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((5-(1-(thiazol-2-yl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; 5-((RS)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one; 4-((S)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one; 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one; 4-((S)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)pyridin-2(1H)-one; 4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxy Sazol-5-yl)cyclohexan-1-one; (2R,3R,4R,5R,6R)-2-((5-(4-hydroxycyclohexyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-2-((5-((1R,4R)-4-hydroxycyclohexyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; tert-butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(propionyloxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl propionate; tert-butyl 4-(3-(((2R,3R,4S,5R,6R)-3-ethoxy-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl propionate; tert-butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-propoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; 2-(((2R,3R,4S,5R,6R)-2-((5-(1-(tert-butoxycarbonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; tert-butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(isobutyryloxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-(((RS)-3-(piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; 1-(4-((RS)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidin-1-yl)ethan-1-one; 1-(4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidin-1-yl)ethan-1-one; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-(((S)-3-(piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; 1-(4-((S)-5-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidin-1-yl)ethan-1-one; 1-(4-((S)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidin-1-yl)ethan-1-one; (2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl acetate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 1-(4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-((RS)-3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-((S)-3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; (2R,3R,4S,5R,6R)-2-((5-(1-acetylpiperidin-4-yl ) isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl acetate; (2R,3R,4S,5R,6R)-2-(((RS)-5-(1-acetylpiperidin-4-yl)-4,5-dihydroisoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl acetate; (2R,3R,4S,5R,6R)-2-(((S)-5-(1-acetylpiperidin-4-yl)-4,5-dihydroisoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl acetate; Ethyl 4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; 4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-N-ethylpiperidine-1-carboxamide; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-2-(hydroxymethyl)-6-((5-(1-methylpiperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; 1-(4-(3-(((2R,3R,4R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)-2,2-dimethylpropan-1-one; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Methyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; 1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)-2-methylpropan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl ethyl)isoxazol-5-yl)piperidin-1-yl)-2,2-dimethylpropan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)butan-1-one; N-ethyl-4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxamide; 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-N-isopropylpiperidine-1-carboxamide; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-methylpiperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((5-(1-isobutylpiperidin-4-yl)isoxazol-3-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-(3,3-dimethylbutyl)piperidin-4-yl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-(cyclopropylmethyl)piperidin-4-yl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(propylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((5-(1-(isopropylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)-3-methylbutan-1-one; Cyclopentyl(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2 5-yl)methyl)isoxazol-5-yl)piperidin-1-yl)methanone; cyclobutyl(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)methanone; 3,3,3-trifluoro-1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)propan-1-one; N-(tert-butyl)-4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxamide; (RS)-1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)-2-methylbutan-1-one; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((1-(tetrahydro-2H-pyran-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 1-(4-(1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)piperidin-1-yl)ethan-1-one; tert-butyl 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate; 1-(4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidin-1-yl)ethan-1-one; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((1-(1-(methylsulfonyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; N-(tert-butyl)-4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxamide; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((1-(1-(propylsulfonyl)piperidin-4-yl)-1H-1,2,3-trimethyl azol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((1-(1-(isopropylsulfonyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(3,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(3,4-difluoro-5-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(4-chloro-3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; (RS)-5-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidin-2-one; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-1-methylpyridin-2(1H)-one; (2R,3R,4S,5R,6R)-6-((3-cyclohexylisoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-Butyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4 -chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; tert-butyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; tert-butyl 4-(5-(((2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-(5-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-(5-(((2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-(5-(((2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-6-((5-(4-bromothiazol-2-yl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-(((S)-5-cyclohexyl-4,5-dihydroisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-butyl (4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)bicyclo[2.2.2]octan-1-yl)carbamate; (2R,3R,4S,5R,6R)-6-((5-(4-aminobicyclo[2.2.2]octan-1-yl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-butyl 4-hydroxy-4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-4-ol; tert-Butyl ((1R,4r)-4-(5-(((2R,3R,4S,5R,6R )-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclohexyl)carbamate; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-((S)-1-(N-methylpropan-2-ylsulfonimidoyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-((R)-1-(N-methylpropan-2-ylsulfonimidoyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-(((RS)-3-(piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-(((RS)-3-(piperidin-4-yl)-4,5-dihydroisoxazole-5- yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-(((RS)-3-(piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (1R,4r)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-1-(isopropylimino)hexahydro-11-6-thiopyran 1-oxide; (1S,4s)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-1-(isopropylimino)hexahydro-11-6-thiopyran 1-oxide; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl) -1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(methylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5- Hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; ... (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-cyclohexylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclohexylisoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(tetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol (3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((5-(1-(N-isopropylpropan-2-ylsulfonimidoyl)piperidin-4-yl)isoxazol-3-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-chloro-5-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-fluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-phenyl hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; Ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate; (2R,3R,4R,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; Ethyl 3-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-3-methylbutanoate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methoxycyclopentyl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methoxycyclohexyl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(3-methyloxetan-3-yl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(3-ethyloxetan-3-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-fluorocyclopropyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-(difluoromethyl)cyclopropyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(2-aminopropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 1-(4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)ethan-1-one; ethyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(3-chloro-4,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-cyclopentylisoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclobutylisoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclobutylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-cyclobutylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; tert-butyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((5-(2-hydroxypropan-2-yl)isoxazol-3-yl)methyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-hydroxycyclohexyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-hydroxycyclopentyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4- (4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclopentylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-hydroxycyclobutyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((5-(2-hydroxypropan-2-yl)isoxazol-3-yl)methyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclohexyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclopentyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-cyclopentylisoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclobutyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((5-(2-hydroxypropan-2-yl)isoxazol-3-yl)methyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclohexyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclopentyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-cyclopentylisoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclobutyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,5-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; tert-butyl 4-(3-(((2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(3-methyloxetan-3-yl)isoxazol-5-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(3-methyloxetan-3-yl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5 -Methoxy-6-((3-(3-methyloxetan-3-yl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-chloro-3-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-chloro-3-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-chloro-3-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-(((RS)-3-(tert-butyl)-4,5-dihydroisoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-(((RS)-3-(tert-butyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; 4-(1-((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-4-yl)-1H-1,2,3-triazol-4-yl)-2,3-difluorobenzonitrile; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-methylcyclopentyl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-methylcyclopentyl)isoxazol-3-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-methylcyclopentyl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-methylcyclopentyl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; 1-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclopentane-1-carbonitrile; 1-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclopentane-1-carbonitrile; 1-(3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclopentane-1-carbonitrile; 1-(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)cyclopentane-1-carbonitrile; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-(((RS)-3-(1-hydroxy-2-methylpropan-2-yl)-4,5-dihydroisoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-5-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(4-methyltetrahydro-2H-pyran-4-yl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-( (3-(1-methylcyclopentyl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopentyl)isoxazol-5-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopentyl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methylcyclopentyl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; 1-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclopentane-1-carbonitrile; 1-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclopentane-1-carbonitrile; 1-(5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclopentane-1-carbonitrile; 1-(5-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclopentane-1-carbonitrile; (2R,3R,4R,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4S,5R,6R)-6-((3-(1,1-difluoro-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((3-isopropylisoxazol-5-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(1-hydroxycyclopentyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 2-(1-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl ethyl)isoxazol-3-yl)cyclopropyl)acetonitrile; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methoxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; tert-butyl (2-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-2-methylpropyl)carbamate; (2R,3R,4S,5R,6R)-6-((3-(1-amino-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((RS)-1-hydroxy-1-phenylethyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-(1-hydroxycyclopropyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((5-(3-methyloxetan-3-yl)isoxazol-3-yl)methyl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((5-(1-(hydroxymethyl)cyclopropyl)isoxazol-3-yl)methyl)-5-methoxytetrahydro-2H-pyran-3-ol; Ethyl 4-(5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-4-methylpiperidine-1-carboxylate; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxycyclopentyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(2-ethoxypropan-2-yl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-Butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl) -5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxy-6-((3-(1-methoxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3-ol; tert-butyl (2-(5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-2-methylpropyl)carbamate; 2-(1-(5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclopropyl)acetonitrile; (2R,3R,4R,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((3-(3-methyloxetan-3-yl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4S,5R,6R)-6-((3-(1-amino-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (RS)-5-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)azepan-2-one; 4-(1-((2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-4-yl)-1H-1,2,3-triazol-4-yl)-2,3-difluorobenzonitrile; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((R)-1-hydroxy-1-phenylethyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; 5-(((4aR,6R,7R,8R,8aR)-8-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-7-methoxy-2,2-dimethylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)methyl)-3-((RS)-1-phenylethyl)isoxazole; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((1RS,2R S)-2-hydroxycyclobutyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-2-((5-((1RS,2RS)-2-hydroxycyclopentyl)isoxazol-3-yl)methyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl acetate; (RS)-5-(5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-1-methylazepan-2-one; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((1S,2S)-2-hydroxycyclobutyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((1R,2R)-2-hydroxycyclobutyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (RS)-5-(5-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)azepan-2-one; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((1S,2R)-2-hydroxycyclopropyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((5-((1R,2R)-2-hydroxycyclopropyl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (RS)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)-1-methylpiperidin-2-one; (RS)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)piperidin-2-one; (RS)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl )methyl)isoxazol-3-yl)pyrrolidin-2-one; tert-butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(4-chloro-2,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-butyl 4-((RS)-5-(((2R,3R,4R,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-isopropoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; tert-butyl 4-(3-(((2R,3R,4S,5R,6R)-3-(2,2-difluoroethoxy)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-5-(2,2-difluoroethoxy)-2-(hydroxymethyl)-6-((5-(piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-morpholinoethan-1-one; tert-Butyl ((S)-1-(((1R,4S)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclohexyl)amino)-3-methyl-1-oxobutan-2-yl ) carbamate; (S)-2-amino-N-((1R,4S)-4-(5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-3-yl)cyclohexyl)-3-methylbutanamide; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-3-ethoxy-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; 2-(((2R,3R,4S,5R,6R)-2-(((RS)-3-(1-(tert -butoxycarbonyl)piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(2-(methylamino)-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-(2-morpholino-2-oxoethoxy)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-4,5-dihydroisoxazol-3-yl)piperidine-1-carboxylate; 2-(((2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-N-methylacetamide; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-((R)-3-hydroxypyrrolidin-1-yl)ethan-1-one; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-(3-hydroxyazetidin-1-yl)ethan-1-one; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-(4-hydroxypiperidin-1-yl)ethan-1-one; 2-(((2R,3R,4S,5R,6R)-2-((5-(tert-butyl)isoxazol-3-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)-1-((S)-3-hydroxypyrrolidin-1-yl)ethan-1-one; 2-(((2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-5-hydroxy-6-(hydroxymethyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; 2-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-((3-(1-methylcyclopropyl)isoxazol-5-yl)methyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; (2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl carbamate; 2-(((2R,3R,4S,5R,6R)-5-hydroxy-2-((3-(1-hydroxy-2-methylpropan-2-yl)isoxazol-5-yl)methyl)-6-(hydroxymethyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-yl)oxy)acetic acid; (2R,3R,4S,5R,6R)-6-((5-(tert-butyl)isoxazol-3-yl)methyl)-4-(4-(4-ethynyl-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4R,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-6-(hydroxymethyl)-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4R,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol; (2R,3R,4S,5R,6R)-2-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl ethylcarbamate; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-((1-methyl-1H-imidazol-2-yl)methoxy)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-(thiazol-2-ylmethoxy)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-(thiazol-4-ylmethoxy)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((3-(tert-butyl)isoxazol-5-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-(oxazol-5-ylmethoxy)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxycyclobutyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxycyclobutyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-6-((3-(1-hydroxycyclobutyl)isoxazol-5-yl)methyl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((3-(2-hydroxypropan-2-yl)isoxazol-5-yl)methyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((3-(2-hydroxypropan-2-yl)isoxazol-5-yl)methyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-6-((3-(2-hydroxypropan-2-yl)isoxazol-5-yl)methyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-((S)-tert-butylsulfinyl)piperidin-4-yl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(2-methylpropan-2-ylsulfonimidoyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(N-methylpropan-2-ylsulfonimidoyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-N,N-dimethylpiperidine-1-sulfonamide; N-cyclopropyl-4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidine-1-carboxamide; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-(((S)-3-(1-(isopropylsulfonyl)piperidin-4-yl)-4,5-dihydroisoxazol-5-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(morpholinosulfonyl)piperidin-4-yl)isoxazole-3 -yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(piperidin-1-ylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(1-(pyrrolidin-1-ylsulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((5-(1-((4,4-difluoropiperidin-1-yl)sulfonyl)piperidin-4-yl)isoxazol-3-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)(piperidin-1-yl)methanone; (4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)(pyrrolidin-1-yl)methanone; N-ethyl-4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-N-methylpiperidine-1-carboxamide; 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)-N,N-dimethylpiperidine-1-carboxamide; (4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isoxazol-5-yl)piperidin-1-yl)(4-methylpiperazin-1-yl)methanone; benzyl 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((1-(tetrahydro-2H-thiopyran-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1 ,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-thiopyran 1-oxide; 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide; 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-iminohexahydro-11-6-thiopyran 1-oxide; 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-(methylimino)hexahydro-11-6-thiopyran 1-oxide; (2R,3R,4S,5R,6R)-6-((1-(1-((S)-tert-butylsulfinyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; benzyl 4-(1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((1-(1-(2-methylpropan-2-ylsulfonimidoyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((4-(1-(isopropylsulfonyl)piperidin-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((4-(1-tosylpiperidin-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 1-(ethylimino)-4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)hexahydro-11-6-thiopyran 1-oxide; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((4-(1-(N-methylpropan-2-ylsulfonimidoyl)piperidin-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3,4,5 -trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 4-(1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)-N,N-dimethylpiperidine-1-sulfonamide; N-(tert-butyl)-4-(1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxamide; 1-(benzylimino)-4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)hexahydro-11-6-thiopyran 1-oxide; (2R,3R,4S,5R,6R)-6-((1-cyclohexyl-1H-1,2,3-triazol-4-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-(isopropylimino)hexahydro-11-6-thiopyran 1-oxide; N-cyclopropyl-4-(1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxamide; 1-((4,4-difluorocyclohexyl)imino)-4-(4-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)hexahydro-11-6-thiopyran 1-oxide; benzyl 4-(4-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate; benzyl 4-(4-(((2R,3R,4S,5R,6R)-4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate; benzyl 4-(4-(((2R,3R,4S,5R,6R)-4-(4-(4-bromo-3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate; benzyl 4-(4-(((2R,3R,4S,5R,6R)-4-(4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-6-((4-(tert-butyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; Ethyl 4-(1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((4-(tetrahydro-2H-pyran-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-6-((4-(2-hydroxypropan-2-yl)-1H-1,2,3-triazol-1-yl)methyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(2,3,4-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((4-cyclopentyl-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((4-(1-methylcyclopentyl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((4-(4-methyltetrahydro-2H-pyran-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((4-(tert-butyl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((4-(tert-butyl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; (RS)-3-(1-acetylpiperidin-4-yl)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)oxazolidin-2-one; (RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-(methylsulfonyl)piperidin-4-yl)oxazolidin-2-one; (S)-3-(1-acetylpiperidin-4-yl)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)oxazolidin-2-one; (S)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-(methylsulfonyl)piperidin-4-yl)oxazolidin-2-one; (R)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-(methylsulfonyl)piperidin-4-yl)oxazolidin-2-one; tert-butyl 4-((RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidin-3-yl)piperidine-1-carboxylate; (RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-isobutyrylpiperidin-4-yl)oxazolidin-2-one; 4-((RS)_5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidin-3-yl)-N,N-dimethylpiperidine-1-carboxamide; (S)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-isobutyrylpiperidin-4-yl)oxazolidin-2-one; tert-Butyl 4-((R)-5-(((2R,3R,4S,5R,6R)-5-butyl hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidin-3-yl)piperidine-1-carboxylate; (RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(tetrahydro-2H-pyran-4-yl)oxazolidin-2-one; (RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-(isobutylsulfonyl)piperidin-4-yl)oxazolidin-2-one; (RS)-3-(1-(3,3-dimethylbutanoyl)piperidin-4-yl)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)oxazolidin-2-one; (RS)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)oxazolidin-2-one; (RS)-3-(1-(tert-butylsulfonyl)piperidin-4-yl)-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)oxazolidin-2-one; (RS)-3-cyclohexyl-5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)oxazolidin-2-one; tert-butyl 4-((RS)-3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-2-oxooxazolidin-5-yl)piperidine-1-carboxylate; tert-butyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)isothiazol-5-yl)piperidine-1-carboxylate; (2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((5-(piperidin-4-yl)isothiazol-3-yl)methyl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; (2R,3R,4S,5R,6R)-6-((4-(tert-butyl)-1H-imidazol-1-yl)methyl)-2-(hydroxymethyl)-5-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-3-ol; 5-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl )-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-phenyloxazol-2(3H)-one; 3-cyclohexyl-1-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxytetrahydro-2H-pyran-2-yl)methyl)imidazolidin-4-one; 1-(1-acetylpiperidin-4-yl)-3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)imidazolidin-4-one; 3-(1-acetylpiperidin-4-yl)-1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)imidazolidin-4-one; 3-cyclohexyl-1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)imidazolidin-4-one; 1-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-3-(tetrahydro-2H-pyran-4-yl)imidazolidin-4-one; Or, 2. The compound of claim 1, which is ethyl 4-(3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-yl)methyl)-5-oxoimidazolidin-1-yl)piperidine-1-carboxylate; or a pharma- ceutically acceptable salt thereof.

11. The compound according to claim 1, which is (2R,3R,4S,5R,6R)-6-((1-(tert-butyl)-1H-1,2,3-triazol-4-yl)methyl)-4-(4-(4-chloro-2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-ol; or a pharma- ceutically acceptable salt thereof.

12. 12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof; and a pharma- ceutically acceptable carrier.

13. A compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, for use as a medicament.

14. A drug for the prevention or treatment of organ fibrosis; liver diseases and disorders; cardiovascular diseases and disorders; cell proliferative disorders and cancer; inflammatory and autoimmune diseases and disorders; gastrointestinal diseases and disorders; pancreatic diseases and disorders; abnormal angiogenesis-related diseases and disorders; brain-related diseases and disorders; neuropathic pain and peripheral neuropathy; eye diseases and disorders; acute kidney injury and chronic kidney disease; interstitial lung diseases and disorders; or transplant rejection, comprising a compound according to any one of claims 1 to 11 or a pharma-ceutically acceptable salt thereof as an active ingredient.

15. Organ fibrosis; Liver diseases and disorders; Cardiovascular diseases and disorders; Cell proliferation disorders and cancer; Inflammatory and autoimmune diseases and disorders; Digestive diseases and disorders; Pancreatic diseases and disorders; Abnormal angiogenesis-related diseases 12. Use of a compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of chronic kidney disease, acute kidney injury, and chronic kidney disease, interstitial lung disease, or transplant rejection.

Images